WO2005005658A1 - Methods and compositions for detecting sars virus and other infectious agents - Google Patents

Methods and compositions for detecting sars virus and other infectious agents Download PDF

Info

Publication number
WO2005005658A1
WO2005005658A1 PCT/CN2003/000561 CN0300561W WO2005005658A1 WO 2005005658 A1 WO2005005658 A1 WO 2005005658A1 CN 0300561 W CN0300561 W CN 0300561W WO 2005005658 A1 WO2005005658 A1 WO 2005005658A1
Authority
WO
WIPO (PCT)
Prior art keywords
sars
cov
virus
nucleotide sequence
coronaviruse
Prior art date
Application number
PCT/CN2003/000561
Other languages
French (fr)
Inventor
Ze Li
Shengce Tao
Jing Cheng
Original Assignee
Capitalbio Corporation
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capitalbio Corporation, Tsinghua University filed Critical Capitalbio Corporation
Priority to EP03817386A priority Critical patent/EP1644516A4/en
Priority to JP2005503791A priority patent/JP2007523594A/en
Priority to AU2003254594A priority patent/AU2003254594A1/en
Priority to US10/564,378 priority patent/US20070042350A1/en
Priority to CNB038267896A priority patent/CN100510101C/en
Priority to PCT/CN2003/000561 priority patent/WO2005005658A1/en
Publication of WO2005005658A1 publication Critical patent/WO2005005658A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • SARS SARS
  • WHO World Health Organization
  • SARS SARS
  • the main symptoms for SARS patients include fever (greater than 38°C), headache, body aches.
  • patients may develop a dry, nonproductive cough that may be accompanied with breathing difficulty.
  • a previously unrecognized coronaviruse has been identified as the cause of SARS.
  • SARS coronaviruse is a positive chain RNA virus which replicates without DNA intermediate step and uses standard codon (Marra et al., Science 2003 May 1; (epub ahead of print); and Rota et al., Science 2003 May 1, (epub ahead of print)).
  • SARS coronaviruse is a newly discovered virus which has not been previously detected in human or animals.
  • the genome structure of SARS coronaviruse is very similar to other coronaviruse.
  • the genome of SARS coronaviruse is 30 K base pairs in length and the genome is considered very large for a virus.
  • RNA polymerase polymerase la and lb
  • S protein spike protein
  • M protein membrane protein
  • N protein nucleocapsid protein
  • ELISA immunological methods
  • RT-PCR reverse transcriptase polymerase chain reaction
  • cell culture methods There are significant drawbacks of the above three detection methods. For example, ELISA can reliably detect antibodies from serum of SARS patients. However, those antibodies can only be detected twenty one days after development of symptoms. Cell culture methods have a relative long detection cycle and can be applied only to limited conditions.
  • RT-PCR is the only existing method that allows detection of nucleic acid of SARS coronaviruse.
  • RT-PCR cannot eliminate infected patient before SARS virus expression, and detection rate for RT-PCR is low.
  • the detection process requires expensive real time PCR equipment.
  • RT-PCR cannot satisfy the need of early clinical screening and diagnosis.
  • SARS severe acute respiratory syndrome
  • the current method for clinical diagnosis is mainly based on symptoms such as fever, shadows on patient's lung, dry cough, and weakness in patient's arms and legs.
  • these symptoms are not specific for SARS; other pathogens can cause the same or similar symptoms.
  • regular pneumonia caused by Chlamydia pneumoniae and Mycoplasma pneumoniae also generates shadows on patient's lung; fever and cough are also associated with influenza; and similar symptoms are also associated with infection of the upper respiratory tract caused by human coronaviruse 229E and OC43.
  • diagnosis for SARS solely based on the symptoms of the patient is problematic.
  • a biochip-based diagnosis is a fast and low cost method for high throughput simultaneous screening of multiple samples.
  • one objective of the invention is to provide a biochips for simultaneous detection of SARS virus and other pathogens that cause SARS-like symptoms.
  • Clinical data also indicate that those SARS patients infected with other pathogens (pathogens that severely interfere and obstruct immunity, such as hepatitis B and HIV) have aggravated symptoms and high probability of infecting others (these patients are called "super-spreaders"). Proper detection of such patients would allow adequate treatment and timely quarantine of patients.
  • the present invention is directed to a chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV) and a non-SARS-CoV infectious organism, which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to a nucleotide sequence of SARS-CoV genome, said nucleotide sequence comprising at least 10 nucleotides, and one or more of the following oligonucleotide probe(s): a) an oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, said nucleotide sequence comprising at least 10 nucleotides; b) an oligonucleotide probe complementary
  • the chip of the invention comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides.
  • the non-SARS-CoV infectious organism causing SARS-like symptoms is selected from the group consisting of a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus.
  • the non-SARS-CoV infectious organism damaging an infectious host's immune system is selected from the group consisting of a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum.
  • the present invention is directed to a method for assaying for a SARS-CoV and a non-SARS-CoV infectious organism in a sample, which methods comprises: a) providing an above-described chip; b) contacting said chip with a sample containing or suspected of containing a nucleotide sequence of a SARS-CoV and a non-SARS-CoV infectious organism under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said nucleotide sequence of said SARS-CoV or said non-S ARS-CoV infectious organism, if present in said sample, and said oligonucleotide probe complementary to a nucleotide sequence of said SARS-CoV genome or said oligonucleotide probe complementary to a nucleotide sequence of said non-S ARS-CoV infectious organism genome, whereby detection of one or both of said hybrids indicates the presence of said SARS-CoV and/or said non-S ARS-CoV
  • the SARS-CoV is assayed by: a) providing a chip comprising a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotide; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and said at least two oligonucleotide probes complementary to two different nucleotide sequences of SARS-CoV genome, respectively, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample.
  • the present methods reduce the occurrence of false negative results compared to a test based on a single hybridization probe as the chance of simultaneous mutations of the multiple hybridization targets is much smaller than the chance of a mutation in the single hybridization target.
  • a negative control probe and a blank spot on the chip the chance of a false positive result can also be reduced.
  • the inclusion of more preferred embodiments, e.g., an immobilization control probe and a positive control probe, on the chip can provide further validation of the assay results.
  • the use of preferred sample preparation procedures, RNA extraction procedures and amplification procedures can further enhance the sensitivity of the present methods.
  • the present invention is directed to an oligonucleotide primer for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adeno virus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide primer comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 1-6; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43 comprising a target
  • HCoV-OC43 Primers Id Sequence PMV a0061 ⁇ TCACTTGCTTCCGTTGAGGTTGGGGTGATGGGTTTCAGATTAA PMV_a0062 . GGTTTCGGATGTTACAGCGTCTCGGGAAGATCGCCTTCTTCTA PMV_b0061 . TTGGGGTGATGGGTTTCAGATTAA PMV b0062 : CTCGGGAAGATCGCCTTCTTCTA
  • the present invention is directed to a kit for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a primer described above; and b) a nucleic acid polymerase that can amplify a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 using said primer.
  • the present invention is directed to an oligonucleotide probe for hybridizing to a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide probe comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 7-12; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43,
  • PBIBJ0009 AAAATCCCTTTGTNGGACATTTGTCTATTGAGGGCATCAAAGANGCAGATATAACCCCAGCACATGGTCC
  • PBIBJD0010 I CTTGGAATACAAGGGAATACAAC ⁇ AAAACAAATGCTGAAGACATAGGAACCAAAGGCCAAATGTGCTCA
  • the present invention is directed to a kit for hybridization analysis of a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a above-described probe; and b) a means for assessing a hybrid formed between a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 and said probe.
  • Figure 1 A and IB illustrate exemplary SARS-CoV genome structures (See Figure 2 of Marra et al., Science 2003 May 1; [epub ahead of print]; and GenBank Accession No. NC_004718).
  • Figure 2 illustrates an exemplary sample preparation procedure.
  • Figure 3 illustrates an exemplary probe labeling to be used in PCR.
  • the sequence of the universal primer is complementary to the common sequence of the specific primer.
  • the universal primers and the specific primers are added into the PCR master mix before the amplification are performed. The specificity of the amplification is ensured by the specific part of the specific primer.
  • the universal primer can be incorporated into the amplicon efficiently. Then the universal primer can anneal to the complementary sequence of the common sequence of the specific primer
  • the PCR can further proceed with the fluorescence dye incorporated in the universal primer.
  • 1 and 6 depict a fluorescence dye; 2 depicts an upstream universal primer; 3 depicts an upstream specific primer with a common sequence; 4 depicts a template; 5 depicts a downstream specific primer with a common sequence; and 7 depicts a downstream universal primer.
  • Figure 4 illustrates probe immobilization on a glass slide surface modified with an amino group, e.g., poly-L-lysine treated.
  • Amine Coupling Chemistry Amine Substrates contain primary amine groups (NH3 + ) attached covalently to the glass surface (rectangles). The amines carry a positive charge at neutral pH, allowing attachment of natively charged DNA (double helix) through the formation of ionic bonds with the negatively charged phosphate backbone (middle panel). Electrostatic attachment is supplemented by treatment with an ultraviolet light or heat, which induces covalent attacliment of the DNA to the surface through the covalent binding between the primary amine and thymine (right panel). The combination of electrostatic binding and covalent attachment couples the DNA to the substrate in a highly stable manner.
  • Figure 5 illustrates an exemplary array format of SARS-CoV detection chip.
  • Figure 6A and 6B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 3).
  • Figure 7A and 7B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 4).
  • Figure 8A and 8B illustrate SARS-CoV detection from a SARS patient sputum sample (sample No. 5).
  • Figure 9A and 9B illustrate SARS-CoV detection from a SARS patient sputum sample (sample No. 6).
  • Figure 10 illustrates another exemplary array format of SARS-CoV detection chip.
  • Figure 11 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 10.
  • Figure 12 illustrates another exemplary array format of SARS-CoV detection chip.
  • Figure 13 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 12.
  • Figure 14 illustrates all possible positive and negative results on the SARS
  • PCR polymerase chain reaction
  • the target DNA is repeatedly denatured (e.g., around 90°C), annealed to the primers (e.g., at 50-60°C) and a daughter strand extended from the primers (e.g. , 72°C).
  • the daughter strands themselves act as templates for subsequent cycles, DNA fragments matching both primers are amplified exponentially, rather than linearly.
  • the original DNA need thus be neither pure nor abundant, and the PCR reaction has accordingly become widely used not only in research, but in clinical diagnostics and forensic science.
  • “nested PCR” refers to a PCR in which specificity is improved by using two sets of primers sequentially.
  • reverse transcription PCR or RT-PCR refers to PCR in which the starting template is RNA, implying the need for an initial reverse transcriptase step to make a DNA template.
  • Some thermostable polymerases have appreciable reverse transcriptase activity; however, it is more common to perform an explicit reverse transcription, inactivate the reverse transcriptase or purify the product, and proceed to a separate conventional PCR.
  • probe refers to an oligonucleotide that hybridizes to a target sequence, typically to prime the nucleic acid in the amplification process.
  • probe refers to an oligonucleotide that hybridizes to a target sequence, typically to facilitate its detection.
  • target sequence refers to a nucleic acid sequence to which the probe specifically binds. Unlike a primer that is used to prime the target nucleic acid in the amplification process, a probe need not be extended to amplify target sequence using a polymerase enzyme. However, it will be apparent to those skilled in the art that probes and primers are structurally similar or identical in many cases.
  • the concentration of said 5' and 3' universal primers equals to or is higher than the concentration of said 5' and 3' specific primers, respectively. means that the concentration of the 5 ' universal primer equals to or is higher than the concentration of the 5' specific primers and the concentration of the 3' universal primer equals to or is higher than the concentration of the 3' specific primers.
  • hairpin structure refers to a polynucleotide or nucleic acid that contains a double-stranded stem segment and a single-stranded loop segment wherein the two polynucleotide or nucleic acid strands that form the double-stranded stem segment is linked and separated by the single polynucleotide or nucleic acid strand that forms the loop segment.
  • the "hairpin structure” can further comprise 3 ' and/or 5' single-stranded region(s) extending from the double-stranded stem segment.
  • nucleic acid refers to deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) in any form, including inter alia, single-stranded, duplex, triplex, linear and circular forms. It also includes polynucleotides, oligonucleotides, chimeras of nucleic acids and analogues thereof.
  • the nucleic acids described herein can be composed of the well-known deoxyribonucleotides and ribonucleotides composed of the bases adenosine, cytosine, guanine, thymidine, and uridine, or may be composed of analogues or derivatives of these bases.
  • oligonucleotide derivatives with nonconventional phosphodiester backbones are also included herein, such as phosphotriester, polynucleopeptides (PNA), methylphosphonate, phosphorothioate, polynucleotides primers, locked nucleic acid (LNA) and the like.
  • PNA polynucleopeptides
  • LNA locked nucleic acid
  • "complementary or matched" means that two nucleic acid sequences have at least 50% sequence identity.
  • the two nucleic acid sequences have at least 60%, 70,%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of sequence identity.
  • “Complementary or matched” also means that two nucleic acid sequences can hybridize under low, middle and/or high stringency condition(s).
  • “substantially complementary or substantially matched” means that two nucleic acid sequences have at least 90% sequence identity. Preferably, the two nucleic acid sequences have at least 95%, 96%, 97%, 98%, 99% or 100%. of sequence identity.
  • “substantially complementary or substantially matched” means that two nucleic acid sequences can hybridize under high stringency condition(s).
  • two perfectly matched nucleotide sequences refers to a nucleic acid duplex wherein the two nucleotide strands match according to the Watson-Crick basepair principle, i.e., A-T and C-G pairs in DNA:DNA duplex and A-U and C-G pairs in DNA:RNA or RNA:RNA duplex, and there is no deletion or addition in each of the two strands.
  • stringency of hybridization in determining percentage mismatch is as follows: 1) high stringency: 0.1 x SSPE (or 0.1 x SSC), 0.1% SDS, 65°C; 2) medium stringency: 0.2 x SSPE (or 1.O SSC), 0.1% SDS, 50°C (also referred to as moderate stringency); and 3) low stringency: 1.0 x SSPE (or 5.0 x SSC), 0.1% SDS, 50°C. It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures.
  • gene refers to the unit of inheritance that occupies a specific locus on a chromosome, the existence of which can be confirmed by the occurrence of different allelic forms.
  • Tm melting temperature
  • sample refers to anything which may contain a target SARS-CoV to be assayed or amplified by the present chips, primers, probes, kits and methods.
  • the sample may be a biological sample, such as a biological fluid or a biological tissue.
  • biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like.
  • Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s). Biological tissues may be processed to obtain cell suspension samples. The sample may also be a mixture of cells prepared in vitro. The sample may also be a cultured cell suspension.
  • the sample may be crude samples or processed samples that are obtained after various processing or preparation on the original samples.
  • various cell separation methods e.g. , magnetically activated cell sorting
  • Samples used for the present invention include such target-cell enriched cell preparation.
  • a “liquid (fluid) sample” refers to a sample that naturally exists as a liquid or fluid, e.g. , a biological fluid.
  • a “liquid sample” also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material.
  • a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue.
  • assessing PCR products refers to quantitative and/or qualitative determination of the PCR products, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the PCR products. Assessment may be direct or indirect and the chemical species actually detected need not of course be the PCR products themselves but may, for example, be a derivative thereof, or some further substance.
  • Chips for assaying for a SARS-CoV and a non-SARS-CoV infectious organism are directed to a chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV) and a non-SARS-CoV infectious organism, which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to a nucleotide sequence of SARS-CoV genome, said nucleotide sequence comprising at least 10 nucleotides, and one or more of the following oligonucleotide probe(s): a) an oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, said nucleotide sequence comprising at least 10 nucleotides; b) an oligonucleotide probe complementary to a nucleotide sequence of a non-
  • the chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides.
  • the at least two different nucleotide sequences can be any suitable combinations.
  • the at least two different nucleotide sequences of SARS-CoV genome can comprise a nucleotide sequence of at least 10 nucleotides located within a conserved region of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a variable region of SARS-CoV genome.
  • the at least two different nucleotide sequences of SARS-CoV genome can comprise a nucleotide sequence of at least 10 nucleotides located within a structural protein coding gene of
  • the present chips can comprise other types of probes or other features.
  • the chip can further comprise: a) at least one of the following three oligonucleotide probes: an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-SARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV or non-SARS-CoV infectious organism sequence but is complementary to a sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample; and b) a blank spot.
  • the present chips can comprise at least two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides, respectively, located within a conserved region of SARS-CoV genome, located within a structural protein coding gene of SARS-CoV genome or located within a non-structural protein coding gene of SARS-CoV genome.
  • Any conserved region of SARS-CoV genome can be used as assay target.
  • the conserved region of SARS-CoV genome can be a region located within the Replicase 1 A, IB gene or the Nucleocapsid (N) gene of SARS-CoV. Any variable region of SARS-CoV genome can be used as assay target.
  • variable region of SARS-CoV genome can be a region located within the Spike glycoprotein (S) gene of SARS-CoV.
  • Any structural protein coding gene of SARS-CoV genome can be used as assay target.
  • the structural protein coding gene of SARS-CoV genome can be a gene encoding the Spike glycoprotein (S), the small envelope protein (E) or the Nucleocapsid protein (N).
  • Any non-structural protein coding gene of SARS-CoV genome can be used as assay target.
  • the non-structural protein coding gene of SARS-CoV genome can be a gene encoding the Replicase 1 A or IB.
  • the present chips can comprise at least two of the following four oligonucleotide probes: two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the N gene of SARS-CoV and an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the S gene of SARS-CoV.
  • one or both of the different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV can comprise a nucleotide sequence that: a) 5 hybridizes, under high stringency, with a Replicase 1 A or IB nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a Replicase 1 A or IB nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, one or both of the different nucleotide sequences located within the Replicase 1 A or IB gene of 10 SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
  • the nucleotide sequence located within the N gene of SARS-CoV can comprise a nucleotide sequence that: a) hybridizes, under high stringency, with a N nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a N nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, the nucleotide sequence located within the N gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
  • the nucleotide sequence located within the S gene of SARS-CoV can comprise a nucleotide sequence that: a) hybridizes, under high stringency, with a S nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a S nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, the nucleotide sequence located within the S gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
  • any suitable label can be used in the immobilization control probe, e.g., a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent or a FRET label.
  • Any suitable non-S ARS-CoV-sequence can be used.
  • the non-S ARS-CoV-sequence can be an endogenous component of a sample to be assayed.
  • the non-SARS-CoV-sequence is spiked in the sample to be assayed.
  • the spiked non-SARS-CoV-sequence can be a sequence of Arabidopsis origin.
  • the present chips can comprise two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-SARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV sequence but is complementary to any sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample.
  • the chip comprises multiple spots of the described probes, e.g., multiple spots of the two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, the immobilization control probe, the positive control probe and the negative control probe.
  • the present chips can further comprise an oligonucleotide probe complementary to a nucleotide sequence of a coronaviruse not related to the SARS-CoV.
  • the coronaviruse not related to the SARS can be the Group I, II or III coronaviruse or is a coronaviruse that infects an avian species, e.g., Avian infectious bronchitis virus and Avian infectious laryngotracheitis virus, an equine species, e.g., Equine coronaviruse, a canine species, e.g., Canine coronaviruse, a feline species, e.g., Feline coronaviruse and Feline infectious peritonitis virus, a porcine species, e.g., Porcine epidemic diarrhea virus, Porcine transmissible gastroenteritis virus and Porcine hemagglutinating encephalomyelitis virus, a calf species, e.g., Neonatal calf diarrhea coronaviruse, a bovine species, e.g., Bovine coronaviruse, a murine species, e.g., Murine he
  • the present chips can further comprise an oligonucleotide probe complementary to a nucleotide sequence of other types of virus or pathogens.
  • An exemplary list of viruses and pathogens that can be assayed using the present chips is set forth in the following Table 14.
  • Virus name Genome Sample Structure nucleic acid 1 Coronaviridae Single-stranded, RNA Having capsid linear RNA SARS-CoV Single-stranded, RNA Having capsid linear RNA Human Single-stranded, RNA Having capsid coronaviruse linear RNA 229E
  • the various probes e.g., the oligonucleotide probe complementary to a nucleotide sequence located within a conserved region of SARS-CoV genome, the oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, the immobilization control probe, the positive control probe or the negative control probe the oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, the oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism damaging an infectious host's immune system, and the oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV coronaviridae virus, can comprise, at its '5 end, a poly dT region to enhance its immobilization on the support.
  • the at least one of the oligonucleotide probes is complementary to a highly expressed nucleotide sequence of SARS-CoV genome.
  • a chip is particularly useful in detecting early-stage SARS-CoV infection.
  • the non-SARS-CoV infectious organism is an infectious organism causing SARS-like symptoms.
  • Such organism includes, but not limited to, a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus.
  • the influenza virus can be influenza virus A or influenza virus B.
  • the parainfluenza virus can be parainfluenza virus 1 , parainfluenza virus 2, parainfluenza virus 3, or parainfluenza virus 4. Exemplary probes for these organisms are set forth in Table 15.
  • the non-SARS-CoV infectious organism is an infectious organism damaging an infectious host's immune system.
  • Such organism includes, but not limited to, a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum.
  • the hepatitis virus can be hepatitis virus A (HAN), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV), or hepatitis virus G (HGV).
  • the HIV can be HIV I.
  • the parvovirus can be parvovirus Bl 9. Exemplary probes are set forth in Table 16.
  • the non-SARS-CoV infectious organism is a non-SARS-CoV coronaviridae virus.
  • virus includes, but not limited to, an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat.
  • Exemplary probes for these viruses are set forth in Table 17.
  • PBEQJ0001 AGGATCAAGAAATAGATCCAATTCCGGCACTAGAACACCCACCTCTGGTGTGACATCTGATATGGCTGAT
  • PBFEJ0001 CACCACCCTCGAACAAGGAGCTAAATTTTGGTATGTATGTCCGAGAGACTTTGTTCCCAAGGGAATAGGT
  • PBPTGVJ0002 GATGGTGACCAGATAGAAGTCACGTTCACACACAAATACCACTTGCCAAAGGATGATCCTAAAACTGGAC
  • PBBOVJ0001 TATTTTTACTATCTTGGAACAGGACCGCATGCCAAAGACCAGTATGGCACCGACATTGACGGAGTCTACT
  • PBBOVJ0002 AGAACCCCTACCTCTGGTGTAACACCTGATATGGCTGATCAAATTGCTAGTCTTGTTCTGGCTAAACTTG
  • PBFIPVJ0001 GAGTGTGGTTAATCAACAGGGTGAAGCGCTGAGTCAACTTACCAGTCAGTTACAGAAAAACTTCCAGGCT
  • PBFIPVJ0002 CCGGCATTGTAGATGGTAATAAGATGGCCATGTACACAGCATCTTTAATTGGAGGTATGGCTTTGGGCTC
  • PBRJ0001 AAATGTTAAAACTTGGAACTAGTGATCCACAGTTCCCCATTCTTGCAGAGTTGGCCCCAACACCTGGTGC
  • PBRJ0002 CCCATTACTCTTGGTTTTCGGGCATTACCCAATTTCAAAAGGGAAAGGAGTTCCAGTTTGCAGATGGGCA
  • PBPHEVJ0001 TAGTAACCAGGCTGATATTAATACCCCGGCTGACATTGTCGATCGGGATCCAAGTAGCGATGAGGCTATT
  • PBPHEV 00002 TTCTTTTAAAACAGCCGATGGCAATCAGCGTCAACTGCTGCCACGATGGTACTTTTACTACCTGGGAACA
  • PBPVJ0001 GTGG ⁇ CCCCATTACTCCTGGTTTTCTGGCATTACCCAATTCCAGAAGGGAAAGGAGTTTAAG ⁇ TGCAG
  • PBPVJ0002 AAG AGTCAGGCAGAAAATTTTAAACAAGCCTCGCCAAAAGAGGACTCCAAACAAGCAGTGCCCAGTGCA PBTKJ0001 TTTGGTGATGACAAGATGAATGAGGAAGGTATTAAGGATGGGCGTGTTACGGCAATGCTCAACCTAGTCC
  • PBTKJ0002 TTTGGTGATGACAAGATGAATGAGGAAGGTATTAAGGATGGGCGTGTTACGGCAATGCTCAACCTAGTCC
  • PBSDAVJ0002 CCCCATTCTTGCAGAGTTGGCCCCAACACCTGGTGCCTTCTTCTTTGGATCTAAATTAGAATTGGTCAAA
  • the oligonucleotide probes and the target SARS-CoV and any non-SARS-CoV infectious organism nucleotide sequences can be any suitable length.
  • the oligonucleotide probes and the target SARS-CoV and any non-SARS-CoV infectious organism nucleotide sequences have a length of at least 7, 10, 20, 30, 40, 50, 60, 80, 90, 100 or more than 100 nucleotides.
  • the oligonucleotide probes and primers can be prepared by any suitable methods, e.g., chemical synthesis, recombinant methods and/or both (See generally, Ausubel et al., (Ed.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (2000)).
  • Any suitable support can be used in the present chips.
  • the support can comprise a surface that is selected from the group consisting of a silicon, a plastic, a glass, a ceramic, a rubber, and a polymer surface.
  • the present invention is directed to a method for assaying for a SARS-CoV and a non-SARS-CoV infectious organism in a sample, which methods comprises: a) providing an above-described chip; b) contacting said chip with a sample containing or suspected of containing a nucleotide sequence of a SARS-CoV and a non-SARS-CoV infectious organism under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said nucleotide sequence of said SARS-CoV or said non-S ARS-CoV infectious organism, if present in said sample, and said oligonucleotide probe complementary to a nucleotide sequence of said SARS-CoV genome or said oligonucleotide probe complementary to a nucleotide sequence of said non-SARS-CoV infectious organism genome, whereby detection of one or
  • the SARS-CoV is assayed by: a) providing a chip comprising a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotide; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and said at least two oligonucleotide probes complementary to two different nucleotide sequences of SARS-CoV genome, respectively, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample.
  • the present methods comprise: a) providing a chip comprising a nucleotide sequence of at least 10 nucleotides located within a conserved region of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a variable region of SARS-CoV genome, or a nucleotide sequence of at least 10 nucleotides located within a structural protein coding gene of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a non-structural protein coding gene of SARS-CoV genome; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and i) said oligonucleotide probe complementary to a nucleotide sequence located within a
  • the present methods comprise: a) providing a chip comprising an oligonucleotide probe complementary to a nucleotide sequence within a conserved region of SARS-CoV genome, an oligonucleotide probe, complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, at least one of the following three oligonucleotide probes: an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV sequence but is complementary to a non-SARS-CoV-sequence contained in the sample and a negative control probe that is not complementary to any nucleotide sequence contained in the sample, and a blank spot; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for
  • the present chips comprise two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe, a positive control probe and a negative control probe and the presence of the SARS-CoV is determined when: a) a positive hybridization signal is detected using at least one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV and the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV;
  • a target sequence in a variable region of SARS-CoV enables an assessment of possible mutation of the SARS-CoV. For example, detecting a positive hybridization signal using at least one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, or the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, while not detecting a positive hybridization signal using the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV indicates a mutation(s) of the SARS-CoV.
  • the present methods can be used for any suitable prognosis and diagnosis purpose.
  • the present method is used to positively identify SARS-CoV infected patients from a population of patients who have SARS-like symptoms, e.g., fever or elevated temperature, nonproductive cough, myalgia, dyspnea, elevated lactate dehydrogenase, hypocalcemia, and lymphopenia (Booth et al., JAMA, 2003 May 6; [epub ahead of print]).
  • SARS-like symptoms e.g., fever or elevated temperature, nonproductive cough, myalgia, dyspnea, elevated lactate dehydrogenase, hypocalcemia, and lymphopenia
  • the present chips, methods and kits can further comprise assaying for elevated lactate dehydrogenase, hypocalcemia, and lymphopenia, etc.
  • a chip further comprising an oligonucleotide probe complementary to a nucleotide sequence of a coronaviruse not related to the SARS-CoV is used and the method is used to positively identify SARS-CoV infected patients from patients who have been infected with a coronaviruse not related to the SARS, e.g., a coronaviruse that infects an avian species, e.g., Avian infectious bronchitis virus and Avian infectious laryngotracheitis virus, an equine species, e.g., Equine coronaviruse, a canine species, e.g., Canine coronaviruse, a feline species, e.g., Feline coronaviruse and Feline infectious peritonitis virus, a porcine species, e.g., Porcine epidemic diarrhea virus, Porcine transmissible gastroenteritis virus and Porcine hemagglutinating encephalomye
  • Puffinosis virus a rat species, e.g. , Rat coronaviruse and a Sialodacryoadenitis virus of rat, e.g., a turkey species e.g., Turkey coronaviruse, or a human species, e.g., Human enteric coronaviruse.
  • a chip comprising an oligonucleotide probes complementary to a highly expressed nucleotide sequence of SARS-CoV genome is used and the method is used to diagnose early-stage SARS patients, e.g. , SARS patients who have been infected with SARS-CoV from about less than one day to about three days.
  • the present methods are used to monitor treatment of SARS, e.g., treatment with an interferon or an agent that inhibits the replication of a variety of RNA viruses such as ribavirin.
  • the present methods can also be used to assess potential anti-S ARS-CoV agent in a drag screening assay.
  • the method of the invention can be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism causing SARS-like symptoms.
  • Non-SARS-CoV infectious organism that causing SARS-like symptoms includes, but not limited to, a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus.
  • the influenza virus can be influenza virus A or influenza virus B.
  • the parainfluenza virus can be parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 or parainfluenza virus 4.
  • the method of the invention can also be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism damaging the subject's immune system.
  • the non-SARS-CoV infectious organism damaging subject's immune system includes, but not limited to, a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum.
  • the hepatitis virus can be hepatitis virus A (HAV), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV), or hepatitis virus G (HGV).
  • the HIV can be HIV I.
  • the parvovirus can be parvovirus B 19.
  • the method of the invention can also be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV coronaviridae virus.
  • the non-S ARS-CoV coronaviridae virus includes, but not limited to, an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat.
  • any suitable SARS-CoV or non-SARS-CoV infectious organism nucleotide sequence can be assayed.
  • the SARS-CoV or the non-SARS-CoV infectious organism nucleotide sequence to be assayed can be a SARS-CoV RNA or a non-SARS-CoV infectious organism genomic sequence or a DNA sequence amplified from an extracted SARS-CoV RNA or a non-SARS-CoV infectious organism genomic sequence.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be prepared by any suitable methods.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from a SARS-CoV or the non-SARS-CoV infectious organism infected cell or other materials using the QIAamp Viral RNA kit, the Chomczynski-Sacchi technique or TRIzol (De Paula et al., J Virol. Methods, 98(2): 119-25 (2001 )).
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence is extracted from a SARS-CoV or the non-SARS-CoV infectious organism infected cell or other materials using the QIAamp Viral RNA kit.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from any suitable source.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from a sputum or saliva sample.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from a lymphocyte of a blood sample.
  • the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be amplified by any suitable methods, e.g. , PCR.
  • a label is incorporated into the amplified DNA sequence during the PCR. Any suitable PCR can be used, e.g.
  • the PCR can comprise a two-step nested PCR, the first step being a RT-PCR and the second step being a conventional PCR.
  • the PCR can comprise a one-step, multiplex RT-PCR using a plurality of 5' and 3' specific primers, each of the specific primers comprising a specific sequence complementary to its target sequence to be amplified and a common sequence, and a 5' and a 3' universal primer, the 5' universal primer being complementary to the common sequence of the 5' specific primers and the 3' universal primer being complementary to the common sequence of the 3' specific primers, and wherein in the PCR, the concentration of the 5' and 3' universal primers equals to or is higher than the concentration of the 5' and 3' specific primers, respectively.
  • the 3' universal primer and/or the 5' universal primer is labeled, e.g. , a fluorescent label.
  • the PCR comprises a multiple step nested PCR or RT-PCR.
  • the PCR is conducted using at least one of the following pairs of primers for SARS-CoV set forth in Table 18.
  • SARS-Cov Replicase PMVJ0004 GGTTTCGGATGTTACAGCGTATAACCAGTCGGTACAGCTAC I
  • SARS-Cov Replicase PMV 0005 TCACTTGCTTCCGTTGAGGGAAGCTATTCGTCACGTTCG '
  • SARS-Cov Replicase PMV 0006 GGTTTCGGATGTTACAGCGTCTGTAGAAAATCCTAGCTGGAG
  • SARS-Cov Replicase PMVJ0007 TCACTTGCTTCCGTTGAGGCCTCTCTTGTTCTTGCTCGCA
  • SARS-Cov Replicase PMVJ0008 GGTTTCGGATGTTACAGCGTGTGAGCCGCCACACATG
  • SARS-Cov Replicase PMVJ0009 TCACTTGCTTCCGTTGAGGCTAACATGCTTAGGATAATGG j
  • SARS-Cov Replicase PMVJ0010 GGTTTCGGATGTTACAGCGTCAGGTAAGCGTAAAACTCATC i
  • the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV infectious organism causing SARS-like symptoms set forth in Table 19.
  • the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV infectious organism damaging the subject's immune system set forth in Table 20.
  • the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV coronaviridae virus set forth in Table 21.
  • the present invention is directed to an oligonucleotide primer for amplifying a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence, which oligonucleotide primer comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21.
  • the present primers can comprise any suitable types of nucleic acids, e.g., DNA, RNA, PNA or a derivative thereof.
  • the primers comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21.
  • the present invention is directed to a kit for amplifying a SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, which kit comprises: a) an above-described primer; and b) a nucleic acid polymerase that can amplify a SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence using the probe.
  • the nucleic acid polymerase is a reverse transcriptase.
  • the present invention is directed to an oligonucleotide probe for hybridizing to a SARS-CoV or a non-SARS-CoV infectious organismnucleotide sequence, which oligonucleotide probe comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17.
  • the present probes can comprise any suitable types of nucleic acids, e.g., DNA, RNA, PNA or a derivative thereof.
  • the probes comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17.
  • the probes are labeled, e.g., a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label.
  • the present invention is directed to a kit for hybridization analysis of a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence
  • kit comprises: a) an above-described probe; and b) a means for assessing a hybrid formed between a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence and said probe.
  • the oligonucleotide primers and probes can be produced by any suitable method.
  • the probes can be chemically synthesized (See generally, Ausubel (Ed.) Current Protocols in Molecular Biology, 2.11. Synthesis and purification of oligonucleotides, John Wiley & Sons, Inc.
  • Synthetic oligonucleotides can also be prepared by using the triester method of Matteucci et al., J. Am. Chem. Soc, 3:3185-3191 (1981). Alternatively, automated synthesis may be preferred, for example, on a Applied Biosynthesis DNA synthesizer using cyanoethyl phosphoramidite chemistry. Preferably, the probes and the primers are chemically synthesized.
  • Suitable bases for preparing the oligonucleotide probes and primers of the present invention may be selected from naturally occurring nucleotide bases such as adenine, cytosine, guanine, uracil, and thymine. It may also be selected from nonnaturally occurring or "synthetic" nucleotide bases such as 8-oxo-guanine, 6-mercaptoguanine, 4-acetylcytidine, 5-(carboxyhydroxyethyl) uridine, 2'-O-methylcytidine,
  • 5-carboxymethylamino-methyl-2-thioridine 5-carboxymethylaminomethyl uridine, dihydrouridine, 2'-O-methylpseudouridine, beta-D-galactosylqueosine, 2'-Omethylguanosine, inosine, N6 -isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6 -methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine, beta-D-mannosylqueosine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6 -isopentenyladenosine, N-(
  • oligonucleotides e.g., oligonucleotides in which the phosphodiester bonds have been modified, e.g., to the methylphosphonate, the phosphotriester, the phosphorothioate, the phosphorodithioate, or the phosphora idate
  • Protection from degradation can be achieved by use of a "3 '-end cap” strategy by which nuclease-resistant linkages are substituted for phosphodiester linkages at the 3' end of the oligonucleotide (Shaw et al., Nucleic Acids Res., 19:747 (1991)).
  • Phosphoramidates, phosphorothioates, and methylphosphonate linkages all function adequately in this manner. More extensive modification of the phosphodiester backbone has been shown to impart stability and may allow for enhanced affinity and increased cellular permeation of oligonucleotides (Milligan et al., J. Med. Chem., 36:1923 (1993)). Many different chemical strategies have been employed to replace the entire phosphodiester backbone with novel linkages.
  • Backbone analogues include phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, boranophosphate, phosphotriester, formacetal, 3 '-thioformacetal, 5'-thioformacetal, 5'-thioether, carbonate, 5'-N-carbamate, sulfate, sulfonate, sulfamate, sulfonamide, sulfone, sulfite, sulfoxide, sulfide, hydroxylamine, methylene (methylimino) (MMI) or methyleneoxy (methylimino) (MOMI) linkages.
  • MMI methylene (methylimino)
  • MOMI methyleneoxy (methylimino)
  • oligonucleotide may be a "peptide nucleic acid" such as described by (Milligan et al., J. Med. Chem., 36:1923 (1993)).
  • the only requirement is that the oligonucleotide probe should possess a sequence at least a portion of which is capable of binding to a portion of the sequence of a target SARS-CoV sequence.
  • Hybridization probes or amplification primers can be of any suitable length.
  • the probes and primers of the present invention can be as short as 50, 40, 30, 20, 15, or 10 nucleotides, or shorter.
  • the probes or primers can be as long as 20, 40, 50, 60, 75, 100 or 200 nucleotides, or longer, e.g., to the full length of the SARS-CoV or the non-SARS-CoV infectious organism target sequence.
  • the probes will have at least 14 nucleotides, preferably at least 18 nucleotides, and more preferably at least 20 to 30 nucleotides of either of the complementary target nucleic acid strands and does not contain any hairpin secondary structures.
  • the probe can have a length of at least 30 nucleotides or at least 50 nucleotides. If there is to be complete complementarity, i.e., if the strand contains a sequence identical to that of the probe, the duplex will be relatively stable under even stringent conditions and the probes may be short, i.e., in the range of about 10-30 base pairs.
  • the probe may be of greater length (i.e., 15-40 bases) to balance the effect of the mismatch(es).
  • the probe need not span the entire SARS-CoV or the non-SARS-CoV infectious organism target gene. Any subset of the target region that has the potential to specifically identify SARS-CoV or the non-SARS-CoV infectious organism target or alelle can be used. Consequently, the nucleic acid probe may hybridize to as few as 8 nucleotides of the target region.
  • fragments of the probes may be used so long as they are sufficiently characteristic of the SARS-CoV or the non-S ARS-CoV infectious organism target gene to be typed.
  • the probe or primer should be able to hybridize with a SARS-CoV or a non-SARS-CoV infectious organism target nucleotide sequence that is at least 8 nucleotides in length under low stringency.
  • the probe or primer hybridizes with a SARS-CoV or a non-SARS-CoV infectious organism target nucleotide sequence under middle or high stringency.
  • the present invention is directed to an array of oligonucleotide probes immobilized on a support for typing a SARS-CoV or a non-SARS-CoV infectious organism target gene, which array comprises a support suitable for use in nucleic acid hybridization having immobilized thereon a plurality of oligonucleotide probes, at least one of said probes comprising a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17.
  • the plurality of probes can comprise DNA, RNA, PNA or a derivative thereof. At least one or some of the probes can comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17. Preferably, probe arrays comprise all of the nucleotide sequences, or a complementary strand thereof, that are set forth in Table 13 or Tables 15-17. At least one, some or all of the probes can be labeled. Exemplary labels include a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label. Any suitable support, e.g., a silicon, a plastic, a glass, a ceramic, a rubber, and a polymer surface, can be used.
  • probes and probe arrays can be used in solution. Preferably, it is conducted in chip format, e.g. , by using the probe(s) immobilized on a solid support.
  • the probes can be immobilized on any suitable surface, preferably, a solid support, such as silicon, plastic, glass, ceramic, rubber, or polymer surface.
  • the probe may also be immobilized in a 3 -dimensional porous gel substrate, e.g., Packard HydroGel chip (Broude et al., Nucleic Acids Res. , 29 ⁇ 19):E92 (2001 )).
  • the probes are preferably immobilized to a solid support such as a "biochip".
  • the solid support may be biological, nonbiological, organic, inorganic, or a combination of any of these, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc.
  • a microarray biochip containing a library of probes can be prepared by a number of well known approaches including, for example, light-directed methods, such as VLSIPSTM described in U.S. Patent Nos. 5,143,854, 5,384,261 or 5,561,071; bead based methods such as described in U.S. Patent No.
  • U.S. Patent No. 5,556,752 which details the preparation of a library of different double stranded probes as a microarray using the VLSIPSTM, is also suitable for preparing a library of hairpin probes in a microarray.
  • Flow channel methods such as described in U.S. Patent Nos. 5,677,195 and 5,384,261, can be used to prepare a microarray biochip having a variety of different probes. In this case, certain activated regions of the substrate are mechanically separated from other regions when the probes are delivered through a flow channel to the support. A detailed description of the flow channel method can be found in U.S.
  • Patent No. 5,556,752 including the use of protective coating wetting facilitators to enhance the directed channeling of liquids though designated flow paths.
  • Sporting methods also can be used to prepare a microarray biochip with a variety of probes immobilized thereon.
  • reactants are delivered by directly depositing relatively small quantities in selected regions of the support.
  • the entire support surface can be sprayed or otherwise coated with a particular solution.
  • a dispenser moves from region to region, depositing only as much probe or other reagent as necessary at each stop.
  • Typical dispensers include micropipettes, nanopippettes, ink-jet type cartridges and pins to deliver the probe containing solution or other fluid to the support and, optionally, a robotic system to control the position of these delivery devices with respect to the support.
  • the dispenser includes a series of tubes or multiple well trays, a manifold, and an array of delivery devices so that various reagents can be delivered to the reaction regions simultaneously.
  • Spotting methods are well known in the art and include, for example, those described in U.S. Patent Nos. 5,288,514, 5,312,233 and 6,024,138.
  • a combination of flow channels and "spotting" on predefined regions of the support also can be used to prepare microarray biochips with immobilized probes.
  • a solid support for immobilizing probes is preferably flat, but may take on alternative surface configurations.
  • the solid support may contain raised or depressed regions on which probe synthesis takes place or where probes are attached.
  • the solid support can be chosen to provide appropriate light-absorbing characteristics.
  • the support may be a polymerized Langmuir Blodgett film, glass or functionalized glass, Si, Ge, GaAs, GaP, SiO 2 , SiN , modified silicon, or any one of a variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidendifluoride, polystyrene, polycarbonate, or combinations thereof.
  • the surface of the solid support can contain reactive groups, which include carboxyl, amino, hydroxyl, thiol, or the like, suitable for conjugating to a reactive group associated with an oligonucleotide or a nucleic acid.
  • the surface is optically transparent and will have surface Si-OH functionalities, such as those found on silica surfaces.
  • the probes can be attached to the support by chemical or physical means such as through ionic, covalent or other forces well known in the art. Immobilization of nucleic acids and oligonucleotides can be achieved by any means well known in the art (see, e.g.
  • the probes can be attached to a support by means of a spacer molecule, e.g. , as described in U.S. Patent No. 5,556,752 to Lockhart et al., to provide space between the double stranded portion of the probe as may be helpful in hybridization assays.
  • a spacer molecule typically comprises between 6-50 atoms in length and includes a surface attaching portion that attaches to the support. Attachment to the support can be accomplished by carbon-carbon bonds using, for example, supports having (poly)trifluorochloroethylene surfaces, or preferably, by siloxane bonds (using, for example, glass or silicon oxide as the solid support). Siloxane bonding can be formed by reacting the support with trichlorosilyl or trialkoxysilyl groups of the spacer.
  • Aminoalkylsilanes and hydroxyalkylsilanes, bis(2-hydroxyethyl)-aminopropyltriethoxysilane, 2-hydroxyethylamino ⁇ ropyltriethoxysilane, aminopropyitriethoxysilane or hydroxypropyltriethoxysilane are useful are surface attaching groups.
  • the spacer can also include an extended portion or longer chain portion that is attached to the surface-attaching portion of the probe.
  • amines, hydroxyl, thiol, and carboxyl groups are suitable for attaching the extended portion of the spacer to the surface-attaching portion.
  • the extended portion of the spacer can be any of a variety of molecules which are inert to any subsequent conditions for polymer synthesis. These longer chain portions will typically be aryl acetylene, ethylene glycol oligomers containing 2-14 monomer units, diamines, diacids, amino acids, peptides, or combinations thereof.
  • the extended portion of the spacer is a polynucleotide or the entire spacer can be a polynucleotide.
  • the extended portion of the spacer also can be constructed of polyethyleneglycols, polynucleotides, alkylene, polyalcohol, polyester, polyamine, polyphosphodiester and combinations thereof.
  • the spacer can have a protecting group attached to a functional group (e.g., hydroxyl, amino or carboxylic acid) on the distal or terminal end of the spacer (opposite the solid support). After deprotection and coupling, the distal end can be covalently bound to an oligomer or probe.
  • the present method can be used to analyze a single sample with a single probe at a time. Preferably, the method is conducted in high-throughput format. For example, a plurality of samples can be analyzed with a single probe simultaneously, or a single sample can be analyzed using a plurality of probes simultaneously. More preferably, a plurality of samples can be analyzed using a plurality of probes simultaneously.
  • Hybridization can be carried out under any suitable technique known in the art. It will be apparent to those skilled in the art that hybridization conditions can be altered to increase or decrease the degree of hybridization, the level of specificity of the hybridization, and the background level of non-specific binding (i.e., by altering hybridization or wash salt concentrations or temperatures).
  • the hybridization between the probe and the target nucleotide sequence can be carried out under any suitable stringencies, including high, middle or low stringency. Typically, hybridizations will be performed under conditions of high stringency.
  • Hybridization between the probe and target nucleic acids can be homogenous, e.g., typical conditions used in molecular beacons (Tyagi S.
  • the target polynucleotide sequence may be detected by hybridization with an oligonucleotide probe that forms a stable hybrid with that of the target sequence under high to low stringency hybridization and wash conditions.
  • the probes will be completely complementary (i.e., about 99% or greater) to the target sequence. If it is expected that the probes will be completely complementary (i.e., about 99% or greater) to the target sequence, high stringency conditions will be used. If some mismatching is expected, for example, if variant strains are expected with the result that the probe will not be completely complementary, the stringency of hybridization may be lessened. However, conditions are selected to minimize or eliminate nonspecific hybridization. Conditions those affect hybridization and those select against nonspecific hybridization are known in the art (Molecular Cloning A Laboratory Manual, second edition, J. Sambrook, E. Fritsch, T. Maniatis, Cold Spring Harbor Laboratory Press, 1989). Generally, lower salt concentration and higher temperature increase the stringency of hybridization.
  • stringent hybridization conditions include incubation in solutions that contain approximately 0.1XSSC, 0.1% SDS, at about 65°C incubation/wash temperature.
  • Middle stringent conditions are incubation in solutions that contain approximately 1-2XSSC, 0.1% SDS and about 50°C - 65°C incubation/wash temperature.
  • the low stringency conditions are 2XSSC and about 30°C - 50°C.
  • An alternate method of hybridization and washing is first to carry out a low stringency hybridization (5XSSPE, 0.5% SDS) followed by a high stringency wash in the presence of 3M tetramethyl-ammonium chloride (TMAC).
  • TMAC tetramethyl-ammonium chloride
  • TMAC The effect of the TMAC is to equalize the relative binding of A-T and G-C base pairs so that the efficiency of hybridization at a given temperature corresponds more closely to the length of the polynucleotide.
  • TMAC it is possible to vary the temperature of the wash to achieve the level of stringency desired (Wood et al., Proc. Natl. Acad. Sci. USA, 82:1585-1588 (1985)).
  • a hybridization solution may contain 25% formamide, 5XSSC, 5XDenhardt's solution, 100 ⁇ g/ml of single stranded DNA, 5% dextran sulfate, or other reagents known to be useful for probe hybridization.
  • the Hybrid Detection of the Hybrid Detection of hybridization between the probe and the target SARS-CoV nucleic acids can be carried out by any method known in the art, e.g. , labeling the probe, the secondary probe, the target nucleic acids or some combination thereof, and are suitable for purposes of the present invention.
  • the hybrid may be detected by mass spectroscopy in the absence of detectable label (e.g., U.S. Patent No. 6,300,076).
  • the detectable label is a moiety that can be detected either directly or indirectly after the hybridization.
  • a detectable label has a measurable physical property (e.g., fluorescence or absorbance) or is participant in an enzyme reaction.
  • the target nucleotide sequence or the probe is labeled, and the formation of the hybrid is assessed by detecting the label in the hybrid.
  • a secondary probe is labeled, and the formation of the hybrid is assessed by the detection of a secondary hybrid formed between the secondary probe and the original hybrid.
  • Methods of labeling probes or nucleic acids are well known in the art. Suitable labels include fluorophores, chromophores, luminophores, radioactive isotopes, electron dense reagents, FRET(fluorescence resonance energy transfer), enzymes and ligands having specific binding partners. Particularly useful labels are enzymatically active groups such as enzymes (Wisdom, Clin.
  • ligands specifically bindable ligands, i.e., protein binding ligands; antigens; and residues comprising radioisotopes such as 3 H, 35 S, 32 P, I, and 14 C.
  • ligands specifically bindable ligands, i.e., protein binding ligands; antigens; and residues comprising radioisotopes such as 3 H, 35 S, 32 P, I, and 14 C.
  • Such labels are detected on the basis of their own physical properties (e.g., fluorescers, chromophores and radioisotopes) or their reactive or binding properties (e.g. , antibodies, enzymes, substrates, coenzymes and inhibitors).
  • Ligand labels are also useful for solid phase capture of the oligonucleotide probe (i.e., capture probes).
  • Exemplary labels include biotin (detectable by binding to labeled avidin or streptavidin) and enzymes, such as horseradish peroxidase or alkaline phosphatase (detectable by addition of enzyme substrates to produce a colored reaction product).
  • a radioisotope-labeled probe or target nucleic acid can be detected by autoradiography.
  • the probe or the target nucleic acid labeled with a fluorescent moiety can detected by fluorimetry, as is known in the art.
  • a hapten or ligand (e.g., biotin) labeled nucleic acid can be detected by adding an antibody or an antibody pigment to the hapten or a protein that binds the labeled ligand (e.g.
  • the probe or nucleic acid may be labeled with a moiety that requires additional reagents to detect the hybridization.
  • the label is an enzyme
  • the labeled nucleic acid e.g., DNA
  • a suitable medium to determine the extent of catalysis.
  • a cofactor-labeled nucleic acid can be detected by adding the enzyme for which the label is a cofactor and a substrate for the enzyme.
  • the enzyme is a phosphatase
  • the medium can contain nitrophenyl phosphate and one can monitor the amount of nitrophenol generated by observing the color.
  • the medium can contain o-nitro-phenyl-D-galacto-pyranoside, which also liberates nitrophenol.
  • exemplary examples of the latter include, but are not limited to, beta-galactosidase, alkaline phosphatase, papain and peroxidase.
  • the final product of the substrate is preferably water insoluble.
  • Other labels, e.g. , dyes, will be evident to one having ordinary skill in the art.
  • the label can be linked directly to the DNA binding ligand, e.g., acridine dyes, phenanthridines, phenazines, furocoumarins, phenothiazines and quinolines, by direct chemical linkage such as involving covalent bonds, or by indirect linkage such as by the incorporation of the label in a microcapsule or liposome, which in turn is linked to the binding ligand.
  • acridine dyes e.g., acridine dyes, phenanthridines, phenazines, furocoumarins, phenothiazines and quinolines
  • direct chemical linkage such as involving covalent bonds
  • indirect linkage such as by the incorporation of the label in a microcapsule or liposome, which in turn is linked to the binding ligand.
  • intercalating agents include mono-or bis-azido aminoalkyl methidium or ethidium compounds, ethidium monoazide ethidium diazide, ethidium dimer azide (Mitchell et al., J. Am. Chem. Soc, 104:4265 (1982))), 4-azido-7-chloroquinoline, 2-azidofluorene, 4'-aminomethyl-4,5'-dimethylangelicin, 4'-aminomethyl-trioxsalen (4'aminomethyl-4,5 , ,8-trimethyl-psoralen), 3-carboxy-5- or -8-amino- or -hydroxy-psoralen.
  • nucleic acid binding azido compound has been described by Forster et al., Nucleic Acid Res., 13:745 (1985).
  • Other useful photoreactable intercalators are the furocoumarins which form (2+2) cycloadducts with pyrimidine residues.
  • Alkylating agents also can be used as the DNA binding ligand, including, for example, bis-chloroethylamines and epoxides or aziridines, e.g., aflatoxins, polycyclic hydrocarbon epoxides, mitomycin and norphillin A.
  • Particularly useful photoreactive forms of intercalating agents are the azidointercalators.
  • the probe may also be modified for use in a specific format such as the addition of 10-100 T residues for reverse dot blot or the conjugation to bovine serum albumin or immobilization onto magnetic beads.
  • a detectably labeled second probe(s) can be added after initial hybridization between the probe and the target or during hybridization of the probe and the target.
  • the hybridization conditions may be modified after addition of the secondary probe.
  • unhybridized secondary probe can be separated from the initial probe, for example, by washing if the initial probe is immobilized on a solid support.
  • detection of label bound to locations on the support indicates hybridization of a target nucleotide sequence in the sample to the probe.
  • the detectably labeled secondary probe can be a specific probe.
  • the detectably labeled probe can be a degenerate probe, e.g., a mixture of sequences such as whole genomic DNA essentially as described in U.S. Patent No. 5,348,855. In the latter case, labeling can be accomplished with intercalating dyes if the secondary probe contains double stranded DNA.
  • a secondary probe also can be a library of random nucleotide probe sequences.
  • the length of a secondary probe should be decided in view of the length and composition of the primary probe or the target nucleotide sequence on the solid support that is to be detected by the secondary probe.
  • Such a probe library is preferably provided with a 3 ' or 5' end labeled with photoactivatable reagent and the other end loaded with a detection reagent such as a fluorophore, enzyme, dye, luminophore, or other detectably known moiety.
  • a detection reagent such as a fluorophore, enzyme, dye, luminophore, or other detectably known moiety.
  • the particular sequence used in making the labeled nucleic acid can be varied.
  • an amino-substituted psoralen can first be photochemically coupled with a nucleic acid, the product having pendant amino groups by which it can be coupled to the label, i.e., labeling is carried out by photochemically reacting a DNA binding ligand with the nucleic acid in the test sample.
  • the psoralen can first be coupled to a label such as an enzyme and then to the nucleic acid.
  • the DNA binding ligand is first combined with label chemically and thereafter combined with the nucleic acid probe.
  • biotin since biotin carries a carboxyl group, it can be combined with a furocoumarin by way of amide or ester formation without interfering with the photochemical reactivity of the furocoumarin or the biological activity of the biotin.
  • Aminomethylangelicin, psoralen and phenanthridium derivatives can similarly be linked to a label, as can phenanthridium halides and derivatives thereof such as aminopropyl methidium chloride (Hertzberg et al, J. Amer. Chem. Soc, 104:313 (1982)).
  • a bifunctional reagent such as dithiobis succinimidyl propionate or 1,4-butanediol diglycidyl ether can be used directly to couple the DNA binding ligand to the label where the reactants have alkyl amino residues, again in a known manner with regard to solvents, proportions and reaction conditions.
  • Certain bifunctional reagents possibly glutaraldehyde may not be suitable because, while they couple, they may modify nucleic acid and thus interfere with the assay. Routine precautions can be taken to prevent such difficulties.
  • the DNA binding ligand can be linked to the label by a spacer, which includes a chain of up to about 40 atoms, preferably about 2 to 20 atoms, including, but not limited to, carbon, oxygen, nitrogen and sulfur.
  • a spacer can be the polyfunctional radical of a member including, but not limited to, peptide, hydrocarbon, polyalcohol, polyether, polyamine, polyimine and carbohydrate, e.g., -glycyl-glycyl-glycyl- or other oligopeptide, carbonyl dipeptides, and omega-amino-alkane-carbonyl radical or the like.
  • Sugar, polyethylene oxide radicals, glyceryl, pentaerythritol, and like radicals also can serve as spacers.
  • Spacers can be directly linked to the nucleic acid-binding ligand and/or the label, or the linkages may include a divalent radical of a coupler such as dithiobis succinimidyl propionate, 1,4-butanediol diglycidyl ether, a diisocyanate, carbodiimide, glyoxal, glutaraldehyde, or the like.
  • Secondary probe for indirect detection of hybridization can be also detected by energy transfer such as in the "beacon probe" method described by Tyagi and Kramer, Nature Biotech.
  • any FRET detection system known in the art can be used in the present method.
  • the AlphaScreenTM system can be used.
  • AlphaScreen technology is an "Amplified Luminescent Proximity Homogeneous Assay" method. Upon illumination with laser light at 680 nm, a photosensitizer in the donor bead converts ambient oxygen to singlet-state oxygen. The excited singlet-state oxygen molecules diffuse approximately 250 nm (one bead diameter) before rapidly decaying.
  • the singlet-state oxygen molecules reacts with chemiluminescent groups in the acceptor beads, which immediately transfer energy to fluorescent acceptors in the same bead. These fluorescent acceptors shift the emission wavelength to 520-620 nm. The whole reaction has a 0.3 second half-life of decay, so measurement can take place in time-resolved mode.
  • FRET donor/acceptor pairs include Fluorescein (donor) and tetramemylrhodamine (acceptor) with an effective distance of 55 A; IAEDANS (donor) and Fluorescein (acceptor) with an effective distance of 46A; and Fluorescein (donor) and QSY-7 dye (acceptor) with an effective distance of 61 A (Molecular Probes).
  • Quantitative assays for nucleic acid detection also can be performed according to the present invention.
  • the amount of secondary probe bound to a microarray spot can be measured and can be related to the amount of nucleic acid target which is in the sample. Dilutions of the sample can be used along with controls containing known amount of the target nucleic acid.
  • the detectable label can be visualized or assessed by placing the probe array next to x-ray film or phosphoimagers to identify the sites where the probe has bound. Fluorescence can be detected by way of a charge-coupled device (CCD) or laser scanning. Test samples Any suitable samples, including samples of human, animal, or environmental (e.g., soil or water) origin, can be analyzed using the present method.
  • Test samples can include body fluids, such as urine, blood, semen, cerebrospinal fluid, pus, amniotic fluid, tears, or semisolid or fluid discharge, e.g., sputum, saliva, lung aspirate, vaginal or urethral discharge, stool or solid tissue samples, such as a biopsy or chorionic villi specimens.
  • Test samples also include samples collected with swabs from the skin, genitalia, or throat.
  • Test samples can be processed to isolate nucleic acid by a variety of means well known in the art (See generally, Ausubel (Ed.) Current Protocols in Molecular Biology, 2. Preparation and Analysis of DNA and 4. Preparation and Analysis of RNA, John Wiley & Sons, Inc. (2000)).
  • target nucleic acids can be RNA or DNA that may be in form of direct sample or purified nucleic acid or amplicons.
  • Purified nucleic acids can be extracted from the aforementioned samples and may be measured spectraphotometrically or by other instrument for the purity.
  • amplicons are obtained as end products by various amplification methods such as PCR (Polymerase Chain Reaction, U.S. Patent Nos. 4,683,195, 4,683,202, 4,800,159 and 4,965,188), NASBA (Nucleic Acid Sequence Based Amplification, U.S. Patent No.
  • a sample of human origin is assayed.
  • a sputum, urine, blood, tissue section, food, soil or water sample is assayed.
  • Kits The present probes can be packaged in a kit format, preferably with an instruction for using the probes to detect a target gene.
  • the components of the kit are packaged together in a common container, typically including written instructions for performing selected specific embodiments of the methods disclosed herein.
  • Components for detection methods, as described herein, may optionally be included in the kit, for example, a second probe, and/or reagents and means for carrying out label detection (e.g., radiolabel, enzyme substrates, antibodies, etc., and the like).
  • Table 23 shows similarities or homologies among the nine genomes of SARS coronaviruse. Table 23. Comparison of similarities between the nine genomes of SARS coronaviruse
  • the similarity of the nine genomes of SARS coronaviruse were compared.
  • the numbers shown in the Table 23 represent the percentage of similarity between two genomes. Each number in Table 23 equals to the number of the same bases in two genomes divided by the total number of bases (about 30,000 bases) compared and then timed by 100.
  • Table 23 shows that the different genomes of SARS coronaviruse are highly similar to each other except B J04. The similarity lower than 99% is caused by the presence of N in the nucleotide sequence. If all the Ns in the nucleotide sequences from BJ01-BJ04 and GZ01 are considered as the same with other genome (this assumption is reasonable based on comparison of other part of the genomes), the nine genomes are 99% similar to each other. Since SARS coronaviruse is conservative as shown in Tables 22 and 23, nucleic acid based detection methods are rational. Figure IB indicates that detection of different parts of SARS coronaviruse genome at the same time can significantly increase the sensitivity and specificity of the detection method. We have two overall designs.
  • One design is to perform a multiplex PCR for different parts of SARS coronaviruse genome and use PCR products as probes for detection.
  • the second design is to perform a multiplex PCR for different parts of SARS coronaviruse genome and use a 70 mer oligonucleotides as probes for detection.
  • Target gene selection Based on analysis of SARS coronaviruse genome, we selected three genes as target genes. These three genes are orf 1 A and IB polymerase proteins, spike protein, and nucleocapsid protein.
  • GAPD glycosyl-glyceraldehyde 3-phosphate dehydrogenase
  • a gene (Arabidopsis ) (GenBank Ace: AJ441252), which has no homology to nucleotide sequence of human and common pathogens, as incorporated positive control.
  • Example 2 Process for pretreatment of blood sample Pretreatment of blood sample involves relatively complicated processes.
  • sample collection and transfer 1) Samples collected from patients in the hospital room are put in a first transfer window. The door of the window is then closed and locked. 2) The samples are then transferred into a second transfer window. The samples are recorded in a notebook and three bar code labels are printed. The samples are tested for conventional detection and transferred into a pretreatment transfer window.
  • biosafe cabinet Hospital personnel for performing pretreatment process enters the pretreatment room and close the door. The biosafe cabinet is then turned on. The fan of the cabinet and light are then automatically turned on. 2) The indicator lights for power switch, air speed switch, and work light switch are checked for normal operation. The indicator light for air selection switch is checked as off status. Abnormal or unusual operation is reported. 3) The indicator light for alarm switch will make an alarm sound which indicates normal status of the biosafe cabinet after self-testing. Fifteen minutes later, the alarm sound from the indicator light for alarm switch is stopped and the process in the biosafe cabinet can be started. 4) The process in the cabinet cannot be started if the alarm sound continues or the process has to be stopped if there is an alarm sound during the process. The incident has to be reported immediately.
  • Serum isolation 1) Blood (1.8 ml) with anticoagulant is centrifuged for 10 minutes at 3,500 rpm. The top layer is marked with a marker pen. 2) The top layer serum (about 1.0 ml) is then collected and put into a 1.5 ml sterile Eppendorf centrifuge tube. 3) The Eppendorf centrifuge tube is labeled with the bar code (marked as "P") and labeled with a sequence number. 4) The sample is then recorded in a notebook. 5) The centrifuge tube containing the serum sample is put in a specialized sample box and stored at -80°C. The outside of the sample box is labeled with SARS, serum and range of sample numbers. 4.
  • Lymphocyte isolation solution (3.6 ml) is added to a 10 ml centrifuge tube. 2) Sterile physiological saline (a volume equal to the serum taken out in the centrifuge tube described above) is added to the centrifuge tube containing the blood cells. The blood cells are resuspended in saline using Pasteur pipette. 3) The resuspended blood cells are slowly loaded on top of the lymphocyte isolation solution and centrifuged for 20 minutes at 1,500 rpm. 4) The cells located between the layers are collected and put in a 1.5 ml sterile Eppendorf centrifuge tube, which is then centrifuged for 5 minutes at 10,000 rpm to spin down the cells. The supernatant is withdrawn.
  • the tube containing the cell pellet is then labeled with the bar code (marked "C") and labeled with a sequence number. 6)
  • the sample is recorded in a notebook.
  • the centrifuge tube containing the blood cell sample is put in a specialized sample box and stored at -80°C. The outside of the sample box is labeled with SARS, blood cells, and range of sample numbers.
  • the glass face plate of the biosafe cabinet is then opened. The bench surface and other surfaces in the biosafe cabinet are then sterilized by wiping with 70% alcohol and spraying 0.5% peracetic acid. 9) After cleaning, the glass face plate is closed. The ultraviolet light is placed inside the cabinet and turned on for 15 minutes.
  • the power switch of the biosafe cabinet is turned off before leaving the sample pretreatment room. 5. Matters needing attention 1) The lymphocyte isolation solution should not be used immediately after being taken out of the refrigerator. The solution should be used after its temperature reaches room temperature and the solution is mixed well. 2) The whole isolation process should be performed at 18-28°C. Too high or too low temperature can impact on the quality of isolation process. 3) The pipette tips, Eppendorf centrifuge tubes, gloves, and disposed reagents or liquids should be discarded in a waist tank (containing 0.5% peracetic acid). Everything in the waster tank should be treated at high pressure after experiment and then discarded. 4) 0.5%) of peracetic acid is prepared by diluting 32 ml of 16% of peracetic acid in H 2 O to make a final volume of 1,000 ml.
  • Example 3 Process for extracting RNA using QIAamp Viral RNA kit The following procedures are used in RNA preparation: 1. Pipet 560 ⁇ l of prepared Buffer AVL containing Carrier RNA into a 1.5-ml microcentrif ⁇ ge tube. If the sample volume is larger than 140 ⁇ l, increase the amount of Buffer AVL/Carrier RNA proportionally (e.g., a 280- ⁇ l sample will require 1120 ⁇ l Buffer AVL/Carrier RNA). 2. Add 140 ⁇ l plasma, serum, urine, cell-culture supernatant, or cell-free body fluid to the Buffer AVL/Carrier RNA in the microcentrifuge tube. Mix by pulse-vortexing for 15 sec.
  • Step 9a Close the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. Continue directly with step 10, or to eliminate any chance of possible Buffer AW2 carryover, perform step 9a, and then continue with step 10.
  • Residual Buffer AW2 in the eluate may cause problems in downstream applications. Some centrifuge rotors may vibrate upon deceleration, resulting in flow-through, containing Buffer AW2, contacting the QIAamp spin column. Removing the QIAamp spin column and collection tube from the rotor may also cause flowthrough to come into contact with the QIAamp spin column. In these cases, the optional step 9a should be performed. 9a.
  • RNA is stable for up to one year when stored at -20°C or -70°C.
  • Equilibrate samples to room temperature 15-25°C.
  • ® Check whether Buffer AW 1 , Buffer AW2, and Carrier R A have been prepared according to the instructions on pages 14-15.
  • Redissolve precipitate in Buffer AVL/Carrier RNA by heating, if necessary, and cool to room temperature before use. • All centrifugation steps are carried out at room temperature.
  • Example 4 An exemplary array format of SARS-CoV detection chip
  • Figure 5 illustrates an exemplary array format of SARS-CoV detection chip.
  • Immobilization control is an oligo-probe that is labeled by a fluorescent dye HEX on its end and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • Positive control(Arabidopsis) is an oligo-probe designed according to an Arabidopsis (one kind of model organism) gene and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • target probes that can hybridize with this positive control perfectly are added into the hybridization solution.
  • Negative control is an oligo-probe that does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • Blank Control is DMSO solution spot. It is used for monitoring arraying quality.
  • SARS probes are 011, 024, 040 and 044 probes.
  • FIG. 5 SARS-CoV detection from a SARS patient blood sample (sample No. 3)
  • Figures 6A and 6B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 3).
  • Lymphocytes were isolated from 3# SARS patient blood sample.
  • RNA from lymphocytes was extracted by QIAamp Kit.
  • RT-nest PCR was performed using RNA extracted above as templates. 044 RT-nest PCR result was good and hybridization result was good too. 040 RT-nest PCR result was poor but hybridization result was good. It shows that the chip-hybridization method is sensitive and specific.
  • Example 6 SARS-CoV detection from a SARS patient blood sample (sample No. 4)
  • Figures 7A and 7B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 4).
  • Lymphocytes were isolated from 4# SARS patient blood sample.
  • RNA from lymphocytes was extracted by QIAamp Kit.
  • RT-nest PCR was performed using RNA extracted above as templates. 024, 040 and 044 RT-nest PCR results were good and hybridization results were good too.
  • Example 7 SARS-CoV detection from a SARS patient sputum sample (sample No. 5)
  • Figure 8 illustrates SARS-CoV detection from a SARS patient sputum sample (sample No. 5).
  • RNA from 5# SARS patient sputum sample was extracted by QIAamp Kit.
  • RT-nest PCR was performed using RNA extracted above as templates. 040 RT-nest PCR result was good and hybridization result was
  • Example 8 SARS-CoV detection from a SARS patient sputum sample (sample No. 6)
  • Figure 9 illustrates SARS-CoV detection from a SARS patient sputum sample (sample No. 6).
  • RNA from 6# SARS patient sputum sample was extracted by QIAamp Kit.
  • RT-nest PCR was performed using RNA extracted above as templates. All probes RT-nest PCR results were good and hybridization results were good too.
  • Example 9 Another exemplary array format of SARS-CoV detection chip
  • Figure 10 illustrates another exemplary array format of SARS-CoV detection chip.
  • Immobilization control is an oligo-probe that is labeled by a fluorescent dye HEX on its end and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • Positive control is an oligo-probe designed according to an Arabidopsis (one kind of model organism) gene and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • target probes that can hybridize with this positive control perfectly are added into the hybridization solution.
  • Negative control is an oligo-probe that does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip.
  • Blank Control is DMSO solution spot. It is used for monitoring arraying quality.
  • SARS probes are 011, 024, 040 and 044 probes.
  • Example 10 Possible positive results on the SARS-CoV detection chip illustrated in Figure 10
  • Figure 11 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 10. There are four sets probes on chips for detecting SARS virus: probe 011, probe 024, probe 040 and probe 044.
  • the first line gives the positive result (1) by signals appearing on all four sets of probes: 011+024+040+044.
  • the second line gives all the possible positive results (4) by signals appearing on three sets probes: 011+024+044, 024+040+044, 011+040+044, 011+024+040.
  • the third line gives all the possible positive results (6) by signals appearing on two sets probes: 011+040, 024+044, 011+044, 040+044, 011+024, 024+040.
  • the fourth line gives all the possible positive results (4) by signals appearing on only one set probes: 011, 024, 040, 044. Example 11. Possible results on the SARS-CoV detection chip illustrated in
  • Figure 12 illustrates all possible positive results on the SARS-CoV detection chip illustrated in Figure 12. There are four sets of probes on chips for detecting SARS virus: probe 011, probe 024, probe 040 and probe 044. The possible positive and negative results are also illustrated in Figure 14.
  • the combinations for positive results include: • 011 + 127; • 040 + 127; • 011 + 127 + 024; 011 + 127 + 044; 024 + 127 + 044; 011 + 127 + 024 + 040; 024 + 127; 044 + 127; 011 + 127 + 040; • 024 + 127 + 040; • 011 + 127 + 044; • 011 + 127 + 024 + 044; • 011 + 127 + 024 + 044; • 011 + 127 + 024 + 044; • 011 + 127 + 024 + 040 + 044; and • 127 + 024 + 040 + 044.
  • a negative result is indicated if only 127 is observed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

This invention relates generally to the field of virus detection. In particular, the invention provides chips, probes, primers, kits and methods for amplifying and detecting SARS-CoV nucleotides sequence. The clinical and other uses of the present chips, probes, primers, kits and methods are also contemplated.

Description

METHODS AND COMPOSITIONS FOR DETECTING SARS VIRUS AND OTHER INFECTIOUS AGENTS
BACKGROUND OF THE INVENTION Since November of 2002, a disease called severe acute respiratory syndrome
(SARS) has been reported in twenty two countries around the world. WHO has reported 6,054 cumulative cases of SARS and 417 death among infected people as of May 2, 2003. For the same period, China has reported 3,788 cumulative cases of SARS and 181 deaths among infected people. The main symptoms for SARS patients include fever (greater than 38°C), headache, body aches. After 2-7 days of illness, patients may develop a dry, nonproductive cough that may be accompanied with breathing difficulty. Based on findings from Hong Kong, Canada, and U.S., a previously unrecognized coronaviruse has been identified as the cause of SARS. Researchers have found that SARS coronaviruse is a positive chain RNA virus which replicates without DNA intermediate step and uses standard codon (Marra et al., Science 2003 May 1; (epub ahead of print); and Rota et al., Science 2003 May 1, (epub ahead of print)). SARS coronaviruse is a newly discovered virus which has not been previously detected in human or animals. The genome structure of SARS coronaviruse is very similar to other coronaviruse. The genome of SARS coronaviruse is 30 K base pairs in length and the genome is considered very large for a virus. The genome of SARS coronaviruse encodes RNA polymerase (polymerase la and lb), S protein (spike protein), M protein (membrane protein), and N protein (nucleocapsid protein), etc. Currently, there are three types of detection methods for SARS coronaviruse: immunological methods (e.g., ELISA), reverse transcriptase polymerase chain reaction (RT-PCR) tests, and cell culture methods. There are significant drawbacks of the above three detection methods. For example, ELISA can reliably detect antibodies from serum of SARS patients. However, those antibodies can only be detected twenty one days after development of symptoms. Cell culture methods have a relative long detection cycle and can be applied only to limited conditions. In addition, cell culture methods can only detect existence of alive virus. The key step of preventing the spread of SARS coronaviruse is early diagnosis and early quarantine and treatment. RT-PCR is the only existing method that allows detection of nucleic acid of SARS coronaviruse. However, RT-PCR cannot eliminate infected patient before SARS virus expression, and detection rate for RT-PCR is low. The detection process requires expensive real time PCR equipment. Thus, RT-PCR cannot satisfy the need of early clinical screening and diagnosis. There exists a need in the art for a quick, sensitive and accurate diagnosis of the severe acute respiratory syndrome (SARS). The present invention address this and other related needs in the art.
BRIEF SUMMARY OF THE INVENTION The current method for clinical diagnosis is mainly based on symptoms such as fever, shadows on patient's lung, dry cough, and weakness in patient's arms and legs. However, these symptoms are not specific for SARS; other pathogens can cause the same or similar symptoms. For example, regular pneumonia caused by Chlamydia pneumoniae and Mycoplasma pneumoniae also generates shadows on patient's lung; fever and cough are also associated with influenza; and similar symptoms are also associated with infection of the upper respiratory tract caused by human coronaviruse 229E and OC43. Thus, diagnosis for SARS solely based on the symptoms of the patient is problematic. Current clinical data indicate that many suspected SARS cases actually did not have infection by SARS virus, and instead, had infection by other pathogens. Thus, there is a need to develop a method for simultaneous detection of SARS and other pathogens that cause symptoms similarly to SARS. Such method would provide quick screening of suspected cases in order to reduce probability of diagnostic errors, to allow timely and adequate treatment, and to avoid unnecessary panic and medical waste. Patients infected with SARS virus are more susceptible to other pathogens due to decreased immunity caused by SARS virus. It is possible that SARS patients are also infected with other pathogens that generate symptoms similar to SARS. For example, if a patient is infected with both SARS and Mycoplasma pneumoniae, treatment with medicine only for SARS will not make symptoms disappear immediately. In this situation, a simultaneous detection of infection by both pathogens would allow immediate and effective treatment of patients for both pathogens. A biochip-based diagnosis is a fast and low cost method for high throughput simultaneous screening of multiple samples. Thus, one objective of the invention is to provide a biochips for simultaneous detection of SARS virus and other pathogens that cause SARS-like symptoms. Clinical data also indicate that those SARS patients infected with other pathogens (pathogens that severely interfere and obstruct immunity, such as hepatitis B and HIV) have aggravated symptoms and high probability of infecting others (these patients are called "super-spreaders"). Proper detection of such patients would allow adequate treatment and timely quarantine of patients. Thus, another objective of the invention is to provide a nucleic acid microarray for simultaneous detection of SARS virus and other pathogens that aggravates symptoms of SARS. In one aspect, the present invention is directed to a chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV) and a non-SARS-CoV infectious organism, which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to a nucleotide sequence of SARS-CoV genome, said nucleotide sequence comprising at least 10 nucleotides, and one or more of the following oligonucleotide probe(s): a) an oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, said nucleotide sequence comprising at least 10 nucleotides; b) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism damaging an infectious host's immune system, said nucleotide sequence comprising at least 10 nucleotides; or c) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV coronaviridae virus, said nucleotide sequence comprising at least 10 nucleotides. In some embodiments, the chip of the invention comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides. In some embodiments, the non-SARS-CoV infectious organism causing SARS-like symptoms is selected from the group consisting of a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus. In some embodiments, the non-SARS-CoV infectious organism damaging an infectious host's immune system is selected from the group consisting of a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum. In another aspect, the present invention is directed to a method for assaying for a SARS-CoV and a non-SARS-CoV infectious organism in a sample, which methods comprises: a) providing an above-described chip; b) contacting said chip with a sample containing or suspected of containing a nucleotide sequence of a SARS-CoV and a non-SARS-CoV infectious organism under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said nucleotide sequence of said SARS-CoV or said non-S ARS-CoV infectious organism, if present in said sample, and said oligonucleotide probe complementary to a nucleotide sequence of said SARS-CoV genome or said oligonucleotide probe complementary to a nucleotide sequence of said non-S ARS-CoV infectious organism genome, whereby detection of one or both of said hybrids indicates the presence of said SARS-CoV and/or said non-S ARS-CoV infectious organism in said sample. In some embodiments, the SARS-CoV is assayed by: a) providing a chip comprising a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotide; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and said at least two oligonucleotide probes complementary to two different nucleotide sequences of SARS-CoV genome, respectively, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample. By using multiple hybridization probes, the present methods reduce the occurrence of false negative results compared to a test based on a single hybridization probe as the chance of simultaneous mutations of the multiple hybridization targets is much smaller than the chance of a mutation in the single hybridization target. When other preferred embodiments are used, e.g. , a negative control probe and a blank spot on the chip, the chance of a false positive result can also be reduced. The inclusion of more preferred embodiments, e.g., an immobilization control probe and a positive control probe, on the chip can provide further validation of the assay results. The use of preferred sample preparation procedures, RNA extraction procedures and amplification procedures can further enhance the sensitivity of the present methods. In still another aspect, the present invention is directed to an oligonucleotide primer for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adeno virus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide primer comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 1-6; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43 comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Tables 1-6.
Table 1. Exemplary Influenza A Virus Primers iύ Sequence PMIAJ0001 TTTGTGCGACAATGCTTCA PMIA_00002 GACATTTGAGAAAGCTTGCC PMIA_00003 AGGGACAACCTNGAACCTGG P IA_00004 AGGAGTTGAACCAAGACGCATT PMIA 0005 ACCACATTCCCTTATACTGGAG PW!IA_00006 TTAGTCATCATCTTTCTCACAACA PMIA_00007 | ACAAATTGCTTCAAATGAGAAC P IA_00008 j TGTCTCCGAAGAAATAAGATCC PMIA_00009 | GCGCAGAGACTTGAAGATGT PW1IA_00010 j CCTTCCGTAGAAGGCCCT
Table 2. Exemplary Influenza B Virus Primers
Id Sequence PMIEL00001 CACAATGGCAGAATTTAGTGA PMIB_00002 GTCAGTTTGATCCCGTAGTG PMIB--00003 CAGATCCCAGAGTGGACTCA PMIBJ0004 TGTATTAGCCAAGGGTTGTTAC . P IBJ0005 GATCAGCATGACAGTAACAGGA -.. PMIB .0006 ATGTTCGGTAAAAGTCGTTTAT i PM1B_00007 CCACAGGGGAGATTCCAAAG PMIB_00008 GAGATTCTTCCTGATTCATAATC P IBJ0009 CAAACAACGGTAGACCAATATA PM!B_00010 AGGTTCAGTATCTATCACAGTCTT PMIB--00011 ATGTCCAACATGGATATTGAC Id Sequence PMIB_00012 GCTCTTCCTATAAATCGAATG PMIB 00013 TGATCAAGTGATCGGAAGTAG PMIB 0014 GATGGTCTGCTTAATTGGAA PMIB_00015 ACAGAAGATGGAGAAGGCAA PM1B_00016 ATTGTTTCTTTGGCCTGGAT
Table 3. Exemplary Human Metapneumovirus Primers
Sequence PMMJ0001 CATCCCAAAAATTGCCAGAT • PMM_00002 TTTGGGCTTTGCCTTAAATG : PMM 0003 ACACCCTCATCATTGCAACA ■' PMMJXKKM I GCCCTTCTGACTGTGGTCTC P M_00005 ' CGACACAGCAGCAGGAATTA ; PM _00006 TCAAAGCTGCTTGACACTGG ! PMMJ0007 CAAGTGCGACATTGATGACC ', PMM 0008 TAATTCCTGCTGCTGTGTCG i ~~ PMM_00009 . GCGACTGTAGCACTTGACGA i j P J300010 _ TCATGATCAGTCCCGCATAA I PM J00011 ', TGTTTCAGGCCAATACACCA ! PMMJ00012 i TCATGATCAGTCCCGCATAA ! PW)M_000013 | TCATGGGTAATGAAGCAGCA ' PMM_000014 GGAGTTTTCCCATCACTGGA PMM_000015 ' TCCAGTGATGGGAAAACTCC PMM--000016 ', TGTTGAGCTCCTTTGCCTTT
Table 4. Exemplary Human Adenovirus Primers
Id Sequence PMAd1_00001 | TGGCGGTATAGGGGTAACTG Id Sequence
P Ad1_00002 ATTGCGGTGATGGTTAAAGG
PMAd1_00003 TTTTGCCGATCCCACTTATC
PMAd1_00004 GCAAGTCTACCACGGCATTT
PMAd2_00001 CTCCGTTATCGCTCCATGTT
PMAd2_00002 AAGGACTGGTCGTTGGTGTC
PWIAd2_00003 AAATGCCGTGGTAGATTTGC
PMAd2_00004 GTTGAAGGGGTTGACGTTGT
PMAd3_00001 TCCTCTGGATGGCATAGGAC
PMAd3_00002 TGTTGGTGTTAGTGGGCAAA
P Ad3_00003 ACATGGTCCTGCAAAGTTCC
P Ad3_00004 GCATTGTGCCACGTTGTATC
PMAd4_00001 CGCTTCGGAGTACCTCAGTC
PMAd4_00002 CTGCATCATTGGTGTCAACC
PMAd4_00003 GGCACCTTTTACCTCAACCA
PMAd4_00004 TCTGGACCAAGAACCAGTCC
PMAd5_00001 GGCCTACCCTGCTAACTTCC
PMAd5_00002 ATAAAGAAGGGTGGGCTCGT_
PMAd5_00003 ATCGCAGTTGAATGCTGTTG
PWIAd5_00004 GTTGAAGGGGTTGACGTTGT
PMAd7_00001 ACATGGTCCTGCAAAGTTCC
PMAd7_00002 GATCGAACCCTGATCCAAGA
PMAd7_00003 AACACCAACCGAAGGAGATG
P Ad7_00004 CCTATGCCATCCAGAGGAAA
PMAd11_00001 CAGATGCTCGCCAACTACAA
PMAd11_00002 AGCCATGTAACCCACAAAGC
P AdljL.00003 ACGGACGTTATGTGCCTTTC
PMAd11J)000 GGGAATATTGGTTGCATTGG
PMAd21_00001 ACTGGTTCCTGGTCCAGATG
PMAd21_00002 AGCCATGTAACCCACAAAGC
Figure imgf000011_0003
Table 5. Exemplary HCoV-OC229E Primers
Id Sequence ; PMV_a0053 , TCACTTGCTTCCGTTGAGGTTGGGCTGGCGGTTTAGAGTTGA j " " " ■ " " " ' " - ! PMV_a0054 • GGTTTCGGATGTTACAGCGTGTGCGACCGCCCTTGTTTATGG
Figure imgf000011_0001
Table 6. Exemplary HCoV-OC43 Primers
Figure imgf000011_0002
Id Sequence PMV a0061 ■ TCACTTGCTTCCGTTGAGGTTGGGGTGATGGGTTTCAGATTAA PMV_a0062 . GGTTTCGGATGTTACAGCGTCTCGGGAAGATCGCCTTCTTCTA PMV_b0061 . TTGGGGTGATGGGTTTCAGATTAA PMV b0062 : CTCGGGAAGATCGCCTTCTTCTA
In yet another aspect, the present invention is directed to a kit for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a primer described above; and b) a nucleic acid polymerase that can amplify a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 using said primer. In yet another aspect, the present invention is directed to an oligonucleotide probe for hybridizing to a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide probe comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 7-12; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 7-12.
Table 7. Exemplary Influenza A Virus Probes
Sequence PBIAJ0001 TTTAGAGCCTATGTGGATGGATTCRAACCGAACGGCTGCATTGAGGGCAAGCTTTCTCAAATGTC PBIA_00002 ' ACAATTGAAGAAAGATTTGAAATCACTGGAACCATGCGCAGGCTTGCCGACCAAAGTCTCCCACCGAACT
Figure imgf000013_0001
Table 8. Exemplary Influenza B Virus Probes
Sequence
PBIB_00001 GCTGGGAAATAGCATGGAACTGATGATATTCAGCTACAATCAAGACTATTCGTTAAGTAATGAATCCTCA
PBIB_00002 TCTGTTCCAGCTGGTTTCTCCAATTTTGAAGGAATGAGGAGCTACATAGACAATATAGATCCTAAAGGAG
PBIB 00003 I TTACAACCATGAGCTACCAGAAGTTCCATATAATGCCTTTCTTCTAATGTCTGATGAATTGGGGCTGGCC
PBIBJ0004 ! ACAAATAAGATCCAAATGAAATGGGGAATGGAAGCTAGAAGATGTCTGCTTCAATCAATGCAACAAATGG PBIB 00005 GAGGGAATGTATTCTGGAATAGANGAATGTATTAGTAACAACCCTTGGGTAATACAGAGTGCATACTGGT
PBIB 00006 CTACCGTGTTGGGAGTAGCCGCACTAGGTATCAAAAACATTGGAAACAAAGAATACTTATGGGATGGACT
PBIBJ0007 ! GGCTATGACTGAAAGAATAACCAGAGACAGCCCAATTTGGTTCCGGGATTTTTGTAGTATAGCACCGGTC PBIB 00008 ACTGATCAGAGGAACATGATTCTTGAGGAACAATGCTACGCTAAGTGTTGCAACCTTTTTGAGGCCTGTT
PBIBJ0009 j AAAATCCCTTTGTNGGACATTTGTCTATTGAGGGCATCAAAGANGCAGATATAACCCCAGCACATGGTCC PBIBJD0010 I CTTGGAATACAAGGGAATACAACπAAAACAAATGCTGAAGACATAGGAACCAAAGGCCAAATGTGCTCA
PBIB 00011 GTGGCAGGAGCAACATCAGCTGAGTTCATAGAAATGCTACACTGCTTACAAGGTGAAAATTGGAGACAAA
PBIB 00012 I GGAACCCATCCCCGGAAAGAGCAACCACAAGCAGTGAAGCTGATGTCGGAAGGAAAACCCAAAAGAAACA
PBIBJ0013 | CTGTTTCCAAAGATCAAAGGCACTAAAAAGAGTTGGACTTGACCCTTCATTAATCAGTACCTTTGCAGGA PBIB 00014 AGAGTTTTGTCTGCATTAACAGGCACAGAATTCAAGCCTAGATCAGCATTAAAATGCAAGGGTTTCCATG
PBIB_00015 GAGGGACGTGATGCAGATGTCAAAGGAAATCTACTCAAGATGATGAATGACTCAATGGCTAAGAAAACCA
PBIBJ0016 CCTATCAGGAATGGGAACAACAGCAACAAAAAAGAAAGGCCTGATTCTAGCTGAGAGAAAAATGAGAAGA
PBIB 00017 GCAAGTCAAAAGAATGGGGAAGGAATTGCAAAGGATGTAATGGAAGTGCTAAAGCAGAGCTCTATGGGAA
Table 9. Exemplary Human Metapneumovirus Probes
Sequence PBWL00001 | AAAAGTGTATCACAGAAGTTTGTTCATTGAGTATGGCAAAGCATTAGGCTCATCATCTACAGGCAGCAAA
Figure imgf000014_0001
PBNL00Q02 GAAAGTCTATΓΓGTTAATATATTCATGCAAGCTTATGGAGCCGGTCAAACAATGCTAAGGTGGGGGGTCA PBMJ0003 ACGCTGTTGTGTGGAGAAATTCTGTATGCTAAACATGCTGATTACAAATATGCTGCAGAAATAGGAATAC PBMJ0004 TTAAGGAATCATCAGGTAATATCCCACAAAATCAGAGGCCCTCAGCACCAGACACACCCATAATCTTATT PBM 30005 I TGAGCAATCAAAGGAGTGCAACATCAACATATCCACTACAAATTACCCATGCAAAGTCAGCACAGGAAGA PBM_00006 i CTGTTCCATTGGCAGCAACAGAGTAGGGATCATCAAGCAGCTGAACAAAGGTTGCTCCTATATAACCAAC : PBWIJ0007 , ACTTAATGACAGATGCTGAACTAGCCAGGGCCGTTTCTAACATGCCGACATCTGCAGGACAAATAAAATT ; PBM_00008 , ' AAAAAAAGGGAAACTATGCTTGCCTCTTAAGAGAAGACCAAGGGTGGTATTGTCAGAATGCAGGGTCAAC PBWL00009 ■ GAAAAGAACACACCAGTTACAATACCAGCATTTATCAAATCGGTTTCTATCAAAGAGAGTGAATCAGCCA ; PBM_00010 CAMTCAGTTGGCAAAMAACACATGATCTGATCGCATTATGTGATTTTATGGATCTAGAAAAGAACACA PBMJ.0011 CAGCTAAAGACACTGACTATAACTACTCTGTATGCTGCATCACAAAGTGGTCCAATACTAAAAGTGAATG PBW1J0012 AAAAGAACACACCAGTTACAATACCAGCATTTATCAAATCGGTTTCTATCAAAGAGAGTGAATCAGCCAC PBMJ.0013 CTATTATAGGAGAAAMGTGMCACTGTATCTGAAACATTGGAATTACCTACTATCAGTAGACCCACCAA PBM_00014 MGTTAGCATGGACAGACAAAGGTGGGGCAATCAAAACTGAAGCAAAGCAAACAATCAAAGTTATGGATC PBM_00015 CAGGAAAATACACAAAGTTGGAGAAAGATGCTCTAGACTTGCTTTCAGACAATGAAGAAGAAGATGCAGA PBM 00016 CTAATAGCAGACATAATAAAAGAAGCCAAGGGAAAAGCAGCAGAAATGATGGAAGAAGAAATGAACCAGC
Table 10. Exemplary Human Adenovirus Probes
Sequence
PBAd OOOI CTGACACCTACCAAGGTATAA TCAMCGGMACGGTAATCCTCAAAACTGGACCAAAAATGACGATTT PBAd_00002 TCCTCTACTCCAACATTGCACTGTACCTGCCTGACAAGCTAAAATACACTCCTACAAATGTGGAAATATC PBAdJ0003 GCTATCGGAGGCAGAGTACTAAAAAAGACTACTCCCATGAAACCATGCTACGGATCGTATGCCAGACCTA PBAd_00004 AGTATTGTTTTGTACAGTGAGGATGTTAATATGGAAACTCCTGATACTCACATTTCATACAAACCAAGCA PBAd_00005 GGGAAACGATCTTAGAGTTGACGGGGCTAGCATTAAGTTTGACAGCATTTGTCTTTACGCCACCTTCTTC PBAd_00006 TTGCCATTAAAAACCTCCTCCTCCTGCCAGGCTCATATACATATGAATGGAACTTCAGGAAGGATGTTAA PBAd_-00007 TTGCAACACGTAATGAAATAGGAGTGGGTAACAACTTTGCCATGGAAATTAACCTAAATGCCAACCTATG '< PBAd_00008 TTGGGGTAACTGACACCTATCAAGCTATTAAGGCTAATGGCAATGGCTCAGGCGATAATGGAGATATTAC j PBAd 0009 AGGTATCAAGGCATTAAAGTTAAAACCGATGACGCTAATGGATGGGAAAAAGATGCTAATGTTGATACAG PBAd OOIO GAGAAGTπTCTGTACTCCAATGTGGCTTTGTACCTTCCAGATGTπACAAGTACACGCCACCTAACATT Id Sequence
PBAd--00011 ATCAGTCATTTAACGACTACCTCTCTGCAGCTAACATGCTTTACCCCATTCCTGCCAATGCAACCAACAT PBAd_00012 CTACTTCGTATATTCTGGATCTATTCCCTACCTGGATGGCACCTTTJACCTTAACCACACTTTCAAGAAG PBAd_00013 ACCTGCCAGTGGAAGGATGCTAACAGCAAAATGCATACCTTTGGGGTAGCTGCCATGCCAGGTGTTACTG PBAd_00014 ATAGAAGCTGATGGGCTGCCTATTAGAATAGATTCAACTTCTGGAACTGACACAGTAATTTATGCTGATA PBAd_00015 TTGAAATTAAGCGCACCGTGGACGGCGAGGGGTACAACGTGGCCCAGTGCAACATGACCAAGGACTGGTT PBAcL 00016 CGGCAACGACCGGCTCCTGACGCCCAACGAGTTTGAAATTAAGCGCACCGTGGACGGCGAGGGGTACAAC
PBAd_00017 CTCCAGTAACTTTATGTCCATGGGCGCACTCACAGACCTGGGCCAAAACCTTCTCTACGCCAACTCCGCC PBAd_00018 GCTAACTTCCCCTATCCGCTTATAGGCAAGACCGCAGTTGACAGCATTACCCAGAAAAAGTTTCTTTGCG PBAd_00019 ACAGTCCTTCCAACGTAAAAATTTCTGATAACCCAAACACCTACGACTACATGAACAAGCGAGTGGTGGC PBAd_00020 AAGATGAACTTCCAAATTACTGCTTTCCACTGGGAGGTGTGATTAATACAGAGACTCTTACCAAGGTAAA PBAd„00021 AGCTAACATGCTTTACCCCATCCCTGCCAATGCAACCAACATTCCAATTTCCATCCCATCTCGCAACTGG PBAd_00022 TTCAACTCTTGAAGCCATGCTGCGCAACGATACCAATGATCAGTCATTCAACGACTACCTCTCTGCAGCT PBAd_00023 AGGCTGTGGACAGCTATGATCCCGATGTTCGTATTATTGAAAATCATGGCGTCGAGGATGAACTGCCTAA PBAd_00024 TGAAATTGTGCTTTACACGGAAAATGTCAATTTGGAAACTCCAGACAGCCATGTGGTATACAAGCCAGGA PBAd_00025 CATCGGCTATCAGGGCTTCTACATTCCAGAAGGATACAAAGATCGCATGTATTCATTTTTCAGAAACTTC PBAd_00026 GCTGCTTCTCCCAGGCTCCTACACTTATGAGTGGAACTTTAGGAAGGATGTGAACATGGTTCTACAGAGT PBAd )0027 ATGACACCAATGATCAGTCATTCAACGACTACCTATCTGCAGCTAACATGCTCTACCCCAπCCTGCCAA PBAd_00028 CTTGCCAACTACAACATTGGATACCAGGGCTTCTACGTTCCTGAGGGTTACAAGGATCGCATGTACTCCT PBAd_00029 GATCGCATGTACTCCTTCTTCAGAAACTTCCAGCCCATGAGTAGACAGGTGGTTGATGAGATTAACTACA PBAd 0030 CCCCTAAGGGCGCTCCCAATACATCTCAGTGGATTGCTGAAGGCGTAAAAAAAGAAGATGGGGGATCTGA PBAd„00031 AGAAAATGTAAATTTGGAAACTCCAGATTCCCATGTTGTTTACAAAGCAGGAACTTCAGACGAAAGCTCT PBAd_00032 TGTGGCTACCAATACTGTTTACCAAGGTGTTAAGTTACAAACTGGTCAAACTGACAAATGGCAGAAAGAT PBAd_00033 CCGAATTGGGAAGGGTAGCGTATTCGCCATGGAAATCAATCTCCAGGCCAACCTGTGGAAGAGTTTTCTG PBAd_00034 TTGATGAGGTCAATTACAAAGACTTCAAGGCCGTCGCCATACCCTACCAACACAACAACTCTGGCTTTGT PBAd_00035 TGACGAAGAGGAAGAGAAAAATCTCACCACTTACACTTTTGGAAATGCCCCAGTGAAAGCAGAAGGTGGT PBAdJ0036 AGAAGATTTTGACATTGACATGGCTTTCTTTGATTCCAACACTATTAACACACCAGATGTTGTGCTGTAT
Table 11. Exemplary HCoV-OC229E Probes Id Sequence PBS10049 AATGGGGTTATGTTGGTTCACTCTCCACTAATCACCATGCAATTTGTAATGTTCATAGAAATGAGCATGT PBS10050 GTGTATGACTGCTTTGTTAAGAATGTGGATTGGTCAATTACCTACCCTATGATAGCTAATGAAAATGCCA I PBS10051 TTGCATCTTCTTTTGTTGGTATGCCATCTTTTGTTGCATATGAAACAGCAAGACAAGAGTATGAAAATGC , PBS10052 AAATGGTTCCTCACCACAAATAATCAAACAATTGAAGAAGGCTATGAATGTTGCAAAAGCJGAGTTTGAC. ' PBS10053 CTGCTGCAGCTATGTACAAAGAAGCACGTGCTGTTAATAGAAAATCAAAAGTTGTTAGTGCCATGCATAG
; PBS10054 ACGTTTGGACATGTCTAGTGTTGACACTATCCTTAATATGGCACGTAATGGTGTTGTCCCTCTTTCCGTT PBS10055 CTGGTGGTAAAGTTTCATπTCTGATGACGTTGAAGTAAAAGACATTGAACCTGTTTACAGAGTCAAGCT '■ PBS10056 TTTACAGAGTCAAGCTTTGCTTTGAGTTTGAAGATGAAAAACTTGTAGATGTTTGTGAAAAGGCAATTGG
. PBS10057 GATGπTGTGAAAAGGCAATTGGCAAGAAAATTAAACATGAAGGTGACTGGGATAGCTTTTGTAAGACTA PBS10058 GCGTTGTTGGCCTTTTTCTTGTCTAAGCATAGTGATTTTGGTCTTGGTGATCTTGTCGATTCTTATTTTG
' PBS10059 AGCAAGACAAGAGTATGAAAATGCTGTTGCAAATGGTTCCTCACCACAAATAATCAAACAATTGAAGAAG PBS10060 TTGAAGAAGGCTATGAATGTTGCAAAAGCTGAGTTTGACAGGGAATCATCTGTTCAAAAGAAAATTAACA PBS10061 CTGCTGCAGCTATGTACAAAGAAGCACGTGCTGTTAATAGAAAATCAAAAGTTGTTAGTGCCATGCATAG
Table 12. Exemplary HCoV-OC43 Probes
Id Sequence PBS10062 CTCACATCCTAGGAAGATGCATAGTTTTAGATGTTAAAGGTGTAGAAGAATTGCATGACGATTTAGTTAA PBS10063 GGATTGGCCATTGCACCATAGCTCAACTCACGGATGCAGCACTGTCCATTAAGGAAAATGTTGATTTTAT PBS10064 GCATGCAATTCAATTATAAAATCACCATCAACCCCTCATCACCGGCTAGACTTGAAATAGTTAAGCTCGG PBS10065 ATAGTTAGTCACTGGATGGGAATTCGTTTTGAATACACATCACCCACTGATAAGCTAGCTATGATTATGG
In yet another aspect, the present invention is directed to a kit for hybridization analysis of a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a above-described probe; and b) a means for assessing a hybrid formed between a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 and said probe. BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWTNG(S) Figure 1 A and IB illustrate exemplary SARS-CoV genome structures (See Figure 2 of Marra et al., Science 2003 May 1; [epub ahead of print]; and GenBank Accession No. NC_004718). Figure 2 illustrates an exemplary sample preparation procedure. Figure 3 illustrates an exemplary probe labeling to be used in PCR. The sequence of the universal primer is complementary to the common sequence of the specific primer. The universal primers and the specific primers are added into the PCR master mix before the amplification are performed. The specificity of the amplification is ensured by the specific part of the specific primer. After one or a few thermal cycles, the universal primer can be incorporated into the amplicon efficiently. Then the universal primer can anneal to the complementary sequence of the common sequence of the specific primer The PCR can further proceed with the fluorescence dye incorporated in the universal primer. 1 and 6 depict a fluorescence dye; 2 depicts an upstream universal primer; 3 depicts an upstream specific primer with a common sequence; 4 depicts a template; 5 depicts a downstream specific primer with a common sequence; and 7 depicts a downstream universal primer. Figure 4 illustrates probe immobilization on a glass slide surface modified with an amino group, e.g., poly-L-lysine treated. Amine Coupling Chemistry: Amine Substrates contain primary amine groups (NH3+) attached covalently to the glass surface (rectangles). The amines carry a positive charge at neutral pH, allowing attachment of natively charged DNA (double helix) through the formation of ionic bonds with the negatively charged phosphate backbone (middle panel). Electrostatic attachment is supplemented by treatment with an ultraviolet light or heat, which induces covalent attacliment of the DNA to the surface through the covalent binding between the primary amine and thymine (right panel). The combination of electrostatic binding and covalent attachment couples the DNA to the substrate in a highly stable manner. Figure 5 illustrates an exemplary array format of SARS-CoV detection chip. Figure 6A and 6B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 3). Figure 7A and 7B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 4). Figure 8A and 8B illustrate SARS-CoV detection from a SARS patient sputum sample (sample No. 5). Figure 9A and 9B illustrate SARS-CoV detection from a SARS patient sputum sample (sample No. 6). Figure 10 illustrates another exemplary array format of SARS-CoV detection chip. Figure 11 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 10. Figure 12 illustrates another exemplary array format of SARS-CoV detection chip. Figure 13 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 12. Figure 14 illustrates all possible positive and negative results on the SARS
SARS-CoV detection chip illustrated in Figure 12.
DETAILED DESCRIPTION OF THE INVENTION For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections that follow.
A. Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly imderstood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entirety. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in the patents, applications, published applications and other publications that are herein incorporated by reference, the definition set forth in this section prevails over the definition that is incorporated herein by reference. As used herein, "a" or "an" means "at least one" or "one or more." As used herein, "coronaviridae" refers to a family of single-stranded RNA viruses responsible for respiratory diseases. The outer envelope of the virus has club-shaped projections that radiate outwards and give a characteristic corona appearance to negatively stained virions. As used herein, "polymerase chain reaction (PCR)" refers to a system for in vitro amplification of DNA. Two synthetic oligonucleotide primers, which are complementary to two regions of the target DNA (one for each strand) to be amplified, are added to the target DNA (that need not be pure), in the presence of excess deoxynucleotides and a heat-stable DNA polymerase, e.g., Taq DNA polymerase. In a series, e.g., 30, of temperature cycles, the target DNA is repeatedly denatured (e.g., around 90°C), annealed to the primers (e.g., at 50-60°C) and a daughter strand extended from the primers (e.g. , 72°C). As the daughter strands themselves act as templates for subsequent cycles, DNA fragments matching both primers are amplified exponentially, rather than linearly. The original DNA need thus be neither pure nor abundant, and the PCR reaction has accordingly become widely used not only in research, but in clinical diagnostics and forensic science. As used herein, "nested PCR" refers to a PCR in which specificity is improved by using two sets of primers sequentially. An initial PCR is performed with the "outer" primer pairs, then a small aliquot is used as a template for a second round of PCR with the "inner" primer pair. As used herein, "reverse transcription PCR or RT-PCR" refers to PCR in which the starting template is RNA, implying the need for an initial reverse transcriptase step to make a DNA template. Some thermostable polymerases have appreciable reverse transcriptase activity; however, it is more common to perform an explicit reverse transcription, inactivate the reverse transcriptase or purify the product, and proceed to a separate conventional PCR. As used herein, "primer" refers to an oligonucleotide that hybridizes to a target sequence, typically to prime the nucleic acid in the amplification process. As used herein, "probe" refers to an oligonucleotide that hybridizes to a target sequence, typically to facilitate its detection. The term "target sequence" refers to a nucleic acid sequence to which the probe specifically binds. Unlike a primer that is used to prime the target nucleic acid in the amplification process, a probe need not be extended to amplify target sequence using a polymerase enzyme. However, it will be apparent to those skilled in the art that probes and primers are structurally similar or identical in many cases. As used herein, "the concentration of said 5' and 3' universal primers equals to or is higher than the concentration of said 5' and 3' specific primers, respectively" means that the concentration of the 5 ' universal primer equals to or is higher than the concentration of the 5' specific primers and the concentration of the 3' universal primer equals to or is higher than the concentration of the 3' specific primers. As used herein, "hairpin structure" refers to a polynucleotide or nucleic acid that contains a double-stranded stem segment and a single-stranded loop segment wherein the two polynucleotide or nucleic acid strands that form the double-stranded stem segment is linked and separated by the single polynucleotide or nucleic acid strand that forms the loop segment. The "hairpin structure" can further comprise 3 ' and/or 5' single-stranded region(s) extending from the double-stranded stem segment. As used herein, "nucleic acid (s)" refers to deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) in any form, including inter alia, single-stranded, duplex, triplex, linear and circular forms. It also includes polynucleotides, oligonucleotides, chimeras of nucleic acids and analogues thereof. The nucleic acids described herein can be composed of the well-known deoxyribonucleotides and ribonucleotides composed of the bases adenosine, cytosine, guanine, thymidine, and uridine, or may be composed of analogues or derivatives of these bases. Additionally, various other oligonucleotide derivatives with nonconventional phosphodiester backbones are also included herein, such as phosphotriester, polynucleopeptides (PNA), methylphosphonate, phosphorothioate, polynucleotides primers, locked nucleic acid (LNA) and the like. As used herein, "complementary or matched" means that two nucleic acid sequences have at least 50% sequence identity. Preferably, the two nucleic acid sequences have at least 60%, 70,%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or 100% of sequence identity. "Complementary or matched" also means that two nucleic acid sequences can hybridize under low, middle and/or high stringency condition(s). As used herein, "substantially complementary or substantially matched" means that two nucleic acid sequences have at least 90% sequence identity. Preferably, the two nucleic acid sequences have at least 95%, 96%, 97%, 98%, 99% or 100%. of sequence identity. Alternatively, "substantially complementary or substantially matched" means that two nucleic acid sequences can hybridize under high stringency condition(s). As used herein, "two perfectly matched nucleotide sequences" refers to a nucleic acid duplex wherein the two nucleotide strands match according to the Watson-Crick basepair principle, i.e., A-T and C-G pairs in DNA:DNA duplex and A-U and C-G pairs in DNA:RNA or RNA:RNA duplex, and there is no deletion or addition in each of the two strands. As used herein: "stringency of hybridization" in determining percentage mismatch is as follows: 1) high stringency: 0.1 x SSPE (or 0.1 x SSC), 0.1% SDS, 65°C; 2) medium stringency: 0.2 x SSPE (or 1.O SSC), 0.1% SDS, 50°C (also referred to as moderate stringency); and 3) low stringency: 1.0 x SSPE (or 5.0 x SSC), 0.1% SDS, 50°C. It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures. As used herein, "gene" refers to the unit of inheritance that occupies a specific locus on a chromosome, the existence of which can be confirmed by the occurrence of different allelic forms. Given the occurrence of split genes, gene also encompasses the set of DNA sequences (exons) that are required to produce a single polypeptide. As used herein, "melting temperature" ("Tm") refers to the midpoint of the temperature range over which nucleic acid duplex, i.e., DNA:DN , DNA:RNA, RNA:RNA, PNA: DNA, LNA:RNA and LNA: DNA, etc., is denatured. As used herein, "sample" refers to anything which may contain a target SARS-CoV to be assayed or amplified by the present chips, primers, probes, kits and methods. The sample may be a biological sample, such as a biological fluid or a biological tissue. Examples of biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like. Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s). Biological tissues may be processed to obtain cell suspension samples. The sample may also be a mixture of cells prepared in vitro. The sample may also be a cultured cell suspension. In case of the biological samples, the sample may be crude samples or processed samples that are obtained after various processing or preparation on the original samples. For example, various cell separation methods (e.g. , magnetically activated cell sorting) may be applied to separate or enrich target cells from a body fluid sample such as blood. Samples used for the present invention include such target-cell enriched cell preparation. As used herein, a "liquid (fluid) sample" refers to a sample that naturally exists as a liquid or fluid, e.g. , a biological fluid. A "liquid sample" also refers to a sample that naturally exists in a non-liquid status, e.g., solid or gas, but is prepared as a liquid, fluid, solution or suspension containing the solid or gas sample material. For example, a liquid sample can encompass a liquid, fluid, solution or suspension containing a biological tissue. As used herein, "assessing PCR products" refers to quantitative and/or qualitative determination of the PCR products, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the PCR products. Assessment may be direct or indirect and the chemical species actually detected need not of course be the PCR products themselves but may, for example, be a derivative thereof, or some further substance. B. Chips for assaying for a SARS-CoV and a non-SARS-CoV infectious organism In one aspect, the present invention is directed to a chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV) and a non-SARS-CoV infectious organism, which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to a nucleotide sequence of SARS-CoV genome, said nucleotide sequence comprising at least 10 nucleotides, and one or more of the following oligonucleotide probe(s): a) an oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, said nucleotide sequence comprising at least 10 nucleotides; b) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism damaging an infectious host's immune system, said nucleotide sequence comprising at least 10 nucleotides; or c) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV coronaviridae virus, said nucleotide sequence comprising at least 10 nucleotides. In some embodiments, the chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides. The at least two different nucleotide sequences can be any suitable combinations. For example, the at least two different nucleotide sequences of SARS-CoV genome can comprise a nucleotide sequence of at least 10 nucleotides located within a conserved region of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a variable region of SARS-CoV genome. In another example, the at least two different nucleotide sequences of SARS-CoV genome can comprise a nucleotide sequence of at least 10 nucleotides located within a structural protein coding gene of
SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a non-structural protein coding gene of SARS-CoV genome. If desired, the present chips can comprise other types of probes or other features. For example, the chip can further comprise: a) at least one of the following three oligonucleotide probes: an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-SARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV or non-SARS-CoV infectious organism sequence but is complementary to a sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample; and b) a blank spot. In a specific embodiment, the present chips can comprise at least two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides, respectively, located within a conserved region of SARS-CoV genome, located within a structural protein coding gene of SARS-CoV genome or located within a non-structural protein coding gene of SARS-CoV genome. Any conserved region of SARS-CoV genome can be used as assay target. For example, the conserved region of SARS-CoV genome can be a region located within the Replicase 1 A, IB gene or the Nucleocapsid (N) gene of SARS-CoV. Any variable region of SARS-CoV genome can be used as assay target. For example, the variable region of SARS-CoV genome can be a region located within the Spike glycoprotein (S) gene of SARS-CoV. Any structural protein coding gene of SARS-CoV genome can be used as assay target. For example, the structural protein coding gene of SARS-CoV genome can be a gene encoding the Spike glycoprotein (S), the small envelope protein (E) or the Nucleocapsid protein (N). Any non-structural protein coding gene of SARS-CoV genome can be used as assay target. For example, the non-structural protein coding gene of SARS-CoV genome can be a gene encoding the Replicase 1 A or IB. In another specific embodiment, the present chips can comprise at least two of the following four oligonucleotide probes: two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the N gene of SARS-CoV and an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the S gene of SARS-CoV. Preferably, one or both of the different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV can comprise a nucleotide sequence that: a) 5 hybridizes, under high stringency, with a Replicase 1 A or IB nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a Replicase 1 A or IB nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, one or both of the different nucleotide sequences located within the Replicase 1 A or IB gene of 10 SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
Table 13. Exemplary SARS-CoV probes 'profe. id Sequence. 5* -S-* ϊegion -
PBS00001 TTΛCCCTΛΛTATGTTTATCACCCGCOAACAAGCTΛTTCGTCACGTτCGTGCGTGGΛ SARS-Cov Replicase IB
PBS00002 CTGACAAGTATGTCCGCMTCTACΛACACΛGGCTCTATGAGTGTCTCTΛTΛGΛAAT SARS-Cov Replicase IB
PBS00003 CΛTAACACTTGCTGTAACTTATCACACCGTTTCTΛCAGGTTΛGCTAACGAGTGTGC SARS-Cov Replicase IB
PBS0000. j TTACCCTAATATGπTATCACCCGCGAAGAAGCTATTCGTCACGTTCGTG SARS-Cov Replicase IB
PBS00009 •' GCGTTCTCTTAAAGCTCCTGCCGTΛGTGTCAGTATCATCΛCCAGATGCTOTTACTACΛTAT TGGATΛC SARS-Cov Replicase IA
PBS00010 CTTTGGCTGGCTCTTACAGΛGΛTTGGTCCTΛTTCΛGGACAGCGTΛCAGΛGTTAGGTGTTGAΛTTTCTTAΛ SARS-Cov Replicase 1Λ
PBS00011 CTACGTΛGTGΛAGCTTTCGΛGTACTΛCCATΛCTCTTGATGAGΛGTTTTCTTGGTΛGGTACΛTGTCTGCTT SARS-Cov Replicase 1A
PBS00012 TGCCΛATTGGTTATGTGACACΛTGGTTTTMTCTTGΛΛGAGGCTGCGCGCTGTATGCGTTCTCTTAAΛGC SARS-Cov Replicase 1Λ
PBS00013 TΛTΛΛΛGTTΛCCΛΛGGGΛΛΛGCCCGTΛAAAGGTGCTTGGAACATTGGACAΛCAGΛGΛTCAGTTTTΛACAC SARS-Cov Replicase 1Λ
PBS00014 TGCTTCATTGΛTGTTGTTΛACΛAGGCACTCGAΛATGTGCATTGATCAΛGTCΛCTΛTCGCTGGCGCΛAΛG SARS-Cov Replicase 1Λ
PBS00015 TGTCGACGCCΛTGGTTTΛTACTTCAGACCTGCTCACCΛACΛGTGTCΛTTATTΛTGGCΛTΛTGTAACTGGT SARS-Cov Replicase 1Λ
PBS00016 TΛCTGTTGΛAAAACTCAGGCCTATCTTTGAATGGΛTTGΛGGCGΛAACπAGTGCΛGGΛGTTGΛATTTCTC SARS-Cov Replicase 1A
PBS00017 ΛCCTΛTTCTGTTGCTTGACCΛΛGCTCTTGTATCΛGΛCGTTGGΛGΛTΛGTACTGAΛGTTTCC SARS-Cov Replicase 1Λ
PBS00018 GCCTATrAATCTCATACTTTTTGATGCCAAGTCCAAATGCGACGAGTCTGCTTCTAAGTCTGCTTCTGTG SARS-Cov Replicase 1A
PBS00019 TGAGAGCT CΛΛCΛCTΛMGGTTCACTGCCTATTΛATGTCATΛGTTTTTGATGGCΛΛGTCCΛΛΛTGCGΛ SARS-Cov Replicase 1Λ
PBS00020 ΛCTTGCΛTGΛTGTGCTATΛAGCGCΛΛTCGTGCCACACGCGTTGΛGTGTACΛACTΛTTGTTΛΛTGGCΛTGΛ SARS-Cov Replicase 1Λ !
PBS0-02I CGCGΛTGTΛGTGGCTΛTTGΛCTΛTΛGΛCACTΛTTCΛGCGΛGπTCAAGΛΛAGGTGCTΛAΛTTΛCTGCΛTΛ SARS-Cov Replicase 1Λ PBS00022 TCAAACCA CACTTGGTGTTTACGTTGTCnTGGAGTACAAAGCCAGTAGATACTTCAAATTCATTTGA SARS-Cov Replicase 1A
PBS00023 TAGTGCTGTTGGCAACATTTGCTACACACCTTCCAAACTCATTGAGTATAGTGATTTTGCTAC SARS-Cov Replicase 1Λ PBS00024 TCATAGCTAACΛTCTTTΛCTCCTCTTGTGCAACCTGTGGGTGCTTTAGΛTGTGTCTGCTTCΛGTAGTGGC SARS-Cov Replicase 1Λ PBS00025 GGTATTATTGCCΛTATTGGTGΛCTTGTGCTGCCTΛCTACTTTATGAΛATTCAGACGTGTTTTTGGTGAGT SARS-Cov Replicase 1Λ PBS00026 GTGATGTCΛGAGAAACTATGACCCΛTCTTCTACΛGCATGCTΛΛTTTGGΛATCTGCΛAΛGCGAGTTCTTAA SARS-Cov Replicase 1A PBS00027 AACCATCAΛGCCTGTGTCGTATΛAACTCGΛTGGAGTTACTTACΛCAGAGATTGΛACCΛΛAATTGGATGGG SARS-Cov Replicase 1Λ PBS00028 GTTTTCTACAAGGAAACATCTTACACTΛCΛACCΛTCAAGCCTGTGTCGTATAAACTCGATGGAGTTACπ SARS-Cov Replicase 1A PBS00029 CCTTGMTGΛGGΛTCTCCTTGAGΛTACTGAGTCGTGAACGTGTTΛACATTAΛCATTGTTGGCGATTTTCA SARS-Cov Replicase 1A PBS00031 GCCATGGTTTATACTTCΛGACCTflCTCACCAACAOTGTCATTATTATGGCATATGTAACTGGTGGTCTTG SARS-Cov Replicase 1A PBS00032 CAΛCAGΛCTTCTCAGTGGTTGTCTAATCTTTTGGGCACTACTGTTGAΛAAACTCΛGGCCTATCTTTGAAT SARS-Cov Replicase 1A PBS00033 TTCCCGTCΛGGCAΛAGTTGAAGGGTGCATGGTACAAGTΛΛCCTGTGGAACTACAΛC SARS-Cov Replicase 1Λ PBS00034 GGTTCACCATCTGGTGTTTATCAGTGTGCCATGAGACCTAATCATACCATTAAAGG SARS-Cov Replicase 1Λ PBS00035 AGATCATGTTGΛCATATTGGGΛCCTCTTTCTGCTCAAΛCAGGΛATTGCCGTC SARS-Cov Replicase 1Λ PBS00036 TAAΛAAGGΛCAAA GAAΛAAGACTGATGMGCTCΛGCCTTTGCCGCAGAGACAAAAGAAGCAGCCCACT SARS-Cov Nucleocapsid gene PBS00037 ΛCGGCAAATGΛAAGAGCTCΛGCCCCAGATGGTΛCTTCTATTACCTAGGAACTGGCCCAGAAGCTTCΛCT SARS-Cov Nucleocapsid gene PBS00038 GGCGCTΛACAAΛGAAGGCATCGTATGGGTTGCAACTGAGGGAGCCTTGAATACACCCΛΛAGΛCCACΛTTG SARS-Cov Nucleocapsid gene PBS00039 GTCCAGATGACCAMTTGGCTACTACCGAAGAGCTACCCGACGAGTTCGTGGTGGTGACGGCAAAATGAA SARS-Cov Nucleocapsid gene PBS00040 GAGGTGGTGΛΛACTGCCCTCGCGCTATTGCTGCTΛGACAGΛTTGAΛCCAGCTTGAGΛGCAΛΛGTTTCTGG SARS-Cov Nucleocapsid gene PBS00041 AAAAGAAAAAGACTGATGAΛGCTCAGCCTTTGCCGCAGAGACAAAAGAAGCAGCCCΛCTGTGACTCTTCT SARS-Cov Nucleocapsid gene PBS00042 AAATTGCACΛΛTTTGCTCCAΛGTGCCTCTGCATTCTTTGGAΛTGTCΛCGCATTGGCATGGΛAGTCACΛCC SARS-Cov Nucleocapsid gene PBS00043 ΛCCAATTTΛACΛAGGCGATTAGTCAAΛTTCAAGAATCACTTACAΛCAΛCATCΛΛCTGCΛTTGGGCΛAGCT SARS-Cov Spike glycoprotein gene PBS00044 CACCTGGΛACAAATGCTTCΛTCTGΛAGTTGCTGTTCTATATCAAGΛTGTTΛΛCTGCACTGΛTGTTTCTΛC SARS-Cov Spike glycoprotein gene PBS00045 AAAGGGCTACCACCTTATGTCCTTCCCACAAGCAGCCCCGCATGGTGTTGTCTTCCTACATCTCACGTAT SARS-Cov Spike glycoprotein gene PBS00046 TCΛGGΛAATTGTGATGTCGTTΛTTGGCATCΛTTΛACAACΛCΛGTTTATGATCCTCTGCAACCTGAGCTTG SARS-Cov Spike glycoprotein gene PBS00047 TTGATCTτGGCGΛCΛTTTCAGGCΛTTΛACGCTTCTGTCGTCAACΛTTCΛAΛAΛGΛΛΛTTGΛCCGCCTCΛΛ SARS-Cov Spike glycoprotein gene PBS00048 GAGGAACTTCACCACAGCGCCAGCAATTTGTCATGAAGGCAAAGCATACTTCCCTCGTGAAGGTGTTTTT SARS-Cov Spike glycoprotein gene
Also preferably, the nucleotide sequence located within the N gene of SARS-CoV can comprise a nucleotide sequence that: a) hybridizes, under high stringency, with a N nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a N nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, the nucleotide sequence located within the N gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13. Also preferably, the nucleotide sequence located within the S gene of SARS-CoV can comprise a nucleotide sequence that: a) hybridizes, under high stringency, with a S nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a S nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13. More preferably, the nucleotide sequence located within the S gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13. Any suitable label can be used in the immobilization control probe, e.g., a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent or a FRET label. Any suitable non-S ARS-CoV-sequence can be used. For example, the non-S ARS-CoV-sequence can be an endogenous component of a sample to be assayed. Alternatively, the non-SARS-CoV-sequence is spiked in the sample to be assayed. In another example, the spiked non-SARS-CoV-sequence can be a sequence of Arabidopsis origin. In still another specific embodiment, the present chips can comprise two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-SARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV sequence but is complementary to any sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample. Preferably, the chip comprises multiple spots of the described probes, e.g., multiple spots of the two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, the immobilization control probe, the positive control probe and the negative control probe. The present chips can further comprise an oligonucleotide probe complementary to a nucleotide sequence of a coronaviruse not related to the SARS-CoV. For example, the coronaviruse not related to the SARS can be the Group I, II or III coronaviruse or is a coronaviruse that infects an avian species, e.g., Avian infectious bronchitis virus and Avian infectious laryngotracheitis virus, an equine species, e.g., Equine coronaviruse, a canine species, e.g., Canine coronaviruse, a feline species, e.g., Feline coronaviruse and Feline infectious peritonitis virus, a porcine species, e.g., Porcine epidemic diarrhea virus, Porcine transmissible gastroenteritis virus and Porcine hemagglutinating encephalomyelitis virus, a calf species, e.g., Neonatal calf diarrhea coronaviruse, a bovine species, e.g., Bovine coronaviruse, a murine species, e.g., Murine hepatitis virus, a puffϊnosis species, e.g., Puffinosis virus, a rat species, e.g., Rat coronaviruse and a Sialodacryoadenitis virus of rat, e.g., a turkey species e.g., Turkey coronaviruse, or a human species, e.g. , Human enteric coronaviruse. The present chips can further comprise an oligonucleotide probe complementary to a nucleotide sequence of other types of virus or pathogens. An exemplary list of viruses and pathogens that can be assayed using the present chips is set forth in the following Table 14.
Table 14. Exemplary viruses and pathogens No. Virus name Genome Sample Structure nucleic acid 1 Coronaviridae Single-stranded, RNA Having capsid linear RNA SARS-CoV Single-stranded, RNA Having capsid linear RNA Human Single-stranded, RNA Having capsid coronaviruse linear RNA 229E
4 Human Single-stranded, RNA Having capsid coronaviruse linear RNA OC43 Influenzavirus Single-stranded, RNA Having capsid A,B,C linear RNA, fragmented Parainfluenza Single-stranded, RNA Having capsid virus linear RNA Respiratory Single-stranded, RNA Having capsid sncytical virus linear RNA Human Single-stranded, RNA Having capsid metapneumoviru s linear RNA Rhinovirus Single-stranded RNA No capsid RNA
10 Adenoviruse Double-stranded, DNA No capsid linear DNA
11 Mycoplasma Double-stranded, DNA and Having cell pneumoniae linear DNA RNA wall
12 Chlamydia Double-stranded, DNA and No cell wall pneumoniae linear DNA RNA
The various probes, e.g., the oligonucleotide probe complementary to a nucleotide sequence located within a conserved region of SARS-CoV genome, the oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, the immobilization control probe, the positive control probe or the negative control probe the oligonucleotide probe complementary to a nucleotide sequence of a non-SARS-CoV infectious organism causing SARS-like symptoms, the oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism damaging an infectious host's immune system, and the oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV coronaviridae virus, can comprise, at its '5 end, a poly dT region to enhance its immobilization on the support. In a specific embodiment, the at least one of the oligonucleotide probes is complementary to a highly expressed nucleotide sequence of SARS-CoV genome. Such a chip is particularly useful in detecting early-stage SARS-CoV infection. In some embodiments, the non-SARS-CoV infectious organism is an infectious organism causing SARS-like symptoms. Such organism includes, but not limited to, a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus. The influenza virus can be influenza virus A or influenza virus B. The parainfluenza virus can be parainfluenza virus 1 , parainfluenza virus 2, parainfluenza virus 3, or parainfluenza virus 4. Exemplary probes for these organisms are set forth in Table 15.
Table 15. Exemplary probes for non-S ARS-CoV infectious organisms causing SARS-like symptoms
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
In some embodiments, the non-SARS-CoV infectious organism is an infectious organism damaging an infectious host's immune system. Such organism includes, but not limited to, a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum. The hepatitis virus can be hepatitis virus A (HAN), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV), or hepatitis virus G (HGV). The HIV can be HIV I. The parvovirus can be parvovirus Bl 9. Exemplary probes are set forth in Table 16.
Table 16. Exemplary probes for non-S ARS-CoV infectious organisms damaging host's immune system
Figure imgf000040_0002
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
In some embodiments, the non-SARS-CoV infectious organism is a non-SARS-CoV coronaviridae virus. Such virus includes, but not limited to, an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat. Exemplary probes for these viruses are set forth in Table 17.
Table 17. Exemplary probes for non-SARS-CoV coronaviridae virus
seqid sequence(5'-3')
PBIBVJ0001 GGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCCAATCAGGGTACAAGAGATCCTG
PBIBVJ0002 GGTATAGTGTGGGTTGCTGCTAAGGGTGCTGATACTAAATCTAGATCCAATCAGGGTACAAGAGATCCTG
PBMHVJ0001 CCAGCCCAAGCAAGTAACGAAGCAAAGTGCCAAAGAAGTCAGGCAGAAAATTTTAAACAAGCCTCGCCAA
PBMHVJ0002 TCTAAACTTTAAGGATGTCTTTTGTTCCTGGGCAAGAAAATGCCGGTGGCAGAAGCTCCTCTGTAAACCG
PBEQJ0001 AGGATCAAGAAATAGATCCAATTCCGGCACTAGAACACCCACCTCTGGTGTGACATCTGATATGGCTGAT
PBEQJ0002 TTTAAAACAGCCGATGGCAATCAACGCCAATTGTTGCCACGCTGGTATTTTTACTACTTGGGAACAGGCC
PBCAJ0001 TTGGAACTTATGTCCGAGAGACTTTGTACCCAAAGGAATAGGTAACAAGGATCAACAGATTGGTTATTGG
PBCAJ0002 GCTGAATGTGTTCCATCTGTATCTAGCATTCTGTTTGGAAGCTATTGGACTGCAAAGGAAGATGGCGACC
PBFEJ0001 CACCACCCTCGAACAAGGAGCTAAATTTTGGTATGTATGTCCGAGAGACTTTGTTCCCAAGGGAATAGGT
PBFEJ0002 GGCACTCGTGGAACCAACAATGAATCCGAACCATTGAGATTTGATGGTAAGATACCACCACAATTCCAGC
PBPEDVJ0001 CTGATCCAAATGTTGAGCTTCTTGTTGCACAGGTGGATGCATTTAAAACTGGGAATGCAAAACCCCAGAG
PBPEDVJ0002 ATGAGCAAATTCGCTGGCGTATGCGCCGTGGTGAGCGAATTGAACAACCTTCAAATTGGCATTTCTACTA
PBPTGVJ0001 GAGAGACTTTGTACCCAAAGGAATAGGTAACAGGGATCAACAGATTGGTTATTGGAATAGACAAACTCGC
PBPTGVJ0002 GATGGTGACCAGATAGAAGTCACGTTCACACACAAATACCACTTGCCAAAGGATGATCCTAAAACTGGAC
PBBOVJ0001 TATTTTTACTATCTTGGAACAGGACCGCATGCCAAAGACCAGTATGGCACCGACATTGACGGAGTCTACT
PBBOVJ0002 AGAACCCCTACCTCTGGTGTAACACCTGATATGGCTGATCAAATTGCTAGTCTTGTTCTGGCTAAACTTG
PBFIPVJ0001 GAGTGTGGTTAATCAACAGGGTGAAGCGCTGAGTCAACTTACCAGTCAGTTACAGAAAAACTTCCAGGCT
PBFIPVJ0002 CCGGCATTGTAGATGGTAATAAGATGGCCATGTACACAGCATCTTTAATTGGAGGTATGGCTTTGGGCTC
PBRJ0001 AAATGTTAAAACTTGGAACTAGTGATCCACAGTTCCCCATTCTTGCAGAGTTGGCCCCAACACCTGGTGC
PBRJ0002 CCCATTACTCTTGGTTTTCGGGCATTACCCAATTTCAAAAGGGAAAGGAGTTCCAGTTTGCAGATGGGCA
PBPHEVJ0001 TAGTAACCAGGCTGATATTAATACCCCGGCTGACATTGTCGATCGGGATCCAAGTAGCGATGAGGCTATT
PBPHEV 00002 TTCTTTTAAAACAGCCGATGGCAATCAGCGTCAACTGCTGCCACGATGGTACTTTTACTACCTGGGAACA
PBPVJ0001 GTGGπCCCCATTACTCCTGGTTTTCTGGCATTACCCAATTCCAGAAGGGAAAGGAGTTTAAGπTGCAG
PBPVJ0002 AAG AGTCAGGCAGAAAATTTTAAACAAGCCTCGCCAAAAGAGGACTCCAAACAAGCAGTGCCCAGTGCA PBTKJ0001 TTTGGTGATGACAAGATGAATGAGGAAGGTATTAAGGATGGGCGTGTTACGGCAATGCTCAACCTAGTCC
PBTKJ0002 TTTGGTGATGACAAGATGAATGAGGAAGGTATTAAGGATGGGCGTGTTACGGCAATGCTCAACCTAGTCC
PBSDAVJ0001 AGCCTGCCTCTACTGTAAAACCTGATATGGCCGAAGAAATTGCTGCTCTTGTTTTGGCTAAGCTAGGCAA
PBSDAVJ0002 CCCCATTCTTGCAGAGTTGGCCCCAACACCTGGTGCCTTCTTCTTTGGATCTAAATTAGAATTGGTCAAA
The oligonucleotide probes and the target SARS-CoV and any non-SARS-CoV infectious organism nucleotide sequences can be any suitable length. Preferably, the oligonucleotide probes and the target SARS-CoV and any non-SARS-CoV infectious organism nucleotide sequences have a length of at least 7, 10, 20, 30, 40, 50, 60, 80, 90, 100 or more than 100 nucleotides. The oligonucleotide probes and primers can be prepared by any suitable methods, e.g., chemical synthesis, recombinant methods and/or both (See generally, Ausubel et al., (Ed.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (2000)). Any suitable support can be used in the present chips. For example, the support can comprise a surface that is selected from the group consisting of a silicon, a plastic, a glass, a ceramic, a rubber, and a polymer surface.
C. Methods for assaying for a SARS-CoV and a non-SARS-CoY infectious organism In another aspect, the present invention is directed to a method for assaying for a SARS-CoV and a non-SARS-CoV infectious organism in a sample, which methods comprises: a) providing an above-described chip; b) contacting said chip with a sample containing or suspected of containing a nucleotide sequence of a SARS-CoV and a non-SARS-CoV infectious organism under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said nucleotide sequence of said SARS-CoV or said non-S ARS-CoV infectious organism, if present in said sample, and said oligonucleotide probe complementary to a nucleotide sequence of said SARS-CoV genome or said oligonucleotide probe complementary to a nucleotide sequence of said non-SARS-CoV infectious organism genome, whereby detection of one or both of said hybrids indicates the presence of said SARS-CoV and/or said non-S ARS-CoV infectious organism in said sample. In some embodiments, the SARS-CoV is assayed by: a) providing a chip comprising a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotide; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and said at least two oligonucleotide probes complementary to two different nucleotide sequences of SARS-CoV genome, respectively, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample. In a specific embodiment, the present methods comprise: a) providing a chip comprising a nucleotide sequence of at least 10 nucleotides located within a conserved region of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a variable region of SARS-CoV genome, or a nucleotide sequence of at least 10 nucleotides located within a structural protein coding gene of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a non-structural protein coding gene of SARS-CoV genome; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and i) said oligonucleotide probe complementary to a nucleotide sequence located within a conserved region of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, respectively; or ii) said oligonucleotide probe complementary to a nucleotide sequence located within a structural protein coding gene of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a non-structural protein coding gene of SARS-CoV genome, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample. In another specific embodiment, the present methods comprise: a) providing a chip comprising an oligonucleotide probe complementary to a nucleotide sequence within a conserved region of SARS-CoV genome, an oligonucleotide probe, complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, at least one of the following three oligonucleotide probes: an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip, a positive control probe that is not complementary to any SARS-CoV sequence but is complementary to a non-SARS-CoV-sequence contained in the sample and a negative control probe that is not complementary to any nucleotide sequence contained in the sample, and a blank spot; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing: (i) hybrids formed between said SARS-CoV nucleotide sequence, if present in the sample, and the oligonucleotide probe complementary to a nucleotide sequence within a conserved region of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, respectively; (ii) a label comprised in the immobilization control probe, or a hybrid(s) involving the positive control probe and/or the negative control probe; and (iii) a signal at said blank spot to determine the presence, absence or amount of said SARS-CoV in a sample. Preferably, the present chips comprise two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe, a positive control probe and a negative control probe and the presence of the SARS-CoV is determined when: a) a positive hybridization signal is detected using at least one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV and the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV; b) a positive signal is detected from the immobilization control probe; c) a positive hybridization signal is detected using the positive control probe; d) a positive hybridization signal is not detected using the negative control probe; and e) a positive hybridization signal is not detected at the blank spot. The inclusion of a target sequence in a variable region of SARS-CoV enables an assessment of possible mutation of the SARS-CoV. For example, detecting a positive hybridization signal using at least one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, or the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, while not detecting a positive hybridization signal using the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV indicates a mutation(s) of the SARS-CoV. The present methods can be used for any suitable prognosis and diagnosis purpose. In one example, the present method is used to positively identify SARS-CoV infected patients from a population of patients who have SARS-like symptoms, e.g., fever or elevated temperature, nonproductive cough, myalgia, dyspnea, elevated lactate dehydrogenase, hypocalcemia, and lymphopenia (Booth et al., JAMA, 2003 May 6; [epub ahead of print]). The present chips, methods and kits can further comprise assaying for elevated lactate dehydrogenase, hypocalcemia, and lymphopenia, etc. In another example, a chip further comprising an oligonucleotide probe complementary to a nucleotide sequence of a coronaviruse not related to the SARS-CoV is used and the method is used to positively identify SARS-CoV infected patients from patients who have been infected with a coronaviruse not related to the SARS, e.g., a coronaviruse that infects an avian species, e.g., Avian infectious bronchitis virus and Avian infectious laryngotracheitis virus, an equine species, e.g., Equine coronaviruse, a canine species, e.g., Canine coronaviruse, a feline species, e.g., Feline coronaviruse and Feline infectious peritonitis virus, a porcine species, e.g., Porcine epidemic diarrhea virus, Porcine transmissible gastroenteritis virus and Porcine hemagglutinating encephalomyelitis virus, a calf species, e.g., Neonatal calf diarrhea coronaviruse, a bovine species, e.g., Bovine coronaviruse, a murine species, e.g., Murine hepatitis virus, a puffinosis species, e.g. , Puffinosis virus, a rat species, e.g. , Rat coronaviruse and a Sialodacryoadenitis virus of rat, e.g., a turkey species e.g., Turkey coronaviruse, or a human species, e.g., Human enteric coronaviruse. In still another example, a chip comprising an oligonucleotide probes complementary to a highly expressed nucleotide sequence of SARS-CoV genome is used and the method is used to diagnose early-stage SARS patients, e.g. , SARS patients who have been infected with SARS-CoV from about less than one day to about three days. In yet another example, the present methods are used to monitor treatment of SARS, e.g., treatment with an interferon or an agent that inhibits the replication of a variety of RNA viruses such as ribavirin. The present methods can also be used to assess potential anti-S ARS-CoV agent in a drag screening assay. The method of the invention can be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism causing SARS-like symptoms. Non-SARS-CoV infectious organism that causing SARS-like symptoms includes, but not limited to, a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus. The influenza virus can be influenza virus A or influenza virus B. The parainfluenza virus can be parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 or parainfluenza virus 4. The method of the invention can also be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism damaging the subject's immune system. The non-SARS-CoV infectious organism damaging subject's immune system includes, but not limited to, a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum. The hepatitis virus can be hepatitis virus A (HAV), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV), or hepatitis virus G (HGV). The HIV can be HIV I. The parvovirus can be parvovirus B 19. The method of the invention can also be used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV coronaviridae virus. The non-S ARS-CoV coronaviridae virus includes, but not limited to, an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat. Any suitable SARS-CoV or non-SARS-CoV infectious organism nucleotide sequence can be assayed. For example, the SARS-CoV or the non-S ARS-CoV infectious organism nucleotide sequence to be assayed can be a SARS-CoV RNA or a non-SARS-CoV infectious organism genomic sequence or a DNA sequence amplified from an extracted SARS-CoV RNA or a non-SARS-CoV infectious organism genomic sequence. The SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be prepared by any suitable methods. For example, the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from a SARS-CoV or the non-SARS-CoV infectious organism infected cell or other materials using the QIAamp Viral RNA kit, the Chomczynski-Sacchi technique or TRIzol (De Paula et al., J Virol. Methods, 98(2): 119-25 (2001 )). Preferably, the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence is extracted from a SARS-CoV or the non-SARS-CoV infectious organism infected cell or other materials using the QIAamp Viral RNA kit. The SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from any suitable source. For example, the SARS-CoV RNA or the non-S ARS-CoV infectious organism genomic sequence can be extracted from a sputum or saliva sample. In another example, the SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be extracted from a lymphocyte of a blood sample. The SARS-CoV RNA or the non-SARS-CoV infectious organism genomic sequence can be amplified by any suitable methods, e.g. , PCR. Preferably, a label is incorporated into the amplified DNA sequence during the PCR. Any suitable PCR can be used, e.g. , conventional, multiplex, nested PCR or RT-PCR. In one example, the PCR can comprise a two-step nested PCR, the first step being a RT-PCR and the second step being a conventional PCR. In another example, the PCR can comprise a one-step, multiplex RT-PCR using a plurality of 5' and 3' specific primers, each of the specific primers comprising a specific sequence complementary to its target sequence to be amplified and a common sequence, and a 5' and a 3' universal primer, the 5' universal primer being complementary to the common sequence of the 5' specific primers and the 3' universal primer being complementary to the common sequence of the 3' specific primers, and wherein in the PCR, the concentration of the 5' and 3' universal primers equals to or is higher than the concentration of the 5' and 3' specific primers, respectively. Preferably, the 3' universal primer and/or the 5' universal primer is labeled, e.g. , a fluorescent label. In still another example, the PCR comprises a multiple step nested PCR or RT-PCR. In yet another example, the PCR is conducted using at least one of the following pairs of primers for SARS-CoV set forth in Table 18.
Table 18. Exemplary SARS-CoV primers
Figure imgf000052_0001
id sequence(5' -3' ', region
PMVJ0044 GGTTTCGGATGTTACAGCGTAGCCGCAGGAAGAAGAGTCACAG SARS-Cov Nucleocapsid gene PMVJ0090 TCGGGGACCAAGACCTAATCAGA SARS-Cov Nucleocapsid gene PMV 0091 AGCCGCAGGAAGAAGAGTCACAG SARS-Cov Nucleocapsid gene PMV 0092 AGGCCAGGGCGTTCCAATC SARS-Cov Nucleocapsid gene PMV_00093 CAATAGCGCGAGGGCAGTTTC SARS-Cov Nucleocapsid gene PMV 0094 GGCACCCGCAATCCTAATAACAA SARS-Cov Nucleocapsid gene PMV 00095 AGCCGCAGGAAGAAGAGTCACAG SARS-Cov Nucleocapsid gene
PMSLJ0001 ACATCACAGCTTCTACACCCGTTAAGGT SARS-Cov Replicase 1A
PMSLJ0002 ATACAGAATACATAGATTGCTGTTATCC j SARS-Cov Replicase 1A
PMSUJ0002 GCATCGTTGACTATGGTGTCCGATTCT ! SARS-Cov Replicase 1A
PMSUJ0003 GCTGCATTGGTTTGTTATATCGTTATGC SARS-Cov Replicase 1A
PMV 0023 TCACTTGCTTCCGTTGAGGAGCCGCTTGTCACAATGCCAATT I SARS-Cov Replicase 1A
PMV 0024 GGTTTCGGATGTTACAGCGTCATCACCAAGCTCGCCAACAGTT , SARS-Cov Replicase 1A
PMV 0025 TCACTTGCTTCCGTTGAGGAGGTTGCCATCATTTTGGCATCTT I SARS-Cov Replicase 1A
PMV 0026 GGTTTCGGATGTTACAGCGTCTTTGCGCCAGCGATAGTGACTT , SARS-Cov Replicase 1A
PMVJ0027 TCACTTGCTTCCGTTGAGGATGGCACCCGTTTCTGCAATGG SARS-Cov Replicase 1A
PMV 0028 GGTTTCGGATGTTACAGCGTTCGGGCAGCTGACACGAATGTAGA , SARS-Cov Replicase 1A
PMVJ0029 TCACTTGCTTCCGTTGAGGGAATGGCGATGTAGTGGCTATTGA i SARS-Cov Replicase 1A
PMV_00030 GGTTTCGGATGTTACAGCGTTAATGCCGGCATCCAAACATAAT ' SARS-Cov Replicase 1A
PMVJ0031 TCACTTGCTTCCGTTGAGGTAGCCAGCGTGGTGGTTCATACAA i SARS-Cov Replicase 1A
PMV 0032 GGTTTCGGATGTTACAGCGTCTCCCGGCAGAAAGCTGTAAGCT ' SARS-Cov Replicase 1A
PMV_00033 TCACTTGCTTCCGTTGAGGTATAGAGCCCGTGCTGGTGATGC j SARS-Cov Replicase 1A
PMV 0034 GGTTTCGGATGTTACAGCGTATCGCCATTCAAGTCTGGGAAGAA SARS-Cov Replicase 1A
PMVJ0035 TCACTTGCTTCCGTTGAGGTGGCTCAGGCCATACTGGCATTAC : SARS-Cov Replicase 1A
PMV_00036 GGTTTCGGATGTTACAGCGTTTTGCGCCAGCGATAGTGACTTG SARS-Cov Replicase 1A
PMVJ0037 TCACTTGCTTCCGTTGAGGTTCCCGTCAGGCAAAGTTGAAGG SARS-Cov Replicase 1A
PMV 0038 GGTTTCGGATGTTACAGCGTGACGGCAATTCCTGTTTGAGCAGA j SARS-Cov Replicase 1A
PMVJ0074 AGCCGCTTGTCACAATGCCAATT I SARS-Cov Replicase 1A
PMV 00075 CATCACCAAGCTCGCCAACAGTT ' SARS-Cov Replicase 1A id sequence (5* -3' ) region
PMV 00076 AGGTTGCCATCATTTTGGCATCTT SARS-Cov Replicase
PMVJ0077 CTTTGCGCCAGCGATAGTGACTT : SARS-Cov Replicase PMV 0078 ATGGCACCCGTTTCTGCAATGG SARS-Cov Replicase PMV 0079 TCGGGCAGCTGACACGAATGTAGA ■ SARS-Cov Replicase PMV 0080 GAATGGCGATGTAGTGGCTATTGA SARS-Cov Replicase PMV 0081 TAATGCCGGCATCCAAACATAAT SARS-Cov Replicase PMV 0082 TAGCCAGCGTGGTGGTTCATACAA SARS-Cov Replicase PMV 0083 CTCCCGGCAGAAAGCTGTAAGCT ' SARS-Cov Replicase PMV 0084 TATAGAGCCCGTGCTGGTGATGC SARS-Cov Replicase PMV_00085 ATCGCCATTCAAGTCTGGGAAGAA SARS-Cov Replicase PMV 0086 TGGCTCAGGCCATACTGGCATTAC ' SARS-Cov Replicase PMV 0087 TTTGCGCCAGCGATAGTGACTTG SARS-Cov Replicase PMV 0088 TTCCCGTCAGGCAAAGTTGAAGG ; SARS-Cov Replicase PMV 0089 GACGGCAATTCCTGTTTGAGCAGA ' SARS-Cov Replicase PMV 0003 TCACTTGCTTCCGTTGAGGATGAATTACCAAGTCAATGGTTAC ! SARS-Cov Replicase PMVJ0004 GGTTTCGGATGTTACAGCGTATAACCAGTCGGTACAGCTAC I SARS-Cov Replicase PMV 0005 TCACTTGCTTCCGTTGAGGGAAGCTATTCGTCACGTTCG ' SARS-Cov Replicase PMV 0006 GGTTTCGGATGTTACAGCGTCTGTAGAAAATCCTAGCTGGAG SARS-Cov Replicase PMVJ0007 TCACTTGCTTCCGTTGAGGCCTCTCTTGTTCTTGCTCGCA , SARS-Cov Replicase PMVJ0008 GGTTTCGGATGTTACAGCGTGTGAGCCGCCACACATG SARS-Cov Replicase PMVJ0009 TCACTTGCTTCCGTTGAGGCTAACATGCTTAGGATAATGG j SARS-Cov Replicase PMVJ0010 GGTTTCGGATGTTACAGCGTCAGGTAAGCGTAAAACTCATC i SARS-Cov Replicase PMV 0011 TCACTTGCTTCCGTTGAGGGCCTCTCTTGTTCTTGCTCGC '< SARS-Cov Replicase PMVJ0013 TCACTTGCTTCCGTTGAGGCACCGTTTCTACAGGTTAGCTAACGA ' SARS-Cov Replicase PMVJ0014 GGTTTCGGATGTTACAGCGTAAATGTTTACGCAGGTAAGCGTAAAA ; SARS-Cov Replicase PMVJ0015 TCACTTGCTTCCGTTGAGGTACACACCTCAGCGTTG 1i SARS-Cov Replicase i ~ PMVJ0016 GGTTTCGGATGTTACAGCGTCACGAACGTGACGAAT j SARS-Cov Replicase PMVJ0017 TCACTTGCTTCCGTTGAGGGCTTAGGATAATGGCCTCTC SARS-Cov Replicase PMV 00018 GGTTTCGGATGTTACAGCGTCCACGAATTCATGATCAACATCCC ' SARS-Cov Replicase id sequence{5' -3') region
PMV 0019 TCACTTGCTTCCGTTGAGGGCTCGCAAACATAACACTTGC SARS-Cov Replicase IB
PMVJ0020 GGTTTCGGATGTTACAGCGTGAGACACTCATAGAGCCTGTG SARS-Cov Replicase IB
PMVJ0055 ATGAATTACCAAGTCAATGGTTAC SARS-Cov Replicase IB
PMVJ0056 ATAACCAGTCGGTACAGCTAC SARS-Cov Replicase IB
PMV 0057 GAAGCTATTCGTCACGTTCG SARS-Cov Replicase IB
PMV 0058 CTGTAGAAAATCCTAGCTGGAG SARS-Cov Replicase IB PMVJ0059 CCTCTCTTGTTCTTGCTCGCA SARS-Cov Replicase IB
PMV 0060 GTGAGCCGCCACACATG SARS-Cov Replicase IB
PMV 0061 CTAACATGCTTAGGATAATGG SARS-Cov Replicase IB
PMVJ0062 CAGGTAAGCGTAAAACTCATC SARS-Cov Replicase IB
PMVJ0063 GCCTCTCTTGTTCTTGCTCGC SARS-Cov Replicase IB
PMV 0064 CACCGTTTCTACAGGTTAGCTAACGA SARS-Cov Replicase IB
PMVJ0065 AAATGTTTACGCAGGTAAGCGTAAAA SARS-Cov Replicase IB _
PMVJ0066 TACACACCTCAGCGTTG SARS-Cov Replicase IB
PMV 0067 CACGAACGTGACGAAT SARS-Cov Replicase IB
PMVJ0068 GCTTAGGATAATGGCCTCTC SARS-Cov Replicase IB
PMVJ0069 CCACGAATTCATGATCAACATCCC SARS-Cov Replicase IB
PMVJ0070 GCTCGCAAACATAACACTTGC SARS-Cov Replicase IB
PMVJ0071 GAGACACTCATAGAGCCTGTG SARS-Cov Replicase IB
PMSLJ0003 CCAGCTCCAATAGGAATGTCGCACTC SARS-Cov Spike glycoprotein gene
PMSLJ0004 TCCGCAGATGTACATATTACAATCTACG ■ SARS-Cov Spike glycoprotein gene
PMSUJ0005 TTAAATGCACCGGCCACGGTTTG SARS-Cov Spike glycoprotein gene
PMVJ00100 ATAGCGCCAGGACAAACTGGTGTT SARS-Cov Spike glycoprotein gene
PMVJOOIOI TATATGCGCCAAGCTGGTGTGAGT SARS-Cov Spike glycoprotein gene
PMV 00102 CGAGGCGGAGGTACAAATTGACAG SARS-Cov Spike glycoprotein gene
PMV 00103 ATGAAGCCGAGCCAAACATACCAA SARS-Cov Spike glycoprotein gene
PMVJ0045 TCACTTGCTTCCGTTGAGGATGCACCGGCCACGGTTTGTG SARS-Cov Spike glycoprotein gene
PMV 0046 GGTTTCGGATGTTACAGCGTATGCGCCAAGCTGGTGTGAGTTGA . SARS-Cov Spike glycoprotein gene
PMV 0047 TCACTTGCTTCCGTTGAGGTGCTGGCGCTGCTCTTCAAATACC SARS-Cov Spike glycoprotein gene id sequence (5' -3' ) region PMV 0048 GGTTTCGGATGTTACAGCGTCGGGGCTGCTTGTGGGAAGG SARS-Cov Spike glycoprotein gene PMV 0049 TCACTTGCTTCCGTTGAGGATAGCGCCAGGACAAACTGGTGTT SARS-Cov Spike glycoprotein gene PMV 0050 GGTTTCGGATGTTACAGCGTTATATGCGCCAAGCTGGTGTGAGT SARS-Cov Spike glycoprotein gene PMV 0051 TCACTTGCTTCCGTTGAGGCGAGGCGGAGGTACAAATTGACAG SARS-Cov Spike glycoprotein gene PMV 0052 GGTTTCGGATGTTACAGCGTATGAAGCCGAGCCAAACATACCAA SARS-Cov Spike glycoprotein gene PMV 0096 ATGCACCGGCCACGGTTTGTG SARS-Cov Spike glycoprotein gene PMV 0097 ATGCGCCAAGCTGGTGTGAGTTGA SARS-Cov Spike glycoprotein gene PMV J0098 TGCTGGCGCTGCTCTTCAAATACC SARS-Cov Spike glycoprotein gene PMV 0099 CGGGGCTGCTTGTGGGAAGG SARS-Cov Spike glycoprotein gene
In yet another example, the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV infectious organism causing SARS-like symptoms set forth in Table 19.
Table 19. Exemplary primers for non-SARS-CoV infectious organism causing SARS-like symptoms
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
In yet another example, the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV infectious organism damaging the subject's immune system set forth in Table 20.
Table 20. Exemplary primers for non-SARS-CoV infectious organism damaging the subject's immune system
Figure imgf000063_0002
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
In yet another example, the PCR is conducted using at least one of the following pairs of primers for a non-S ARS-CoV coronaviridae virus set forth in Table 21.
Table 21. Exemplary primers for non-S ARS-CoV coronaviridae virus seqid sequence(5'-3') PMIBV_00001 GGAACAGGACCTGCCGCTGA PMIBV_00002 ATCAGGTCCGCCATCCGAGA PMIBV_00003 AAAGGTGGAAGAAAACCAGTCCCAGA PMIBV_00004 GCCATCCGAGAATCGTAGTGGGTATT PMMHV_00001 CAGCGCCAGCCTGCCTCTAC PMMHV_00002 TGCTGCACTGGGCACTGCTT PMMHV_00003 GGAAATTACCGACTGCCCTCAAACA PMMHV_00004 TGATTATTTGGTCCACGCTCGGTTT PMEQ_00001 TCCCGCGCATCCAGTAGAGC PMEQ_00002 CTGCGGCTTTGTGGCATCCT PMEQ_00003 TTTGCTGAAGGACAAGGTGTGCCTA PMEQ 00004 CCAGAAGACTCCGTCAATGTTGGTG
PMCA_00001 AAAAACGTGGTCGTTCCAATTCTCG
PMCA_00002 CCATGCGATAGCGGCTTTGTCTATT
PMCA_00003 TGGGAACGGTGCCAAGCATT
PMCA_00004 GCCACCTCTGATGGACGAGCA
PMFE_00001 CGCGTCAACTGGGGAGATGAA
PMFE_00002 GCGCGCCTGTCTGTTCCAAT
PMFE_00003 GAGTCTTCTGGGTTGCAAAGGATGG
PMFE_00004 CCCCTGGATTGAGACCTGTTTCTTG
PMPEDV_00001 GCAGCATTGCTCTTTGGTGGTAATG
PMPEDV_00002 TGCTGAATGGTTTCACGCTTGTTCT
PMPEDV_00003 CCGCAAACGGGTGCCATTAT
PMPEDV_00004 TCGCCGTGAGGTCCTGTTCC
PMPTGV_00001 TCGCTCCAATTCCCGTGGTC
PMPTGV_00002 ACGTTGGCCCTTCACCATGC
PMPTGV_00003 CAAGCATTACCCACAATTGGCTGAA
PMPTGV_00004 TTCTTTTGCCACTTCTGATGGACGA
PMBOV_00001 TTCCTTTAAAACAGCCGATGGCAAC
PMBOV_00002 TCGGAATAGCCTCATCGCTACTTGG
PMBOV_00003 TTCCGCCTGGCACGGTACTC
PMBOV_00004 TGGCTTAGCGGCATCCTTGC
PMFIPV_00001 CACCATGGCCTCAGCCTTGA
PMFIPV_00002 GTGCCGCCAACCTGCCAGTA
PMFIPV_00003 GGTCTTGGCACTGTGGATGATGATT
PMFIPV_00004 GAAAAAGGGACAGCTACAGCGGATG
PMR_00001 CCCAATCAGAATTTTGGAGGCTCTG
PMR_00002 AGCGAATTGCACCTGAATACTGCAA
PMR_00003 TGACCAAACCGAGCGTGCAG
PMR_00004 CAGTGGCGGGGATTCCATTG
PMPHEV 00001 AGCGTCAACTGCTGCCACGA PMPHEV_00002 AGTACCGTGCCAGGCGGAAA PMPHEV_00003 AAGGTGTGCCTATTGCACCAGGAGT PMPHEV_00004 ACTAGCGACCCAGAAGACTCCGTCA PMPV_00001 AGAAGACCACTTGGGCTGACCAAAC PMPV_00002 TTGGCAATAGGCACTCCTTGTCCTT PMPV_00003 GCGCCAGCCTGCCTCTATTG PMPV_00004 TGGGGCCCCTCTTTCCAAAA PMTK .0001 ATGGCTCACCGCCGGTATTG PMTK_00002 TGGGCGTCACTCTGCTTCCA PMTK_00003 GCTAAGGCTGATGAAATGGCTCACC PMTK_00004 TCCAAAAAGACAAGCATGGCTGCTA PMSDAV_00001 TCTATGTTGAAGGCTCGGGAAGGTC PMSDAV_00002 TACTTGCTTAGGCTGTCCGGCATCT PMSDAV_00003 AGCAGTGCCCAGTGCAGCAG PMSDAV 00004 TGGGTTCATCAACGCCACCA
D. SARS-CoV and non-SARS-CoV infectious organism primers, probes, kit and uses thereof In still another aspect, the present invention is directed to an oligonucleotide primer for amplifying a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence, which oligonucleotide primer comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21. The present primers can comprise any suitable types of nucleic acids, e.g., DNA, RNA, PNA or a derivative thereof. Preferably, the primers comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 18 or Tables 19-21. In a specific embodiment, the present invention is directed to a kit for amplifying a SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, which kit comprises: a) an above-described primer; and b) a nucleic acid polymerase that can amplify a SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence using the probe. Preferably, the nucleic acid polymerase is a reverse transcriptase. In yet another aspect, the present invention is directed to an oligonucleotide probe for hybridizing to a SARS-CoV or a non-SARS-CoV infectious organismnucleotide sequence, which oligonucleotide probe comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17. The present probes can comprise any suitable types of nucleic acids, e.g., DNA, RNA, PNA or a derivative thereof. Preferably, the probes comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17. Also preferably, the probes are labeled, e.g., a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label. In a specific embodiment, the present invention is directed to a kit for hybridization analysis of a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence, which kit comprises: a) an above-described probe; and b) a means for assessing a hybrid formed between a SARS-CoV and/or a non-SARS-CoV infectious organism nucleotide sequence and said probe. The oligonucleotide primers and probes can be produced by any suitable method. For example, the probes can be chemically synthesized (See generally, Ausubel (Ed.) Current Protocols in Molecular Biology, 2.11. Synthesis and purification of oligonucleotides, John Wiley & Sons, Inc. (2000)), isolated from a natural source, produced by recombinant methods or a combination thereof. Synthetic oligonucleotides can also be prepared by using the triester method of Matteucci et al., J. Am. Chem. Soc, 3:3185-3191 (1981). Alternatively, automated synthesis may be preferred, for example, on a Applied Biosynthesis DNA synthesizer using cyanoethyl phosphoramidite chemistry. Preferably, the probes and the primers are chemically synthesized. Suitable bases for preparing the oligonucleotide probes and primers of the present invention may be selected from naturally occurring nucleotide bases such as adenine, cytosine, guanine, uracil, and thymine. It may also be selected from nonnaturally occurring or "synthetic" nucleotide bases such as 8-oxo-guanine, 6-mercaptoguanine, 4-acetylcytidine, 5-(carboxyhydroxyethyl) uridine, 2'-O-methylcytidine,
5-carboxymethylamino-methyl-2-thioridine, 5-carboxymethylaminomethyl uridine, dihydrouridine, 2'-O-methylpseudouridine, beta-D-galactosylqueosine, 2'-Omethylguanosine, inosine, N6 -isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6 -methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine, beta-D-mannosylqueosine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6 -isopentenyladenosine, N-((9-.beta.-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine, N-((9-beta-D-ribofuranosylpurine-6-yl) N-methylcarbamoyl) threonine, uridine-5-oxyacetic acid methylester, uridine-5-oxyacetic acid, wybutoxosine, pseudouridine, queosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 2-thiouridine, 5-methyluridine, N-((9-beta-D-ribofuranosylpurine-6-yl) carbamoyl) threonine, 2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine, and 3 -(3 -amino-3 -carboxypropyl) uridine. Likewise, chemical analogs of oligonucleotides (e.g., oligonucleotides in which the phosphodiester bonds have been modified, e.g., to the methylphosphonate, the phosphotriester, the phosphorothioate, the phosphorodithioate, or the phosphora idate) may also be employed. Protection from degradation can be achieved by use of a "3 '-end cap" strategy by which nuclease-resistant linkages are substituted for phosphodiester linkages at the 3' end of the oligonucleotide (Shaw et al., Nucleic Acids Res., 19:747 (1991)). Phosphoramidates, phosphorothioates, and methylphosphonate linkages all function adequately in this manner. More extensive modification of the phosphodiester backbone has been shown to impart stability and may allow for enhanced affinity and increased cellular permeation of oligonucleotides (Milligan et al., J. Med. Chem., 36:1923 (1993)). Many different chemical strategies have been employed to replace the entire phosphodiester backbone with novel linkages. Backbone analogues include phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, boranophosphate, phosphotriester, formacetal, 3 '-thioformacetal, 5'-thioformacetal, 5'-thioether, carbonate, 5'-N-carbamate, sulfate, sulfonate, sulfamate, sulfonamide, sulfone, sulfite, sulfoxide, sulfide, hydroxylamine, methylene (methylimino) (MMI) or methyleneoxy (methylimino) (MOMI) linkages. Phosphorothioate and methylphosphonate-modified oligonucleotides are particularly preferred due to their availability through automated oligonucleotide synthesis. The oligonucleotide may be a "peptide nucleic acid" such as described by (Milligan et al., J. Med. Chem., 36:1923 (1993)). The only requirement is that the oligonucleotide probe should possess a sequence at least a portion of which is capable of binding to a portion of the sequence of a target SARS-CoV sequence. Hybridization probes or amplification primers can be of any suitable length.
There is no lower or upper limits to the length of the probe or primer, as long as the probe hybridizes to the SARS-CoV or the non-SARS-CoV infectious organism target nucleic acids and functions effectively as a probe or primer (e.g., facilitates detection or amplification). The probes and primers of the present invention can be as short as 50, 40, 30, 20, 15, or 10 nucleotides, or shorter. Likewise, the probes or primers can be as long as 20, 40, 50, 60, 75, 100 or 200 nucleotides, or longer, e.g., to the full length of the SARS-CoV or the non-SARS-CoV infectious organism target sequence. Generally, the probes will have at least 14 nucleotides, preferably at least 18 nucleotides, and more preferably at least 20 to 30 nucleotides of either of the complementary target nucleic acid strands and does not contain any hairpin secondary structures. In specific embodiments, the probe can have a length of at least 30 nucleotides or at least 50 nucleotides. If there is to be complete complementarity, i.e., if the strand contains a sequence identical to that of the probe, the duplex will be relatively stable under even stringent conditions and the probes may be short, i.e., in the range of about 10-30 base pairs. If some degree of mismatch is expected in the probe, i.e., if it is suspected that the probe would hybridize to a variant region, or to a group of sequences such as all species within a specific genus, the probe may be of greater length (i.e., 15-40 bases) to balance the effect of the mismatch(es). The probe need not span the entire SARS-CoV or the non-SARS-CoV infectious organism target gene. Any subset of the target region that has the potential to specifically identify SARS-CoV or the non-SARS-CoV infectious organism target or alelle can be used. Consequently, the nucleic acid probe may hybridize to as few as 8 nucleotides of the target region. Further, fragments of the probes may be used so long as they are sufficiently characteristic of the SARS-CoV or the non-S ARS-CoV infectious organism target gene to be typed. The probe or primer should be able to hybridize with a SARS-CoV or a non-SARS-CoV infectious organism target nucleotide sequence that is at least 8 nucleotides in length under low stringency. Preferably, the probe or primer hybridizes with a SARS-CoV or a non-SARS-CoV infectious organism target nucleotide sequence under middle or high stringency. In still another aspect, the present invention is directed to an array of oligonucleotide probes immobilized on a support for typing a SARS-CoV or a non-SARS-CoV infectious organism target gene, which array comprises a support suitable for use in nucleic acid hybridization having immobilized thereon a plurality of oligonucleotide probes, at least one of said probes comprising a nucleotide sequence that: a) hybridizes, under high stringency, with a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17; or b) has at least 90% identity to a target SARS-CoV or a non-SARS-CoV infectious organism nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17. The plurality of probes can comprise DNA, RNA, PNA or a derivative thereof. At least one or some of the probes can comprise a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 or Tables 15-17. Preferably, probe arrays comprise all of the nucleotide sequences, or a complementary strand thereof, that are set forth in Table 13 or Tables 15-17. At least one, some or all of the probes can be labeled. Exemplary labels include a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label. Any suitable support, e.g., a silicon, a plastic, a glass, a ceramic, a rubber, and a polymer surface, can be used.
E. Assay formats Immobilization of Probes The present methods, probes and probe arrays can be used in solution. Preferably, it is conducted in chip format, e.g. , by using the probe(s) immobilized on a solid support. The probes can be immobilized on any suitable surface, preferably, a solid support, such as silicon, plastic, glass, ceramic, rubber, or polymer surface. The probe may also be immobilized in a 3 -dimensional porous gel substrate, e.g., Packard HydroGel chip (Broude et al., Nucleic Acids Res. , 29{19):E92 (2001 )). For an array-based assay, the probes are preferably immobilized to a solid support such as a "biochip". The solid support may be biological, nonbiological, organic, inorganic, or a combination of any of these, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc. A microarray biochip containing a library of probes can be prepared by a number of well known approaches including, for example, light-directed methods, such as VLSIPS™ described in U.S. Patent Nos. 5,143,854, 5,384,261 or 5,561,071; bead based methods such as described in U.S. Patent No. 5,541 ,061 ; and pin based methods such as detailed in U.S. Patent No. 5,288,514. U.S. Patent No. 5,556,752, which details the preparation of a library of different double stranded probes as a microarray using the VLSIPS™, is also suitable for preparing a library of hairpin probes in a microarray. Flow channel methods, such as described in U.S. Patent Nos. 5,677,195 and 5,384,261, can be used to prepare a microarray biochip having a variety of different probes. In this case, certain activated regions of the substrate are mechanically separated from other regions when the probes are delivered through a flow channel to the support. A detailed description of the flow channel method can be found in U.S. Patent No. 5,556,752, including the use of protective coating wetting facilitators to enhance the directed channeling of liquids though designated flow paths. Sporting methods also can be used to prepare a microarray biochip with a variety of probes immobilized thereon. In this case, reactants are delivered by directly depositing relatively small quantities in selected regions of the support. In some steps, of course, the entire support surface can be sprayed or otherwise coated with a particular solution. In particular formats, a dispenser moves from region to region, depositing only as much probe or other reagent as necessary at each stop. Typical dispensers include micropipettes, nanopippettes, ink-jet type cartridges and pins to deliver the probe containing solution or other fluid to the support and, optionally, a robotic system to control the position of these delivery devices with respect to the support. In other formats, the dispenser includes a series of tubes or multiple well trays, a manifold, and an array of delivery devices so that various reagents can be delivered to the reaction regions simultaneously. Spotting methods are well known in the art and include, for example, those described in U.S. Patent Nos. 5,288,514, 5,312,233 and 6,024,138. In some cases, a combination of flow channels and "spotting" on predefined regions of the support also can be used to prepare microarray biochips with immobilized probes. A solid support for immobilizing probes is preferably flat, but may take on alternative surface configurations. For example, the solid support may contain raised or depressed regions on which probe synthesis takes place or where probes are attached. In some embodiments, the solid support can be chosen to provide appropriate light-absorbing characteristics. For example, the support may be a polymerized Langmuir Blodgett film, glass or functionalized glass, Si, Ge, GaAs, GaP, SiO2, SiN , modified silicon, or any one of a variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidendifluoride, polystyrene, polycarbonate, or combinations thereof. Other suitable solid support materials will be readily apparent to those of skill in the art. The surface of the solid support can contain reactive groups, which include carboxyl, amino, hydroxyl, thiol, or the like, suitable for conjugating to a reactive group associated with an oligonucleotide or a nucleic acid. Preferably, the surface is optically transparent and will have surface Si-OH functionalities, such as those found on silica surfaces. The probes can be attached to the support by chemical or physical means such as through ionic, covalent or other forces well known in the art. Immobilization of nucleic acids and oligonucleotides can be achieved by any means well known in the art (see, e.g. , Dattagupta et al., Analytical Biochemistry, 177:85-89(1989); Saiki et al., Proc. Natl. Acad. Sci. USA, 86:6230-6234(1989); and Gravitt et al., J Clin. Micro., 36:3020-3027(1998)). The probes can be attached to a support by means of a spacer molecule, e.g. , as described in U.S. Patent No. 5,556,752 to Lockhart et al., to provide space between the double stranded portion of the probe as may be helpful in hybridization assays. A spacer molecule typically comprises between 6-50 atoms in length and includes a surface attaching portion that attaches to the support. Attachment to the support can be accomplished by carbon-carbon bonds using, for example, supports having (poly)trifluorochloroethylene surfaces, or preferably, by siloxane bonds (using, for example, glass or silicon oxide as the solid support). Siloxane bonding can be formed by reacting the support with trichlorosilyl or trialkoxysilyl groups of the spacer. Aminoalkylsilanes and hydroxyalkylsilanes, bis(2-hydroxyethyl)-aminopropyltriethoxysilane, 2-hydroxyethylaminoρropyltriethoxysilane, aminopropyitriethoxysilane or hydroxypropyltriethoxysilane are useful are surface attaching groups. The spacer can also include an extended portion or longer chain portion that is attached to the surface-attaching portion of the probe. For example, amines, hydroxyl, thiol, and carboxyl groups are suitable for attaching the extended portion of the spacer to the surface-attaching portion. The extended portion of the spacer can be any of a variety of molecules which are inert to any subsequent conditions for polymer synthesis. These longer chain portions will typically be aryl acetylene, ethylene glycol oligomers containing 2-14 monomer units, diamines, diacids, amino acids, peptides, or combinations thereof. In some embodiments, the extended portion of the spacer is a polynucleotide or the entire spacer can be a polynucleotide. The extended portion of the spacer also can be constructed of polyethyleneglycols, polynucleotides, alkylene, polyalcohol, polyester, polyamine, polyphosphodiester and combinations thereof. Additionally, for use in synthesis of probes, the spacer can have a protecting group attached to a functional group (e.g., hydroxyl, amino or carboxylic acid) on the distal or terminal end of the spacer (opposite the solid support). After deprotection and coupling, the distal end can be covalently bound to an oligomer or probe. The present method can be used to analyze a single sample with a single probe at a time. Preferably, the method is conducted in high-throughput format. For example, a plurality of samples can be analyzed with a single probe simultaneously, or a single sample can be analyzed using a plurality of probes simultaneously. More preferably, a plurality of samples can be analyzed using a plurality of probes simultaneously.
Hybridization Conditions Hybridization can be carried out under any suitable technique known in the art. It will be apparent to those skilled in the art that hybridization conditions can be altered to increase or decrease the degree of hybridization, the level of specificity of the hybridization, and the background level of non-specific binding (i.e., by altering hybridization or wash salt concentrations or temperatures). The hybridization between the probe and the target nucleotide sequence can be carried out under any suitable stringencies, including high, middle or low stringency. Typically, hybridizations will be performed under conditions of high stringency. Hybridization between the probe and target nucleic acids can be homogenous, e.g., typical conditions used in molecular beacons (Tyagi S. et al., Nature Biotechnology, 14:303-308 (1996); and U.S. Patent No. 6,150,097 ) and in hybridization protection assay (Gen-Probe, Inc) (U. S. Patent No. 6,004,745), or heterogeneous (typical conditions used in different type of nitrocellulose based hybridization and those used in magnetic bead based hybridization). The target polynucleotide sequence may be detected by hybridization with an oligonucleotide probe that forms a stable hybrid with that of the target sequence under high to low stringency hybridization and wash conditions. An advantage of detection by hybridization is that, depending on the probes used, additional specificity is possible. If it is expected that the probes will be completely complementary (i.e., about 99% or greater) to the target sequence, high stringency conditions will be used. If some mismatching is expected, for example, if variant strains are expected with the result that the probe will not be completely complementary, the stringency of hybridization may be lessened. However, conditions are selected to minimize or eliminate nonspecific hybridization. Conditions those affect hybridization and those select against nonspecific hybridization are known in the art (Molecular Cloning A Laboratory Manual, second edition, J. Sambrook, E. Fritsch, T. Maniatis, Cold Spring Harbor Laboratory Press, 1989). Generally, lower salt concentration and higher temperature increase the stringency of hybridization. For example, in general, stringent hybridization conditions include incubation in solutions that contain approximately 0.1XSSC, 0.1% SDS, at about 65°C incubation/wash temperature. Middle stringent conditions are incubation in solutions that contain approximately 1-2XSSC, 0.1% SDS and about 50°C - 65°C incubation/wash temperature. The low stringency conditions are 2XSSC and about 30°C - 50°C. An alternate method of hybridization and washing is first to carry out a low stringency hybridization (5XSSPE, 0.5% SDS) followed by a high stringency wash in the presence of 3M tetramethyl-ammonium chloride (TMAC). The effect of the TMAC is to equalize the relative binding of A-T and G-C base pairs so that the efficiency of hybridization at a given temperature corresponds more closely to the length of the polynucleotide. Using TMAC, it is possible to vary the temperature of the wash to achieve the level of stringency desired (Wood et al., Proc. Natl. Acad. Sci. USA, 82:1585-1588 (1985)). A hybridization solution may contain 25% formamide, 5XSSC, 5XDenhardt's solution, 100 μg/ml of single stranded DNA, 5% dextran sulfate, or other reagents known to be useful for probe hybridization.
Detection of the Hybrid Detection of hybridization between the probe and the target SARS-CoV nucleic acids can be carried out by any method known in the art, e.g. , labeling the probe, the secondary probe, the target nucleic acids or some combination thereof, and are suitable for purposes of the present invention. Alternatively, the hybrid may be detected by mass spectroscopy in the absence of detectable label (e.g., U.S. Patent No. 6,300,076). The detectable label is a moiety that can be detected either directly or indirectly after the hybridization. In other words, a detectable label has a measurable physical property (e.g., fluorescence or absorbance) or is participant in an enzyme reaction. Using direct labeling, the target nucleotide sequence or the probe is labeled, and the formation of the hybrid is assessed by detecting the label in the hybrid. Using indirect labeling, a secondary probe is labeled, and the formation of the hybrid is assessed by the detection of a secondary hybrid formed between the secondary probe and the original hybrid. Methods of labeling probes or nucleic acids are well known in the art. Suitable labels include fluorophores, chromophores, luminophores, radioactive isotopes, electron dense reagents, FRET(fluorescence resonance energy transfer), enzymes and ligands having specific binding partners. Particularly useful labels are enzymatically active groups such as enzymes (Wisdom, Clin. Chem., 22 l243 (1976)); enzyme substrates (British Pat. No. 1,548,741); coenzymes (U.S. Patent Nos. 4,230,797 and 4,238,565) and enzyme inhibitors (U.S. Patent No. 4,134,792); fluorescers (Soini and Hemmila, Clin. Chem., 25:353 (1979)); chromophores including phycobiliproteins, luminescers such as chemiluminescers and bioluminescers (Gorus and Schram, Clin. Chem., 25:512 (1979) and ibid, 1531); specifically bindable ligands, i.e., protein binding ligands; antigens; and residues comprising radioisotopes such as 3 H, 35 S, 32 P, I, and 14 C. Such labels are detected on the basis of their own physical properties (e.g., fluorescers, chromophores and radioisotopes) or their reactive or binding properties (e.g. , antibodies, enzymes, substrates, coenzymes and inhibitors). Ligand labels are also useful for solid phase capture of the oligonucleotide probe (i.e., capture probes). Exemplary labels include biotin (detectable by binding to labeled avidin or streptavidin) and enzymes, such as horseradish peroxidase or alkaline phosphatase (detectable by addition of enzyme substrates to produce a colored reaction product). For example, a radioisotope-labeled probe or target nucleic acid can be detected by autoradiography. Alternatively, the probe or the target nucleic acid labeled with a fluorescent moiety can detected by fluorimetry, as is known in the art. A hapten or ligand (e.g., biotin) labeled nucleic acid can be detected by adding an antibody or an antibody pigment to the hapten or a protein that binds the labeled ligand (e.g. , avidin). As a further alternative, the probe or nucleic acid may be labeled with a moiety that requires additional reagents to detect the hybridization. If the label is an enzyme, the labeled nucleic acid, e.g., DNA, is ultimately placed in a suitable medium to determine the extent of catalysis. For example, a cofactor-labeled nucleic acid can be detected by adding the enzyme for which the label is a cofactor and a substrate for the enzyme. Thus, if the enzyme is a phosphatase, the medium can contain nitrophenyl phosphate and one can monitor the amount of nitrophenol generated by observing the color. If the enzyme is a beta-galactosidase, the medium can contain o-nitro-phenyl-D-galacto-pyranoside, which also liberates nitrophenol. Exemplary examples of the latter include, but are not limited to, beta-galactosidase, alkaline phosphatase, papain and peroxidase. For in situ hybridization studies, the final product of the substrate is preferably water insoluble. Other labels, e.g. , dyes, will be evident to one having ordinary skill in the art. The label can be linked directly to the DNA binding ligand, e.g., acridine dyes, phenanthridines, phenazines, furocoumarins, phenothiazines and quinolines, by direct chemical linkage such as involving covalent bonds, or by indirect linkage such as by the incorporation of the label in a microcapsule or liposome, which in turn is linked to the binding ligand. Methods by which the label is linked to a DNA binding ligand such as an intercalator compound are well known in the art and any convenient method can be used. Representative intercalating agents include mono-or bis-azido aminoalkyl methidium or ethidium compounds, ethidium monoazide ethidium diazide, ethidium dimer azide (Mitchell et al., J. Am. Chem. Soc, 104:4265 (1982))), 4-azido-7-chloroquinoline, 2-azidofluorene, 4'-aminomethyl-4,5'-dimethylangelicin, 4'-aminomethyl-trioxsalen (4'aminomethyl-4,5,,8-trimethyl-psoralen), 3-carboxy-5- or -8-amino- or -hydroxy-psoralen. A specific nucleic acid binding azido compound has been described by Forster et al., Nucleic Acid Res., 13:745 (1985). Other useful photoreactable intercalators are the furocoumarins which form (2+2) cycloadducts with pyrimidine residues. Alkylating agents also can be used as the DNA binding ligand, including, for example, bis-chloroethylamines and epoxides or aziridines, e.g., aflatoxins, polycyclic hydrocarbon epoxides, mitomycin and norphillin A. Particularly useful photoreactive forms of intercalating agents are the azidointercalators. Their reactive nitrenes are readily generated at long wavelength ultraviolet or visible light and the nitrenes of arylazides prefer insertion reactions over their rearrangement products (White et al., Meth. EnzymoL, 46:644 (1977)). The probe may also be modified for use in a specific format such as the addition of 10-100 T residues for reverse dot blot or the conjugation to bovine serum albumin or immobilization onto magnetic beads. When detecting hybridization by an indirect detection method, a detectably labeled second probe(s) can be added after initial hybridization between the probe and the target or during hybridization of the probe and the target. Optionally, the hybridization conditions may be modified after addition of the secondary probe. After hybridization, unhybridized secondary probe can be separated from the initial probe, for example, by washing if the initial probe is immobilized on a solid support. In the case of a solid support, detection of label bound to locations on the support indicates hybridization of a target nucleotide sequence in the sample to the probe. The detectably labeled secondary probe can be a specific probe. Alternatively, the detectably labeled probe can be a degenerate probe, e.g., a mixture of sequences such as whole genomic DNA essentially as described in U.S. Patent No. 5,348,855. In the latter case, labeling can be accomplished with intercalating dyes if the secondary probe contains double stranded DNA. Preferred DNA-binding ligands are intercalator compounds such as those described above. A secondary probe also can be a library of random nucleotide probe sequences. The length of a secondary probe should be decided in view of the length and composition of the primary probe or the target nucleotide sequence on the solid support that is to be detected by the secondary probe. Such a probe library is preferably provided with a 3 ' or 5' end labeled with photoactivatable reagent and the other end loaded with a detection reagent such as a fluorophore, enzyme, dye, luminophore, or other detectably known moiety. The particular sequence used in making the labeled nucleic acid can be varied. Thus, for example, an amino-substituted psoralen can first be photochemically coupled with a nucleic acid, the product having pendant amino groups by which it can be coupled to the label, i.e., labeling is carried out by photochemically reacting a DNA binding ligand with the nucleic acid in the test sample. Alternatively, the psoralen can first be coupled to a label such as an enzyme and then to the nucleic acid. Advantageously, the DNA binding ligand is first combined with label chemically and thereafter combined with the nucleic acid probe. For example, since biotin carries a carboxyl group, it can be combined with a furocoumarin by way of amide or ester formation without interfering with the photochemical reactivity of the furocoumarin or the biological activity of the biotin. Aminomethylangelicin, psoralen and phenanthridium derivatives can similarly be linked to a label, as can phenanthridium halides and derivatives thereof such as aminopropyl methidium chloride (Hertzberg et al, J. Amer. Chem. Soc, 104:313 (1982)). Alternatively, a bifunctional reagent such as dithiobis succinimidyl propionate or 1,4-butanediol diglycidyl ether can be used directly to couple the DNA binding ligand to the label where the reactants have alkyl amino residues, again in a known manner with regard to solvents, proportions and reaction conditions. Certain bifunctional reagents, possibly glutaraldehyde may not be suitable because, while they couple, they may modify nucleic acid and thus interfere with the assay. Routine precautions can be taken to prevent such difficulties. Also advantageously, the DNA binding ligand can be linked to the label by a spacer, which includes a chain of up to about 40 atoms, preferably about 2 to 20 atoms, including, but not limited to, carbon, oxygen, nitrogen and sulfur. Such spacer can be the polyfunctional radical of a member including, but not limited to, peptide, hydrocarbon, polyalcohol, polyether, polyamine, polyimine and carbohydrate, e.g., -glycyl-glycyl-glycyl- or other oligopeptide, carbonyl dipeptides, and omega-amino-alkane-carbonyl radical or the like. Sugar, polyethylene oxide radicals, glyceryl, pentaerythritol, and like radicals also can serve as spacers. Spacers can be directly linked to the nucleic acid-binding ligand and/or the label, or the linkages may include a divalent radical of a coupler such as dithiobis succinimidyl propionate, 1,4-butanediol diglycidyl ether, a diisocyanate, carbodiimide, glyoxal, glutaraldehyde, or the like. Secondary probe for indirect detection of hybridization can be also detected by energy transfer such as in the "beacon probe" method described by Tyagi and Kramer, Nature Biotech. , 14:303-309 (1996) or U.S. Patent Nos. 5, 119,801 and 5,312,728 to Lizardi et al. Any FRET detection system known in the art can be used in the present method. For example, the AlphaScreen™ system can be used. AlphaScreen technology is an "Amplified Luminescent Proximity Homogeneous Assay" method. Upon illumination with laser light at 680 nm, a photosensitizer in the donor bead converts ambient oxygen to singlet-state oxygen. The excited singlet-state oxygen molecules diffuse approximately 250 nm (one bead diameter) before rapidly decaying. If the acceptor bead is in close proximity of the donor bead, by virtue of a biological interaction, the singlet-state oxygen molecules reacts with chemiluminescent groups in the acceptor beads, which immediately transfer energy to fluorescent acceptors in the same bead. These fluorescent acceptors shift the emission wavelength to 520-620 nm. The whole reaction has a 0.3 second half-life of decay, so measurement can take place in time-resolved mode. • Other exemplary FRET donor/acceptor pairs include Fluorescein (donor) and tetramemylrhodamine (acceptor) with an effective distance of 55 A; IAEDANS (donor) and Fluorescein (acceptor) with an effective distance of 46A; and Fluorescein (donor) and QSY-7 dye (acceptor) with an effective distance of 61 A (Molecular Probes). Quantitative assays for nucleic acid detection also can be performed according to the present invention. The amount of secondary probe bound to a microarray spot can be measured and can be related to the amount of nucleic acid target which is in the sample. Dilutions of the sample can be used along with controls containing known amount of the target nucleic acid. The precise conditions for performing these steps will be apparent to one skilled in the art. In microarray analysis, the detectable label can be visualized or assessed by placing the probe array next to x-ray film or phosphoimagers to identify the sites where the probe has bound. Fluorescence can be detected by way of a charge-coupled device (CCD) or laser scanning. Test samples Any suitable samples, including samples of human, animal, or environmental (e.g., soil or water) origin, can be analyzed using the present method. Test samples can include body fluids, such as urine, blood, semen, cerebrospinal fluid, pus, amniotic fluid, tears, or semisolid or fluid discharge, e.g., sputum, saliva, lung aspirate, vaginal or urethral discharge, stool or solid tissue samples, such as a biopsy or chorionic villi specimens. Test samples also include samples collected with swabs from the skin, genitalia, or throat. Test samples can be processed to isolate nucleic acid by a variety of means well known in the art (See generally, Ausubel (Ed.) Current Protocols in Molecular Biology, 2. Preparation and Analysis of DNA and 4. Preparation and Analysis of RNA, John Wiley & Sons, Inc. (2000)). It will be apparent to those skilled in the art that target nucleic acids can be RNA or DNA that may be in form of direct sample or purified nucleic acid or amplicons. Purified nucleic acids can be extracted from the aforementioned samples and may be measured spectraphotometrically or by other instrument for the purity. For those skilled in the art of nucleic acid amplification, amplicons are obtained as end products by various amplification methods such as PCR (Polymerase Chain Reaction, U.S. Patent Nos. 4,683,195, 4,683,202, 4,800,159 and 4,965,188), NASBA (Nucleic Acid Sequence Based Amplification, U.S. Patent No. 5,130,238), TMA (Transcription Mediated Amplification) (Kwoh et al., Proc. Natl. Acad. Set, USA, 86:1173-1177 (1989)), SDA (Strand Displacement Amplification, described by Walker et al., U.S. Patent No. 5,270,184), tSDA (thermophilic Strand Displacement Amplification (U.S. Patent No. 5,648,211 and Euro. Patent No. EP 0 684315), SSSR (Self-Sustained Sequence Replication) (U. S. Patent No. 6,156,508). In a specific embodiment, a sample of human origin is assayed. In yet another specific embodiment, a sputum, urine, blood, tissue section, food, soil or water sample is assayed.
Kits The present probes can be packaged in a kit format, preferably with an instruction for using the probes to detect a target gene. The components of the kit are packaged together in a common container, typically including written instructions for performing selected specific embodiments of the methods disclosed herein. Components for detection methods, as described herein, may optionally be included in the kit, for example, a second probe, and/or reagents and means for carrying out label detection (e.g., radiolabel, enzyme substrates, antibodies, etc., and the like).
F. Examples Example 1. Probe designs Various genome sequences of SARS-CoV are available (See e.g., Table 22).
Table 22: Genome sequences of SARS coronaviruse currently obtained (as of 5/2/2003)
Figure imgf000086_0001
Figure imgf000087_0001
The sizes of the nine genomes shown in Table 22 are very similar. The five genomes submitted by China contam various levels of unidentified nucleotides (N).
The following Table 23 shows similarities or homologies among the nine genomes of SARS coronaviruse. Table 23. Comparison of similarities between the nine genomes of SARS coronaviruse
Figure imgf000088_0001
The similarity of the nine genomes of SARS coronaviruse were compared. The numbers shown in the Table 23 represent the percentage of similarity between two genomes. Each number in Table 23 equals to the number of the same bases in two genomes divided by the total number of bases (about 30,000 bases) compared and then timed by 100.
Table 23 shows that the different genomes of SARS coronaviruse are highly similar to each other except B J04. The similarity lower than 99% is caused by the presence of N in the nucleotide sequence. If all the Ns in the nucleotide sequences from BJ01-BJ04 and GZ01 are considered as the same with other genome (this assumption is reasonable based on comparison of other part of the genomes), the nine genomes are 99% similar to each other. Since SARS coronaviruse is conservative as shown in Tables 22 and 23, nucleic acid based detection methods are rational. Figure IB indicates that detection of different parts of SARS coronaviruse genome at the same time can significantly increase the sensitivity and specificity of the detection method. We have two overall designs. One design is to perform a multiplex PCR for different parts of SARS coronaviruse genome and use PCR products as probes for detection. The second design is to perform a multiplex PCR for different parts of SARS coronaviruse genome and use a 70 mer oligonucleotides as probes for detection.
Target gene selection Based on analysis of SARS coronaviruse genome, we selected three genes as target genes. These three genes are orf 1 A and IB polymerase proteins, spike protein, and nucleocapsid protein. We selected human housekeeping gene GAPD (glyceraldehyde 3-phosphate dehydrogenase) (GenBank Ace: NM_002046) as a positive control for RNA isolation. We selected a gene (Arabidopsis ) (GenBank Ace: AJ441252), which has no homology to nucleotide sequence of human and common pathogens, as incorporated positive control.
Design of primers and probes The three proteins of SARS coronaviruse were analyzed and their conservative sequences were compared. According to the requirement of multiplex PCR, multiple pairs of primers, which have similar Tm values and are 1.5 Kb in distance, and have amplified products between 200 to 900 bp, were designed based on the conservative sequence between different genomes. In addition, multiple non-overlapping oligonucleotides (70 mer) were designed based on amplified product of each pair of primers. These primers and probes were compared with the most updated NCBI nucleic acid non-redundant nucleotide database using BLASTN, and the specificities of the probes and primers were assured.
Example 2. Process for pretreatment of blood sample Pretreatment of blood sample involves relatively complicated processes.
However, considering the relative low concentration SARS virus in serum reported, pretreatment described herein can effectively enrich lymphocytes from about 2 ml of the whole blood in order to increase the chances of detection. 1. Sample collection and transfer 1) Samples collected from patients in the hospital room are put in a first transfer window. The door of the window is then closed and locked. 2) The samples are then transferred into a second transfer window. The samples are recorded in a notebook and three bar code labels are printed. The samples are tested for conventional detection and transferred into a pretreatment transfer window.
2. Use of biosafe cabinet 1) Hospital personnel for performing pretreatment process enters the pretreatment room and close the door. The biosafe cabinet is then turned on. The fan of the cabinet and light are then automatically turned on. 2) The indicator lights for power switch, air speed switch, and work light switch are checked for normal operation. The indicator light for air selection switch is checked as off status. Abnormal or unusual operation is reported. 3) The indicator light for alarm switch will make an alarm sound which indicates normal status of the biosafe cabinet after self-testing. Fifteen minutes later, the alarm sound from the indicator light for alarm switch is stopped and the process in the biosafe cabinet can be started. 4) The process in the cabinet cannot be started if the alarm sound continues or the process has to be stopped if there is an alarm sound during the process. The incident has to be reported immediately. 5) After the biosafe cabinet operates normally, samples are taken from the second transfer window and placed in the cabinet. The transfer window top is cleaned by wiping with 75% alcohol and spraying with 0.5% peracetic acid. The door for the transfer window is then closed and locked. 6) The complete process of sample pretreatment is then performed in the biosafe cabinet.
3. Serum isolation 1) Blood (1.8 ml) with anticoagulant is centrifuged for 10 minutes at 3,500 rpm. The top layer is marked with a marker pen. 2) The top layer serum (about 1.0 ml) is then collected and put into a 1.5 ml sterile Eppendorf centrifuge tube. 3) The Eppendorf centrifuge tube is labeled with the bar code (marked as "P") and labeled with a sequence number. 4) The sample is then recorded in a notebook. 5) The centrifuge tube containing the serum sample is put in a specialized sample box and stored at -80°C. The outside of the sample box is labeled with SARS, serum and range of sample numbers. 4. Isolation of blood cells 1) Lymphocyte isolation solution (3.6 ml) is added to a 10 ml centrifuge tube. 2) Sterile physiological saline (a volume equal to the serum taken out in the centrifuge tube described above) is added to the centrifuge tube containing the blood cells. The blood cells are resuspended in saline using Pasteur pipette. 3) The resuspended blood cells are slowly loaded on top of the lymphocyte isolation solution and centrifuged for 20 minutes at 1,500 rpm. 4) The cells located between the layers are collected and put in a 1.5 ml sterile Eppendorf centrifuge tube, which is then centrifuged for 5 minutes at 10,000 rpm to spin down the cells. The supernatant is withdrawn. 5) The tube containing the cell pellet is then labeled with the bar code (marked "C") and labeled with a sequence number. 6) The sample is recorded in a notebook. 7) The centrifuge tube containing the blood cell sample is put in a specialized sample box and stored at -80°C. The outside of the sample box is labeled with SARS, blood cells, and range of sample numbers. 8) The glass face plate of the biosafe cabinet is then opened. The bench surface and other surfaces in the biosafe cabinet are then sterilized by wiping with 70% alcohol and spraying 0.5% peracetic acid. 9) After cleaning, the glass face plate is closed. The ultraviolet light is placed inside the cabinet and turned on for 15 minutes. 10) The power switch of the biosafe cabinet is turned off before leaving the sample pretreatment room. 5. Matters needing attention 1) The lymphocyte isolation solution should not be used immediately after being taken out of the refrigerator. The solution should be used after its temperature reaches room temperature and the solution is mixed well. 2) The whole isolation process should be performed at 18-28°C. Too high or too low temperature can impact on the quality of isolation process. 3) The pipette tips, Eppendorf centrifuge tubes, gloves, and disposed reagents or liquids should be discarded in a waist tank (containing 0.5% peracetic acid). Everything in the waster tank should be treated at high pressure after experiment and then discarded. 4) 0.5%) of peracetic acid is prepared by diluting 32 ml of 16% of peracetic acid in H2O to make a final volume of 1,000 ml.
Example 3. Process for extracting RNA using QIAamp Viral RNA kit The following procedures are used in RNA preparation: 1. Pipet 560 μl of prepared Buffer AVL containing Carrier RNA into a 1.5-ml microcentrifύge tube. If the sample volume is larger than 140 μl, increase the amount of Buffer AVL/Carrier RNA proportionally (e.g., a 280-μl sample will require 1120 μl Buffer AVL/Carrier RNA). 2. Add 140 μl plasma, serum, urine, cell-culture supernatant, or cell-free body fluid to the Buffer AVL/Carrier RNA in the microcentrifuge tube. Mix by pulse-vortexing for 15 sec. To ensure efficient lysis, it is essential that the sample is mixed thoroughly with Buffer AVL to yield a homogeneous solution. Frozen samples that have only been thawed once can also be used. 3. Incubate at room temperature (15-25°C) for 10 min. Viral particle lysis is complete after lysis for 10 min at room temperature. Longer incubation times have no effect on the yield or quality of the purified RNA. Potentially infectious agents and RNases are inactivated in Buffer AVL. 4. Briefly centrifuge the 1.5-ml microcentrifuge tube to remove drops from the inside of the lid. 5. Add 560 μl of ethanol (96-100%) to the sample, and mix by pulse- vortexing for 15 sec. After mixing, briefly centrifuge the 1.5-ml microcentrifuge tube to remove drops from inside the lid. Only ethanol is preferred since other alcohols may result in reduced RNA yield and purity. If the sample volume is greater than 140 μl, increase the amount of ethanol proportionally (e.g., a 280-μl sample will require 1120 μl of ethanol). In order to ensure efficient binding, it is essential that the sample is mixed thoroughly with the ethanol to yield a homogeneous solution. 6. Carefully apply 630 μl of the solution from step 5 to the QIAamp spin column (in a 2-ml collection tube) without wetting the ri . Close the cap, and centrifuge at 6000 x g (8000 rpm) for 1 min. Place the QIAamp spin column into a clean 2-ml collection tube, and discard the tube containing the filtrate. Close each spin column in order to avoid cross-contamination during cenfrifugation. Centrifugation is performed at 6,000 x g(8,000 rpm) in order to limit microcentrifuge noise. Centrifugation at full speed will not affect the yield or purity of the viral RNA. If the solution has not completely passed through the membrane, centrifuge again at a higher speed until all of the solution has passed through. 7. Carefully open the QIAamp spin column, and repeat step 6. If the sample volume is greater than 140 μl, repeat this step until all of the lysate has been loaded onto the spin column. 8. Carefully open the QIAamp spin column, and add 500 μl of Buffer AW1.
Close the cap, and centrifuge at 6,000 x g (8,000 rpm) for 1 min. Place the QIAamp spin column in a clean 2-ml collection tube (provided), and discard the tube containing the filtrate. It is not necessary to increase the volume of Buffer AW1 even if the original sample volume was larger than 140 μl. 9. Carefully open the QIAamp spin column, and add 500 μl of Buffer AW2.
Close the cap and centrifuge at full speed (20,000 x g; 14,000 rpm) for 3 min. Continue directly with step 10, or to eliminate any chance of possible Buffer AW2 carryover, perform step 9a, and then continue with step 10. Note: Residual Buffer AW2 in the eluate may cause problems in downstream applications. Some centrifuge rotors may vibrate upon deceleration, resulting in flow-through, containing Buffer AW2, contacting the QIAamp spin column. Removing the QIAamp spin column and collection tube from the rotor may also cause flowthrough to come into contact with the QIAamp spin column. In these cases, the optional step 9a should be performed. 9a. (Optional): Place the QIAamp spin column in a new 2-ml collection tube (not provided), and discard the old collection tube with the filtrate. Centrifuge at full speed for 1 min. 10. Place the QIAamp spin column in a clean 1.5-ml microcentrifuge tube (not provided). Discard the old collection tube containing the filtrate. Carefully open the QIAamp spin column and add 60 μl of Buffer AVE equilibrated to room temperature. Close the cap, and incubate at room temperature for 1 min. Centrifuge at 6,000 x g(8,000 rpm) for 1 min. A single elution with 60 μl of Buffer AVE is sufficient to elute at least 90% of the viral RNA from the QIAamp spin column. Performing a double elution using 2 x 40 μl of Buffer AVE will increase yield by up to 10%. Elution with volumes of less than 30 μl will lead to reduced yields and will not increase the final concentration of RNA in the eluate. Viral RNA is stable for up to one year when stored at -20°C or -70°C. The following are further information pertaining to the above procedures: • Equilibrate samples to room temperature (15-25°C). • Equilibrate Buffer AVE to room temperature for elution in step 10. ® Check whether Buffer AW 1 , Buffer AW2, and Carrier R A have been prepared according to the instructions on pages 14-15. • Redissolve precipitate in Buffer AVL/Carrier RNA by heating, if necessary, and cool to room temperature before use. • All centrifugation steps are carried out at room temperature.
Example 4. An exemplary array format of SARS-CoV detection chip Figure 5 illustrates an exemplary array format of SARS-CoV detection chip. Immobilization control is an oligo-probe that is labeled by a fluorescent dye HEX on its end and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. Positive control(Arabidopsis) is an oligo-probe designed according to an Arabidopsis (one kind of model organism) gene and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. During hybridization reaction, target probes that can hybridize with this positive control perfectly are added into the hybridization solution. Signals of the positive control can be applied to monitor the hybridization reaction. Negative control is an oligo-probe that does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. Blank Control is DMSO solution spot. It is used for monitoring arraying quality. SARS probes are 011, 024, 040 and 044 probes.
Example 5. SARS-CoV detection from a SARS patient blood sample (sample No. 3) Figures 6A and 6B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 3). Lymphocytes were isolated from 3# SARS patient blood sample. RNA from lymphocytes was extracted by QIAamp Kit. RT-nest PCR was performed using RNA extracted above as templates. 044 RT-nest PCR result was good and hybridization result was good too. 040 RT-nest PCR result was poor but hybridization result was good. It shows that the chip-hybridization method is sensitive and specific.
Example 6. SARS-CoV detection from a SARS patient blood sample (sample No. 4) Figures 7A and 7B illustrate SARS-CoV detection from a SARS patient blood sample (sample No. 4). Lymphocytes were isolated from 4# SARS patient blood sample. RNA from lymphocytes was extracted by QIAamp Kit. RT-nest PCR was performed using RNA extracted above as templates. 024, 040 and 044 RT-nest PCR results were good and hybridization results were good too. Example 7. SARS-CoV detection from a SARS patient sputum sample (sample No. 5) Figure 8 illustrates SARS-CoV detection from a SARS patient sputum sample (sample No. 5). RNA from 5# SARS patient sputum sample was extracted by QIAamp Kit. RT-nest PCR was performed using RNA extracted above as templates. 040 RT-nest PCR result was good and hybridization result was good too.
Example 8. SARS-CoV detection from a SARS patient sputum sample (sample No. 6) Figure 9 illustrates SARS-CoV detection from a SARS patient sputum sample (sample No. 6). RNA from 6# SARS patient sputum sample was extracted by QIAamp Kit. RT-nest PCR was performed using RNA extracted above as templates. All probes RT-nest PCR results were good and hybridization results were good too.
Example 9. Another exemplary array format of SARS-CoV detection chip Figure 10 illustrates another exemplary array format of SARS-CoV detection chip. Immobilization control is an oligo-probe that is labeled by a fluorescent dye HEX on its end and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. Positive control (Arabidopsis) is an oligo-probe designed according to an Arabidopsis (one kind of model organism) gene and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. During hybridization reaction, target probes that can hybridize with this positive control perfectly are added into the hybridization solution. Signals of the positive control can be applied to monitor the hybridization reaction. Negative control is an oligo-probe that does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV is contacted with the chip. Blank Control is DMSO solution spot. It is used for monitoring arraying quality. SARS probes are 011, 024, 040 and 044 probes. Example 10. Possible positive results on the SARS-CoV detection chip illustrated in Figure 10 Figure 11 illustrates all possible positive results on the SARS SARS-CoV detection chip illustrated in Figure 10. There are four sets probes on chips for detecting SARS virus: probe 011, probe 024, probe 040 and probe 044. The first line gives the positive result (1) by signals appearing on all four sets of probes: 011+024+040+044. The second line gives all the possible positive results (4) by signals appearing on three sets probes: 011+024+044, 024+040+044, 011+040+044, 011+024+040. The third line gives all the possible positive results (6) by signals appearing on two sets probes: 011+040, 024+044, 011+044, 040+044, 011+024, 024+040. The fourth line gives all the possible positive results (4) by signals appearing on only one set probes: 011, 024, 040, 044. Example 11. Possible results on the SARS-CoV detection chip illustrated in
Figure 12 Figure 13 illustrates all possible positive results on the SARS-CoV detection chip illustrated in Figure 12. There are four sets of probes on chips for detecting SARS virus: probe 011, probe 024, probe 040 and probe 044. The possible positive and negative results are also illustrated in Figure 14. The combinations for positive results include: • 011 + 127; • 040 + 127; • 011 + 127 + 024; 011 + 127 + 044; 024 + 127 + 044; 011 + 127 + 024 + 040; 024 + 127; 044 + 127; 011 + 127 + 040; • 024 + 127 + 040; • 044 + 127 + 040; • 011 + 127 + 044; • 011 + 127 + 024 + 044; • 011 + 127 + 024 + 040 + 044; and • 127 + 024 + 040 + 044. A negative result is indicated if only 127 is observed. To be a valid assay result, positive or negative, the immobilization control signal (HEX) should always be observed. The above examples are included for illustrative purposes only and are not intended to limit the scope of the invention. Many variations to those described above are possible. Since modifications and variations to the examples described above will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

Claims

1. A chip for assaying for a coronaviruse causing the severe acute respiratory syndrome (SARS-CoV) and a non-SARS-CoV infectious organism, which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon an oligonucleotide probe complementary to a nucleotide sequence of SARS-CoV genome, said nucleotide sequence comprising at least 10 nucleotides, and one or more of the following oligonucleotide probe(s): a) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism causing SARS-like symptoms, said nucleotide sequence comprising at least 10 nucleotides; b) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV infectious organism damaging an infectious host's immune system, said nucleotide sequence comprising at least 10 nucleotides; or c) an oligonucleotide probe complementary to a nucleotide sequence of a non-S ARS-CoV coronaviridae virus, said nucleotide sequence comprising at least 10 nucleotides.
2. The chip of claim 1 , which chip comprises a support suitable for use in nucleic acid hybridization having immobilized thereon at least two oligonucleotide probes complementary to at least two different nucleotide sequences of SARS-CoV genome, each of said two different nucleotide sequences comprising at least 10 nucleotides.
3. The chip of claim 2, wherein the at least two different nucleotide sequences of SARS-CoV genome comprises: a) a nucleotide sequence of at least 10 nucleotides located within a conserved region of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a variable region of SARS-CoV genome; or b) a nucleotide sequence of at least 10 nucleotides located within a structural protein coding gene of SARS-CoV genome and a nucleotide sequence of at least 10 nucleotides located within a non-structural protein coding gene of SARS-CoV genome.
4. The chip of claim 2, which further comprises: a) at least one of the following three oligonucleotide probes: an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-SARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any sequence of a SARS-CoV or non-SARS-CoV infectious organism but is complementary to a sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample; and b) a blank spot.
5. The chip of claim 2, which comprises at least two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides, respectively, located within a conserved region of SARS-CoV genome, located within a structural protein coding gene of SARS-CoV genome or located within a non-structural protein coding gene of SARS-CoV genome.
6. The chip of claim 2, wherein: a) the conserved region of SARS-CoV genome is a region located within the Replicase 1 A or IB gene or the Nucleocapsid (N) gene of SARS-CoV; b) the structural protein coding gene of SARS-CoV genome is a gene encoding the Spike glycoprotein (S), the small envelope protein (E) or the Nucleocapsid protein
(N); or c) the non-structural protein coding gene of SARS-CoV genome is a gene encoding the Replicase 1 A or IB.
7. The chip of claim 2, wherein the variable region of SARS-CoV genome is a region located within the Spike glycoprotein (S) gene of SARS-CoV.
8. The chip of claim 2, which comprises at least two of the following four oligonucleotide probes: two oligonucleotide probes complementary to two different nucleotide sequences of at least 10 nucleotides located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the N gene of SARS-CoV and an oligonucleotide probe complementary to a nucleotide sequence of at least 10 nucleotides located within the S gene of SARS-CoV.
9. The chip of claim 8, wherein one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a Replicase 1 A or IB nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a Replicase 1 A or IB nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13.
10. The chip of claim 9, wherein one of the two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
11. The chip of claim 8, wherein the nucleotide sequence located within the N gene of SARS-CoV comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a N nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13; or b) has at least 90% identity to a N nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13.
12. The chip of claim 11 , wherein the nucleotide sequence located within the N gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
13. The chip of claim 8, wherein the nucleotide sequence located within the S gene of SARS-CoV comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a S nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13 ; or b) has at least 90% identity to a S nucleotide sequence comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Table 13.
14. The chip of claim 13, wherein the nucleotide sequence located within the S gene of SARS-CoV comprises a nucleotide sequence that is set forth in Table 13.
15. The chip of claim 4, wherein the label of the immobilization control probe is selected from the group consisting of a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label.
16. The chip of claim 4, wherein the non-S ARS-CoV-sequence is spiked in the sample to be assayed.
17. The chip of claim 16, wherein the spiked non-S ARS-CoV-sequence is a sequence of Arabidopsis origin.
18. The chip of claim 8, which comprises two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe that is labeled and does not participate in any hybridization reaction when a sample containing or suspected of containing of a SARS-CoV or a non-S ARS-CoV infectious organism is contacted with the chip, a positive control probe that is not complementary to any sequence of a SARS-CoV or non-SARS-CoV infectious organism but is complementary to a sequence contained in the sample not found in the SARS-CoV or the non-SARS-CoV infectious organism and a negative control probe that is not complementary to any nucleotide sequence contained in the sample.
19. The chip of claim 18, which comprises multiple spots of the two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, the immobilization control probe, the positive control probe and the negative control probe.
20. The chip of claim 4, wherein at least one of the oligonucleotide probe comprises, at its 5' end, a poly dT region to enhance its immobilization on the support.
21. The chip of claim 2, wherein at least one of the oligonucleotide probes is complementary to a highly expressed nucleotide sequence of SARS-CoV genome.
22. The chip of claim 1 , wherein the non-S ARS-CoV infectious organism causing SARS-like symptoms is selected from the group consisting of a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus.
23. The chip of claim 22, wherein the influenza virus is influenza virus A or influenza virus B.
24. The chip of claim 22, wherein the parainfluenza virus is selected from the group consisting of parainfluenza virus 1 , parainfluenza virus 2, parainfluenza virus 3 and parainfluenza virus 4.
25. The chip of claim 1, wherein the non-S ARS-CoV infectious organism damaging an infectious host's immune system is selected from the group consisting of a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum.
26. The chip of claim 25, wherein the hepatitis virus is selected from the group consisting of hepatitis virus A (HAV), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV) and hepatitis virus G (HGV).
27. The chip of claim 25, wherein the HIV is HIV I.
28. The chip of claim 25, wherein the parvovirus is parvovirus B19.
29. The chip of claim 1 , wherein the non-S ARS-CoV coronaviridae virus is selected from the group consisting of an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat.
30. The chip of claim 1, wherein the support comprises a surface that is selected from the group consisting of a silicon, a plastic, a glass, a ceramic, a rubber, and a polymer surface.
31. A method for assaying for a SARS-CoV and a non-SARS-CoV infectious organism in a sample, which methods comprises: a) providing a chip of claim 1 ; b) contacting said chip with a sample containing or suspected of containing a nucleotide sequence of a SARS-CoV and a non-SARS-CoV infectious organism under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said nucleotide sequence of said
SARS-CoV or said non-S ARS-CoV infectious organism, if present in said sample, and said oligonucleotide probe complementary to a nucleotide sequence of said SARS-CoV genome or said oligonucleotide probe complementary to a nucleotide sequence of said non-SARS-CoV infectious organism genome, whereby detection of one or both of said hybrids indicates the presence of said
SARS-CoV and/or said non-SARS-CoV infectious organism in said sample.
32. The method of claim 31 , wherein the SARS-CoV is assayed by: a) providing a chip of claim 2; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and said at least two oligonucleotide probes complementary to two different nucleotide sequences of SARS-CoV genome, respectively, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said SARS-CoV in said sample.
33. The method of claim 31, wherein the SARS-CoV is assayed by: a) providing a chip of claim 3 ; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing hybrids formed between said SARS-CoV nucleotide sequence, if present in said sample, and i) said oligonucleotide probe complementary to a nucleotide sequence located within a conserved region of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, respectively; or ii) said oligonucleotide probe complementary to a nucleotide sequence located within a structural protein coding gene of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a non-structural protein coding gene of SARS-CoV genome, to determine the presence, absence or amount of said SARS-CoV in said sample, whereby detection of one or both said hybrids indicates the presence of said
SARS-CoV in said sample.
34. The method of claim 31 , wherein the SARS-CoV is assayed by: a) providing a chip of claim 4; b) contacting said chip with a sample containing or suspected of containing a SARS-CoV nucleotide sequence under conditions suitable for nucleic acid hybridization; and c) assessing: (i) hybrids formed between said SARS-CoV nucleotide sequence, if present in the sample, and the oligonucleotide probe complementary to a nucleotide sequence within a conserved region of SARS-CoV genome and an oligonucleotide probe complementary to a nucleotide sequence located within a variable region of SARS-CoV genome, respectively; (ii) a label comprised in the immobilization control probe, or a hybrid(s) involving the positive control probe and/or the negative control probe; and (iii) a signal at said blank spot to determine the presence, absence or amount of said SARS-CoV in a sample.
35. The method of claim 34, wherein the chip comprises two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1A or IB gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, an oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV, an immobilization control probe, a positive control probe and a negative control probe and the presence of the SARS-CoV is determined when: a) a positive hybridization signal is detected using at least one of the two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV and/or the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV; b) a positive signal is detected from the immobilization control probe; c) a positive hybridization signal is detected using the positive control probe; d) a positive hybridization signal is not detected using the negative control probe; and e) a positive hybridization signal is not detected at the blank spot.
36. The method of claim 35, wherein detecting a positive hybridization signal using at least one of the two oligonucleotide probes complementary to two different nucleotide sequences located within the Replicase 1 A or IB gene of SARS-CoV, or the oligonucleotide probe complementary to a nucleotide sequence located within the N gene of SARS-CoV, while not detecting a positive hybridization signal using the oligonucleotide probe complementary to a nucleotide sequence located within the S gene of SARS-CoV indicates mutation of the SARS-CoV.
37. The method of claim 31 , wherein the chip of claim 21 is used and the method is used to diagnose early-stage SARS patients.
38. The method of claim 37, wherein the early-stage SARS patients have been infected with SARS-CoV from about less than one day to about three days.
39. The method of claim 31 , which is used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism causing SARS-like symptoms.
40. The method of claim 39, wherein the SARS-like symptoms are caused by a non-SARS-CoV infectious organism selected from the group consisting of a human coronaviruse 229E, a human coronaviruse OC43, a human enteric coronaviruse, an influenza virus, a parainfluenza virus, a respiratory sncytical virus, a human metapneumovirus, a rhinovirus, an adenoviruse, a mycoplasma pneumoniae, a chlamydia pneumoniae, a measles virus and a rubella virus.
41. The method of claim 40, wherein the influenza virus is influenza virus A or influenza virus B.
42. The method of claim 40, wherein the parainfluenza virus is selected from the group consisting of parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 and parainfluenza virus 4.
43. The method of claim 31 , which is used to determine whether a subject is infected by a SARS-CoV and/or a non-SARS-CoV infectious organism damaging the subject's immune system.
44. The method of claim 43, wherein the non-S ARS-CoV infectious organism damaging subject's immune system is selected from the group consisting of a hepatitis virus, a transfusion transmitting virus (TTV), a human immunodeficiency virus (HIV), a parvovirus, a human cytomegalovirus (HCMV), an Epstein-Barr virus (EBV) and a tre-ponema palidum.
45. The method of claim 44, wherein the hepatitis virus is selected from the group consisting of hepatitis virus A (HAV), hepatitis virus B (HBV), hepatitis virus C (HCV), hepatitis virus D (HDV), hepatitis virus E (HEV) and hepatitis virus G (HGV).
46. The method of claim 44, wherein the HIV is HIV I.
47. The method of claim 44, wherein the parvovirus is parvovirus B 19.
48. The method of claim 31 , which is used to determine whether a subj ect is infected by a SARS-CoV and/or a non-SARS-CoV coronaviridae virus.
49. The method of claim 48, wherein the non-SARS-CoV coronaviridae virus is selected from the group consisting of an avian infectious bronchitis virus, an avian infectious laryngotracheitis virus, a murine hepatitis virus, an equine coronaviruse, a canine coronaviruse, a feline coronaviruse, a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus, a bovine coronaviruse, a feline infectious peritonitis virus, a rat coronaviruse, a neonatal calf diarrhea coronaviruse, a porcine hemagglutinating encephalomyelitis virus, a puffinosis virus, a turkey coronaviruse and a sialodacryoadenitis virus of rat.
50. The method of claim 31 , wherein the nucleotide sequence of the SARS-CoV or the non-SARS-Co V infectious organism is a genomic sequence of the SARS-CoV or the non-SARS-CoV infectious organism or a DNA sequence amplified from an extracted SARS-CoV RNA genomic sequence or an extracted genomic sequence of the non-S ARS-CoV infectious organism.
51. The method of claim 50, wherein the SARS-CoV RNA genomic sequence is extracted from a SARS-CoV infected cell using the QIAamp Viral RNA kit, the
Chomczynski-Sacchi technique or TRIzol.
52. The method of claim 50, wherein the SARS-CoV RNA genomic sequence is extracted from a SARS-CoV infected cell using the QIAamp Viral RNA kit.
53. The method of claim 31, wherein the genomic sequence of the of the SARS-CoV or the non-SARS-CoV infectious organism is extracted from a sputum or saliva sample, a lymphocyte of a blood sample.
54. The method of claim 31 , wherein the genomic sequence of the of the SARS-CoV or the non-SARS-CoV infectious organism is extracted from nasopharyngeal, oropharyngeal, tracheal, bronchaleolar lavage, pleural fluid, urine, stool, conjunctiva, tissue from human, mouse, dog, rat, cat, horse, avian, earth, water, air.
55. The method of claim 50, wherein the genomic sequence of the of the SARS-CoV or the non-SARS-CoV infectious organism is amplified by PCR.
56. The method of claim 55, wherein a label is incorporated into the amplified DNA sequence during the PCR.
57. The method of claim 55, wherein the PCR comprises conventional, multiplex, nested PCR or RT-PCR.
58. The method of claim 55, wherein the PCR comprises a two-step nested PCR, the first step being a RT-PCR and the second step being a conventional PCR.
59. The method of claim 55, wherein the PCR comprises a one-step, multiplex
RT-PCR using a plurality of 5' and 3' specific primers, each of the specific primers comprising a specific sequence complementary to its target sequence to be amplified and a common sequence, and a 5' and a 3' universal primer, the 5' universal primer being complementary to the common sequence of the 5' specific primers and the 3' universal primer being complementary to the common sequence of the 3' specific primers, and wherein in the PCR, the concentration of the 5' and 3' universal primers equals to or is higher than the concentration of the 5' and 3' specific primers, respectively.
60. The method of claim 59, wherein the 3 ' universal primer and/or the 5' universal primer is labeled.
61. The method of claim 60, wherein the label is a fluorescent label.
62. The method of claim 55, wherein the PCR comprises a multiplex nested PCR.
63. The method of claim 55, wherein the PCR is conducted using at least one of the following pairs of primers set forth in Table 18 or Tables 19-21.
64. An oligonucleotide primer for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide primer comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 1-6; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43 comprising a nucleotide sequence, or a complementary strand thereof, that is set forth in Tables 1-6.
65. The primer of claim 64, which comprises DNA, RNA, PNA or a derivative thereof.
66. The primer of claim 64, which comprises a nucleotide sequence, or a complementary strand thereof, that is set forth in Tables 1-6.
67. A kit for amplifying a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a primer of claim 64; and b) a nucleic acid polymerase that can amplify a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 using said primer of claim 64.
68. The kit of claim 67, wherein the nucleic acid polymerase is a reverse transcriptase.
69. An oligonucleotide probe for hybridizing to a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which oligonucleotide probe comprises a nucleotide sequence that: a) hybridizes, under high stringency, with a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 7-12; or b) has at least 90% identity to a target nucleotide sequence of influenza A virus, influenza B virus, human metapneumovirus, human adenovirus, human coronaviruse 229E or human coronaviruse OC43, or a complementary strand thereof, that is set forth in Tables 7-12.
70. The probe of claim 69, which comprises DNA, RNA, PNA or a derivative thereof.
71. The probe of claim 69, which comprises a nucleotide sequence, or a complementary strand thereof, that is set forth in Tables 7-12.
72. The probe of claim 69, which is labeled.
73. The probe of claim 72, wherein the label is selected from the group consisting of a chemical, an enzymatic, an immunogenic, a radioactive, a fluorescent, a luminescent and a FRET label.
74. A kit for hybridization analysis of a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43, which kit comprises: a) a probe of claim 69; and b) a means for assessing a hybrid formed between a nucleotide sequence of an influenza A virus, an influenza B virus, a human metapneumovirus, a human adenovirus, a human coronaviruse 229E or a human coronaviruse OC43 and said probe.
PCT/CN2003/000561 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents WO2005005658A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP03817386A EP1644516A4 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents
JP2005503791A JP2007523594A (en) 2003-07-14 2003-07-14 Methods and compositions for detecting SARS virus and other infectious agents
AU2003254594A AU2003254594A1 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents
US10/564,378 US20070042350A1 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents
CNB038267896A CN100510101C (en) 2003-07-14 2003-07-14 Methods and compositions for detecting SARS virus and other infectious agents
PCT/CN2003/000561 WO2005005658A1 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2003/000561 WO2005005658A1 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents

Publications (1)

Publication Number Publication Date
WO2005005658A1 true WO2005005658A1 (en) 2005-01-20

Family

ID=33569592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000561 WO2005005658A1 (en) 2003-07-14 2003-07-14 Methods and compositions for detecting sars virus and other infectious agents

Country Status (6)

Country Link
US (1) US20070042350A1 (en)
EP (1) EP1644516A4 (en)
JP (1) JP2007523594A (en)
CN (1) CN100510101C (en)
AU (1) AU2003254594A1 (en)
WO (1) WO2005005658A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059177A1 (en) * 2003-12-17 2005-06-30 Agency For Science, Technology And Research A sensitive and specific test to detect sars coronavirus
EP1877418A2 (en) * 2005-05-06 2008-01-16 Gen-Probe Incorporated Compositions and assays to detect influenza virus a and b nucleic acids
EP1877582A2 (en) * 2005-05-06 2008-01-16 Applera Corporation Pna probes, mixtures, methods and kits pertaining to the determination of mycoplasma and related mollicutes
WO2008046923A2 (en) * 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
EP2016199A2 (en) * 2006-05-11 2009-01-21 GeneOhm Sciences, Inc. 100% sequence identity detection methods for variable genomes
EP2023142A1 (en) * 2007-07-30 2009-02-11 Mikrogen Molekularbiologische Entwicklungs-GmbH Immunoassay utilizing recombinant nucleocapsid-proteins for detection of antibodies to human coronaviruses
WO2011035322A2 (en) * 2009-09-21 2011-03-24 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza a; influenza b; 2009 inlfuenza a/h1n1; and a 2009 influenza a/h1n1 rna sequence mutation associated with oseltamivir resistance
US8063197B2 (en) 2004-07-13 2011-11-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US20140134605A1 (en) * 2011-06-20 2014-05-15 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting HCV
WO2014198833A1 (en) * 2013-06-14 2014-12-18 Deutsches Krebsforschungszentrum Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
WO2015188899A1 (en) * 2014-06-12 2015-12-17 Deutsches Krebsforschungszentrum Novel ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
CN107475450A (en) * 2017-09-13 2017-12-15 河南省农业科学院畜牧兽医研究所 A kind of primer sets and kit for the strain of Porcine epidemic diarrhea virus novel variant and vaccine strain antidiastole
CN108761077A (en) * 2018-08-06 2018-11-06 南京农业大学 Poultry diease viral disease protein chip antibody assay kit and its preparation method and application
US10294534B2 (en) 2011-12-09 2019-05-21 The Secretary Of State For Health Respiratory infection assay
CN111074001A (en) * 2019-12-19 2020-04-28 苏州华益美生物科技有限公司 9 respiratory tract pathogen nucleic acid synergistic multiplex PCR detection
CN111826273A (en) * 2020-07-22 2020-10-27 赵毅 Automatic totally-enclosed micro-fluidic chip for nucleic acid detection
WO2021156882A1 (en) * 2020-02-04 2021-08-12 Indian Institute Of Technology Delhi Primer sets, biomarkers, kit and applications thereof
GB2596634A (en) * 2020-04-28 2022-01-05 Quantumdx Group Ltd A SARS-CoV-2 molecular diagnostic test
US20220333215A1 (en) * 2020-03-31 2022-10-20 The Hopes Institute Methods and compositions for detecting co-infection with sars-cov-2 and influenza a virus and/or influenza b virus

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060094105A1 (en) 1998-04-24 2006-05-04 University Hospitals Of Cleveland Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
EA201190178A1 (en) * 2009-03-20 2012-06-29 Алиос Биофарма, Инк. REPLACED NUCLEOSIDE AND NUCLEOTIC ANALOGUES
KR20110081717A (en) * 2010-01-08 2011-07-14 주식회사 파나진 Pna probes, kits and methods for detecting antiviral-resistant hepatitis b viruses
EP2572001A2 (en) * 2010-05-19 2013-03-27 QIAGEN Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
CN101838710A (en) * 2010-06-04 2010-09-22 湖州市疾病预防控制中心 Hepatitis A virus nucleic acid fluorescence quantitative RT-PRC assay kit and using method thereof
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
JP6321318B2 (en) * 2012-09-14 2018-05-09 日本碍子株式会社 Target nucleic acid detection method
CN103725799B (en) * 2014-01-15 2015-03-11 湖南圣维尔医学检验所有限公司 Method and kit for detecting RV RNA (Rubella Virus Ribose Nucleic Acid)
CN104846119A (en) * 2015-04-18 2015-08-19 湖北创瑞生物科技有限公司 One-step real-time fluorescence quantitative RT-PCR kit of measles virus
CN106313043B (en) * 2015-10-14 2019-04-26 山东世纪元通智能科技有限公司 A kind of control method of path point type walking robot system
CN107164562B (en) * 2017-06-27 2021-07-09 华东医院 Diarrhea-associated virus multiple gene detection system and kit and application thereof
CN109420242A (en) * 2017-08-27 2019-03-05 南京乐朋电子科技有限公司 Nanoscale medical robot
CN107586884B (en) * 2017-10-25 2020-08-18 东北农业大学 RT-PCR primer group for detecting feline infectious peritonitis virus, kit containing primer group and application of kit
CN109825567B (en) * 2018-12-27 2022-06-10 博奥生物集团有限公司 CircRNA biomarker for pneumonia diagnosis, application, primer and reagent
WO2021168427A1 (en) * 2020-02-20 2021-08-26 The Trustees Of Columbia University In The City Of New York Compositions and methods for rapid detection of sars-cov-2
WO2021164488A1 (en) * 2020-02-21 2021-08-26 The University Of Hong Kong COMPOSITIONS AND METHODS FOR DETECTING SARS-CoV-2
CN111273026B (en) * 2020-02-21 2023-05-09 无锡市人民医院 Novel rapid detection test strip for coronavirus and application thereof
US20210285061A1 (en) * 2020-03-09 2021-09-16 Roche Molecular Systems, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus 2 (sars-cov-2), influenza a and influenza b
CN111041129B (en) * 2020-03-13 2020-06-05 博奥生物集团有限公司 Primer-probe combination for detecting 6 respiratory viruses, kit and application
CN111388018B (en) * 2020-03-20 2023-09-19 威图姆卡医疗中心 Method and device for collecting lower respiratory tract sample, air disinfection method and device thereof
CN111206123B (en) * 2020-04-21 2020-07-24 珠海丽珠试剂股份有限公司 Nucleic acid compositions and kits for blood screening
WO2021212523A1 (en) * 2020-04-25 2021-10-28 Huang Wanqiu Primer pair, probe and kit for detecting sars-cov-2 by means of using nested rpa technology and use thereof
US20230241163A1 (en) * 2020-06-02 2023-08-03 Apc Research Assets Llc Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and Coronavirus
CN111893212A (en) * 2020-06-17 2020-11-06 安徽农业大学 Real-time fluorescence quantitative PCR (polymerase chain reaction) primer group and kit for feline infectious peritonitis virus
CN111808989A (en) * 2020-06-18 2020-10-23 重庆浦洛通基因医学研究院有限公司 Coronavirus/influenza virus/rhinovirus nucleic acid combined detection kit and use method thereof
WO2022013761A1 (en) * 2020-07-14 2022-01-20 University Of Peradeniya System and method for screening patients infected with severe acute respiratory syndrome coronavirus 2
CN112063752A (en) * 2020-08-20 2020-12-11 广东省科学院动物研究所 Universal coronavirus PCR primer and application thereof
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies
JP7133247B2 (en) * 2021-02-04 2022-09-08 株式会社Icst Inspection instrument, inspection kit and inspection method
JP6976621B1 (en) * 2021-02-04 2021-12-08 株式会社Icst Inspection equipment, inspection kits and inspection methods
CN113981147B (en) * 2021-11-17 2023-08-01 华南农业大学 Composition for detecting various respiratory viruses, kit and application thereof
CN114561492A (en) * 2022-02-28 2022-05-31 宁夏回族自治区疾病预防控制中心(宁夏回族自治区性病艾滋病防治中心) New coronavirus nucleic acid detection positive quality control product and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1469126A (en) * 2003-04-26 2004-01-21 杭州华大基因研发中心 Method for detecting SARS coronavirus antibody and its reagent kit
CN1472342A (en) * 2003-06-26 2004-02-04 上海科华生物工程股份有限公司 Reagent box for quantitatively inspecting number of copies of sars virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
EP0880598A4 (en) * 1996-01-23 2005-02-23 Affymetrix Inc Nucleic acid analysis techniques
EP1203945B1 (en) * 2000-10-26 2006-12-20 Agilent Technologies, Inc. (a Delaware corporation) Microarray
US7582740B2 (en) * 2003-04-17 2009-09-01 The Trustees Of Columbia University In The City Of New York Methods and kits for detecting SARS-associated coronavirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1469126A (en) * 2003-04-26 2004-01-21 杭州华大基因研发中心 Method for detecting SARS coronavirus antibody and its reagent kit
CN1472342A (en) * 2003-06-26 2004-02-04 上海科华生物工程股份有限公司 Reagent box for quantitatively inspecting number of copies of sars virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1644516A4 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059177A1 (en) * 2003-12-17 2005-06-30 Agency For Science, Technology And Research A sensitive and specific test to detect sars coronavirus
US8063197B2 (en) 2004-07-13 2011-11-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US9469881B2 (en) 2004-07-13 2016-10-18 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US8461324B2 (en) 2004-07-13 2013-06-11 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US10392656B2 (en) 2004-07-13 2019-08-27 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US8563707B2 (en) 2004-07-13 2013-10-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
EP1877582A4 (en) * 2005-05-06 2009-06-17 Applera Corp Pna probes, mixtures, methods and kits pertaining to the determination of mycoplasma and related mollicutes
US8753821B2 (en) 2005-05-06 2014-06-17 Applied Biosystems, Llc PNA probes, mixtures, methods and kits pertaining to the determination of Mycoplasma and related Mollicutes
EP1877582A2 (en) * 2005-05-06 2008-01-16 Applera Corporation Pna probes, mixtures, methods and kits pertaining to the determination of mycoplasma and related mollicutes
EP1877418A4 (en) * 2005-05-06 2009-12-09 Gen Probe Inc Compositions and assays to detect influenza virus a and b nucleic acids
EP1877418A2 (en) * 2005-05-06 2008-01-16 Gen-Probe Incorporated Compositions and assays to detect influenza virus a and b nucleic acids
US8338095B2 (en) 2005-05-06 2012-12-25 Gen-Probe Incorporated Compositions and assays to detect influenza virus A and B nucleic acids
US8124335B2 (en) 2005-05-06 2012-02-28 Gen-Probe Incorporated Compositions and assays to detect influenza virus A and B nucleic acids
EP2016199A4 (en) * 2006-05-11 2009-12-30 Geneohm Sciences Inc 100% sequence identity detection methods for variable genomes
JP2009536825A (en) * 2006-05-11 2009-10-22 ジーンオーム サイエンシーズ、インク． 100% sequence match detection method for variable genome
EP2016199A2 (en) * 2006-05-11 2009-01-21 GeneOhm Sciences, Inc. 100% sequence identity detection methods for variable genomes
WO2008046923A3 (en) * 2006-10-20 2009-07-23 Innogenetics Nv Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
WO2008046923A2 (en) * 2006-10-20 2008-04-24 Innogenetics N.V. Methodology for analysis of sequence variations within the hcv ns3/4a genomic region
EP2023142A1 (en) * 2007-07-30 2009-02-11 Mikrogen Molekularbiologische Entwicklungs-GmbH Immunoassay utilizing recombinant nucleocapsid-proteins for detection of antibodies to human coronaviruses
WO2011035322A3 (en) * 2009-09-21 2011-06-03 Intelligent Medical Devices, Inc. Probes and primers for binding, detecting, differentiating, isolating and sequencing of influenza a strains
WO2011035322A2 (en) * 2009-09-21 2011-03-24 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza a; influenza b; 2009 inlfuenza a/h1n1; and a 2009 influenza a/h1n1 rna sequence mutation associated with oseltamivir resistance
US8758996B2 (en) 2009-09-21 2014-06-24 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of influenza A; influenza B; novel influenza A/H1N1; and a novel influenza A/H1N1 RNA sequence mutation associated with oseltamivir resistance
US20140134605A1 (en) * 2011-06-20 2014-05-15 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting HCV
US9528163B2 (en) * 2011-06-20 2016-12-27 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting HCV
US11987851B2 (en) 2011-06-20 2024-05-21 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting HCV
US10982294B2 (en) 2011-06-20 2021-04-20 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting HCV
US10294534B2 (en) 2011-12-09 2019-05-21 The Secretary Of State For Health Respiratory infection assay
US10457938B2 (en) 2013-06-14 2019-10-29 Deutsches Krebsforschungszentrum TTV miRNA sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
WO2014198833A1 (en) * 2013-06-14 2014-12-18 Deutsches Krebsforschungszentrum Ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
WO2015188899A1 (en) * 2014-06-12 2015-12-17 Deutsches Krebsforschungszentrum Novel ttv mirna sequences as an early marker for the future development of cancer and as a target for cancer treatment and prevention
CN107475450A (en) * 2017-09-13 2017-12-15 河南省农业科学院畜牧兽医研究所 A kind of primer sets and kit for the strain of Porcine epidemic diarrhea virus novel variant and vaccine strain antidiastole
CN108761077A (en) * 2018-08-06 2018-11-06 南京农业大学 Poultry diease viral disease protein chip antibody assay kit and its preparation method and application
CN111074001A (en) * 2019-12-19 2020-04-28 苏州华益美生物科技有限公司 9 respiratory tract pathogen nucleic acid synergistic multiplex PCR detection
CN111074001B (en) * 2019-12-19 2023-03-21 苏州华益美生物科技有限公司 9 respiratory tract pathogen nucleic acid synergistic multiplex PCR detection
WO2021156882A1 (en) * 2020-02-04 2021-08-12 Indian Institute Of Technology Delhi Primer sets, biomarkers, kit and applications thereof
US20220333215A1 (en) * 2020-03-31 2022-10-20 The Hopes Institute Methods and compositions for detecting co-infection with sars-cov-2 and influenza a virus and/or influenza b virus
GB2596634A (en) * 2020-04-28 2022-01-05 Quantumdx Group Ltd A SARS-CoV-2 molecular diagnostic test
CN111826273A (en) * 2020-07-22 2020-10-27 赵毅 Automatic totally-enclosed micro-fluidic chip for nucleic acid detection

Also Published As

Publication number Publication date
US20070042350A1 (en) 2007-02-22
CN1802440A (en) 2006-07-12
EP1644516A4 (en) 2007-03-21
EP1644516A1 (en) 2006-04-12
AU2003254594A1 (en) 2005-01-28
AU2003254594A8 (en) 2005-01-28
CN100510101C (en) 2009-07-08
JP2007523594A (en) 2007-08-23

Similar Documents

Publication Publication Date Title
US20070042350A1 (en) Methods and compositions for detecting sars virus and other infectious agents
US5283171A (en) Compositions for and detection of human papillomavirus by specific oligonucleotide polymerase primers using the polymerase chain reaction
EP1654381A1 (en) A rapid method to detect nucleic acid molecules
US7718362B2 (en) DNA chip based genetic typing
KR101063037B1 (en) Method for detecting human papilloma virus using nucleic acid amplification and nucleic acid chain immobilization carrier
WO2007130519A2 (en) Viral nucleic acid microarray and method of use
US20070037140A1 (en) Methods and compositions for detecting sars virus
WO2009009900A1 (en) Nucleic acid sequences for the amplification and detection of respiratory viruses
JP2692702B2 (en) Method for detecting herpes simplex virus and reagent therefor
US20220333215A1 (en) Methods and compositions for detecting co-infection with sars-cov-2 and influenza a virus and/or influenza b virus
KR100832860B1 (en) Oligonucleotide and dna chip for detecting respiratory viral pathogen
WO2009105739A2 (en) Dna detection by dna chip
JP2010515451A (en) DNA chip for E. coli detection
EP0622464A2 (en) Nucleic acid assay procedure
US20030219757A1 (en) IS6110 based molecular detection of Mycobacterium tuberculosis
EP1697541A2 (en) Reagents and methods for detecting neisseria gonorrhoeae
US20040009574A1 (en) Compositions and methods for detecting streptococcus agalactiae capsular polysaccharide synthesis genes
US20030219755A1 (en) Compositions and methods for performing hybridization assays using target enhanced signal amplification (TESA)
US20040009482A1 (en) Compositions and methods for detecting streptococcus agalactiae surface immunogenic protein genes
US20060073475A1 (en) Compositions and methods for detecting pathogenic bacteria expressing chaperonin proteins
US20230220499A1 (en) Methods and compositions for detecting sars-cov-2 nucleic acid
AU2021372524A9 (en) Compositions and methods for detecting influenza a, influenza b, and sars-cov-2
WO2010125420A1 (en) A method for detection and identification of hpv16 variants using primers and probes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 03826789.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12006500117

Country of ref document: PH

Ref document number: 2005503791

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003817386

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1200600210

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 2003817386

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007042350

Country of ref document: US

Ref document number: 10564378

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10564378

Country of ref document: US